EXHIBIT 10.54



 Exhibit 10.54 

 
 Note: Redacted portions have been marked with [*]. The redacted
portions are subject to a request for 
 confidential treatment that has been filed with the Securities and Exchange
Commission. 
 COLLABORATION AND LICENCE AGREEMENT 

Between 

AMGEN INC. 

and 

CELLTECH R&D LIMITED 
 Re 
 BEER 







 BEER 
 COLLABORATION AND LICENCE AGREEMENT 
 I N DE X 

 

							
	  Article    
	 	
                        
     Description
	 	     Page   

	 		 
	 	 	  Recitals
	 	 1
	 		 
	1  	 	  Definitions
	 	 2
	 		 
	2  	 	  Scope of Relationship
	 	 18
	 	 	  
  2.1    
	 	 Exclusive Collaboration
	 	 18
	 	 	  
  2.2
	 	 Provision of Assistance
	 	 18
	 	 	  
  2.3
	 	 Decision Making and Obligations
	 	 19
	 	 	  
  2.4
	 	 Transfer of Materials
	 	 19
	 	 	  
  2.5
	 	 Third Party Research Agreements
	 	 19
	 	 	  
  2.6
	 	 Employee Obligations
	 	 19
	 	 	  
  2.7
	 	 No Parking
	 	 20
	 		 
	3  	 	  Research & Development of Antibody Products
	 	 21
	 			 
	 	 	 3.1	 	 Collaboration Regarding Research & Development
	 	 21
	 			 
	 	 	 3.2	 	 Activities
	 	 23
	 			 
	 	 	 3.3	 	 Sharing of Information
	 	 29
	 			 
	 	 	 3.4	 	 Celltech Opt-Out Right
	 	 30
	 			 
	 	 	 3.5	 	 Budgets
	 	 34
	 			 
	 	 	 3.6	 	 Costs
	 	 35
	 			 
	 	 	 3.7	 	 Governance of Research and Development
	 	 38
	 	 		 		 	 


  
 i 









							
	     Article     	 	                           
  Description	 	    Page      
	 	 	     

    
	 	 
	 		 
	4	 	 Regulatory
	 	41
	 			 
	 	 	 4.1
	 	  Rights and Responsibilities through [*]	 	41
	 			 
	 	 	 4.2
	 	Rights and Responsibilities of Territorial Commercial Leads	 	43
	 			 
	 	 	 4.3
	 	Additional Rights and Responsibilities of Manufacturing Lead	 	43
	 			 
	 	 	 4.4
	 	Co-operation	 	43
	 			 
	 	 	 4.5
	 	Access to INDs	 	44
	 			 
	 	 	 4.6
	 	Adverse Event Reporting; Customer Complaints	 	44
	 			 
	 	 	 4.7
	 	Communications	 	45
	 			 
	 	 	 4.8
	 	Recalls	 	47
	 			 
	 	 	 4.9
	 	Applications for Regulatory Exclusivity	 	48
	 		 
	5	 	 Commercialisation of Antibody Products
	 	48
	 			 
	 	 	 5.1
	 	Territorial Commercial Lead	 	48
	 			 
	 	 	 5.2
	 	Co-Detailer	 	50
	 			 
	 	 	 5.3
	 	Third Parties	 	51
	 			 
	 	 	 5.4
	 	Joint Commercialisation Committee Formation	 	51
	 			 
	 	 	 5.5
	 	Joint Commercialisation Committee and Territorial Commercial Lead Responsibilities	 	52
	 			 
	 	 	 5.6
	 	Decision Making	 	53
	 			 
	 	 	 5.7
	 	Dispute Resolution	 	54
	 	 		 		 	 


  
 ii 










							
	     Article     	 	                           
  Description	 	    Page      
	 	 	     

    
	 	 
	 	 	 5.8
	 	Commercialisation Plan	 	54
	 			 
	 	 	 5.9
	 	Country Plans	 	55
	 			 
	 	 	 5.10
	 	Implementation of Commercialisation Plan and Country Plan	 	55
	 			 
	 	 	 5.11
	 	Co-Detailing	 	56
	 			 
	 	 	 5.12
	 	Commercialisation Budget	 	58
	 			 
	 	 	 5.13
	 	Public Statements Regarding Antibody Products	 	59
	 			 
	 	 	 5.14
	 	Medical and Other Inquiries	 	59
	 			 
	 	 	 5.15
	 	Compliance with Laws	 	60
	 			 
	 	 	 5.16
	 	Detailing Reports	 	61
	 			 
	 	 	 5.17
	 	Post-Regulatory Approval Activities	 	63
	 		 
	6	 	 Manufacture and Supply
	 	63
	 			 
	 	 	 6.1
	 	Manufacturing	 	63
	 			 
	 	 	 6.2
	 	Manufacture of Antibody Products for Development	 	64
	 			 
	 	 	 6.3
	 	Manufacture of Antibody Product(s) for Commercialisation	 	65
	 			 
	 	 	 6.4
	 	Third Party Manufacturers	 	65
	 			 
	 	 	 6.5
	 	Standards of Supply	 	67
	 			 
	 	 	 6.6
	 	Audit	 	67
	 			 
	 	 	 6.7
	 	Manufacturing Option	 	67
	 			 
	 	 	 6.8
	 	Quality Responsibility	 	70
	 	 		 		 	 
	 	 		 		 	 


  
 iii










							
	     Article     	 	                           
  Description	 	    Page     
	 	 	     

    
	 	 
	7	 	 Consideration
	 	71
	 			 
	 	 	 7.1
	 	Up-front Fees	 	71
	 			 
	 	 	 7.2
	 	Milestone Payments	 	71
	 		 
	8	 	 Compensation
	 	72
	 			 
	 	 	8.1	 	Product Contribution	 	72
	 			 
	 	 	8.2	 	Calculation and Duration of Product Contribution	 	72
	 			 
	 	 	8.3	 	Quarterly Reconciliation of Product Contribution	 	72
	 			 
	 	 	8.4	 	Payments; Tax Matters	 	74
	 			 
	 	 	8.5	 	Records; Audits	 	75
	 		 
	9	 	 Collaboration
	 	77
	 			 
	 	 	9.1	 	Collaboration Committee Formation	 	77
	 			 
	 	 	9.2	 	Collaboration Committee Responsibilities	 	77
	 			 
	 	 	9.3	 	Decision Making; Administrative Matters	 	77
	 		 
	10	 	 Grant of Rights
	 	79
	 			 
	 	 	 10.1
	 	Patent Licences	 	79
	 			 
	 	 	 10.2
	 	Trademark; Copyright Licences	 	80
	 		 
	11	 	 Intellectual Property Rights
	 	81
	 			 
	 	 	 11.1
	 	Ownership	 	81
	 			 
	 	 	 11.2
	 	Prosecution and Defence	 	82
	 	 		 		 	 


  
 iv 










							
	     Article     	 	                           
  Description	 	    Page      
	 	 	     

    
	 	 
	 	 	 11.3
	 	Patent and Trademark Expenses	 	88
	 			 
	 	 	 11.4
	 	Enforcement	 	88
	 			 
	 	 	 11.5
	 	Infringement Defence	 	90
	 			 
	 	 	 11.6
	 	Trademarks	 	91
	 			 
	 	 	 11.7
	 	Patent Markings	 	91
	 			 
	 	 	 11.8
	 	Co-operation	 	92
	 			 
	 	 	 11.9
	 	Third Party Licences	 	93
	 		 
	12	 	 Confidentiality and Non-Use
	 	94
	 			 
	 	 	 12.1
	 	Confidential Information	 	94
	 			 
	 	 	 12.2
	 	Disclosure	 	94
	 			 
	 	 	 12.3
	 	Exceptions	 	96
	 			 
	 	 	 12.4
	 	Terms of Agreement	 	97
	 			 
	 	 	 12.5
	 	Public Announcements	 	98
	 			 
	 	 	 12.6
	 	Residual Information	 	98
	 			 
	 	 	 12.7
	 	Third Party Obligations	 	99
	 		 
	13	 	 Publications
	 	99
	 			 
	 	 	 13.1
	 	Procedure	 	99
	 			 
	 	 	 13.2
	 	Credit	 	100
	 	 		 		 	 
	 	 		 		 	 


  
 v 









							
	     Article     	 	                           
  Description	 	    Page      
	 	 	     

    
	 	 
	14	 	 Term and Termination
	 	100
	 			 
	 	 	 14.1
	 	Term	 	100
	 			 
	 	 	 14.2
	 	Termination for Convenience	 	100
	 			 
	 	 	 14.3
	 	Mutual Consent	 	101
	 			 
	 	 	 14.4
	 	Termination for Default	 	102
	 			 
	 	 	 14.5
	 	Bankruptcy	 	103
	 			 
	 	 	 14.6
	 	Additional Termination Right of Celltech	 	104
	 			 
	 	 	 14.7
	 	Opt-Out by Celltech	 	105
	 			 
	 	 	 14.8
	 	Continuing Party; Effective Date of Termination	 	105
	 			 
	 	 	 14.9
	 	Effects of Termination	 	106
	 			 
	 	 	 14.10
	 	Accrued Rights	 	114
	 		 
	15	 	 Dispute Resolution
	 	114
	 			 
	 	 	 15.1
	 	Referral of Unresolved Matters to [*]	 	114
	 		 
	16	 	 Representations and Warranties
	 	115
	 			 
	 	 	 16.1
	 	Authority and Consents	 	115
	 			 
	 	 	 16.2
	 	Mutual Representations and Warranties	 	116
	 			 
	 	 	 16.3
	 	Additional Representation and Warranty of Celltech	 	116
	 			 
	 	 	 16.4
	 	Mutual Covenants	 	116
	 			 
	 	 	 16.5
	 	Disclaimer of Representation and Warranty	 	118
	 			 
	 	 		 		 	 


  
 vi 










							
	     Article     	 	                           
  Description	 	    Page      
	 	 	     

    
	 	 
	17	 	 Change of Control
	 	118
	 			 
	 	 	 17.1
	 	Change of Control	 	118
	 		 
	18	 	 Indemnification; Insurance
	 	119
	 			 
	 	 	 18.1
	 	Indemnification by Amgen	 	119
	 			 
	 	 	 18.2
	 	Indemnification by Celltech	 	120
	 			 
	 	 	 18.3
	 	Joint Liability	 	121
	 			 
	 	 	 18.4
	 	Insurance	 	122
	 			 
	 	 	 18.5
	 	No Liability	 	122
	 			 
	 	 	 18.6
	 	Pre-Effective Date Losses	 	123
	 		 
	19	 	 Miscellaneous
	 	123
	 			 
	 	 	 19.1
	 	Amendments	 	123
	 			 
	 	 	 19.2
	 	Notices	 	123
	 			 
	 	 	 19.3
	 	Force Majeure	 	124
	 			 
	 	 	 19.4
	 	Use of Names, Logos or Symbols	 	124
	 			 
	 	 	 19.5
	 	Governing Law; Jurisdiction	 	125
	 			 
	 	 	 19.6
	 	Performance by Affiliates	 	126
	 			 
	 	 	 19.7
	 	Assignment	 	126
	 			 
	 	 	 19.8
	 	[*]	 	127
	 			 
	 	 	 19.9
	 	Joint Committees	 	127
	 			 
	 	 	 19.10
	 	Subcontracting	 	127
	 	 		 		 	 


  
 vii










									
	     Article     	 	                           
  Description	 	 	 	    Page      
	 	 	     

    
	 	 	 	 
	 	 	 19.11
	 	No Strict Construction	 		 	128
	 				 
	 	 	 19.12
	 	Interpretation and Schedules	 		 	128
	 				 
	 	 	 19.13
	 	Severability	 		 	129
	 				 
	 	 	 19.14
	 	No Consequential Damages	 		 	129
	 				 
	 	 	 19.15
	 	General Provisions	 		 	130
	 				 
	 	 	 19.16
	 	Whole Agreement	 		 	131
	 				 
	 	 		 		 		 	 
	 	 	 	 	 	 	 	 	 
	Schedule  	 	 	 	 	 	  
	 		 
	A  	 	 Research Plan
	 	A1 to A5
	 		 
	B  	 	 Costs and Calculation of Product Contribution
	 	B1 to B6
	 		 
	C  	 	 Principles for Detail Cost
	 	C1
	 		 
	D  	 	 Net Sales Definition
	 	D1 to D2
	 		 
	E  	 	 Calculation of Fully Absorbed Manufacturing Cost
	 	E1 to E5
	 		 
	F  	 	 Patent Rights
	 	F1 to F11
	 		 
	G  	 	 Antibody Licence Agreement

 
	 	 


  
 viii









 COLLABORATION AND LICENCE AGREEMENT 

This Collaboration and Licence Agreement (the “Agreement”) is made and entered into the 10th day of May, 2002 (the “Effective Date”) by and
between: 
 AMGEN INC., a corporation organised and existing under the laws of the State of Delaware, USA and having its
principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799 USA (“Amgen”), and 

CELLTECH R & D LIMITED, a company organised and existing under the laws of England and having its principal office at 208 Bath
Road, Slough, Berkshire SL1 3WE, England (“Celltech”). 
 RECITALS 

WHEREAS, 
  

	A.	 Celltech and Amgen are biopharmaceutical companies with an ongoing interest in the research, development, manufacture and commercialisation of
pharmaceutical products for the treatment of human diseases. 


  

	B.	 Celltech and/or its Affiliates have developed certain intellectual property rights, technology, know-how and expertise which relate to BEER, the
modulation of which may be useful in the treatment of the Osteoporosis Indication and Other Indications (all terms used in these recitals as defined in Article 1), and which may be useful in Developing and exploiting of BEER technology and know-how
and Antibody Products. 


  

	C.	 Amgen has reviewed and evaluated the technology, know-how and intellectual property rights relating to Celltech’s BEER programme supplied by
Celltech under terms of confidentiality and limited use and Amgen now wishes to collaborate with Celltech regarding using BEER technology, intellectual property rights and know-how in the further Research, Development and Commercialisation of
Antibody Products. 



  
 1 









	D.	 Amgen and/or its Affiliates have certain technology, know-how and expertise which may be useful in Developing and exploiting of BEER technology and
know-how and Antibody Products, and Celltech now wishes to collaborate with Amgen regarding using BEER technology and know-how in the further Research, Development and Commercialisation of Antibody Products. 



 

	E.	 The Parties believe it to be in their mutual interest and in the interest of the public to grant each other such intellectual property licences and
other rights as are necessary to continue the research and development begun by Celltech so as to Commercialise Antibody Products resulting from the aforesaid Research and Development. 



NOW, THEREFORE, Celltech and Amgen, intending to be legally bound, hereby agree as follows: 

ARTICLE 1 

DEFINITIONS 
 When used in this Agreement, each of the following terms shall have the meanings set forth in this Article 1: 
 “Affiliate” means any corporation, company, partnership, joint venture and/or firm which controls, is controlled by, or is under common control with a Party. For purposes of this
definition, “control” shall be presumed to exist if one of the following conditions is met: (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares having the
right to vote for the election of directors, and (b) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with the power to direct the management and policies of such
non-corporate entities. The Parties acknowledge that in the case of certain entities organised under the laws of certain countries outside of the United States, the maximum percentage ownership permitted by law for a foreign investor may be less
than fifty percent (50%), and that in such case such lower percentage shall be substituted in the preceding sentence, provided that such foreign investor has the power to direct the management and policies of such entity. 

  
 2









 “Amgen Initial Countries” means the United States, Canada, Mexico and
Japan. 
 “Amgen Know-How” means, other than [*] Know-How and [*] Know-How, all Information and Materials which
are [*] for the [*] of Antibody Products to the extent the same are [*] whether [*]. 
 “Amgen Patent Rights”
means, other than [*] Patent Rights and [*] Patent Rights, (i) all Patent Rights to the extent the same are [*] and which claim [*] Know-How and (ii) all Patent Rights of [*] to the extent the same are [*]; and in each case which if not
licensed herein would be infringed by [*] Antibody Products. 
 “Amgen [*] Know-How” means all
Information and Materials characterized, conceived, developed, derived, discovered, generated or identified solely by employees of or consultants to Amgen in the course of the [*] of Antibody Products [*] and, in each case, [*] of [*]. 

“Amgen [*] Patent Rights” means those Patent Rights of [*] which specifically disclose and claim [*] Know-How.

 “Amgen Technology” means, collectively, [*] Know-How, [*] Know-How, [*] Patent Rights, [*] Patent Rights,
and Amgen’s interest in [*] Know-How and Amgen’s interest in [*] Patent Rights. 
 “Amgen Territory”
means each or all countries (a) in the Amgen Initial Countries and (b) in the Territory in which Amgen is designated the Territorial Commercial Lead pursuant to Article 5.1. 

“Amgen Trademarks” means the Trademarks including house marks and house dress [*] from time to time [*] and used on or
in connection with Antibody Products, but excluding the [*] Trademarks. 
 “Antibody(ies)” means a polyclonal
or monoclonal antibody, whether multiple or single chain, recombinant or naturally occurring or a combination of the foregoing, whole or fragment, monospecific or multi-specific, and any analogs, constructs, conjugates, fusions or chemical or other
modifications and/or attachments thereof. 

  
 3









 “Antibody Product(s)” means any Antibody or Antibodies in whatever form
that is (i) delivered by [*] to [*]; (ii) [*] by [*]; or (iii) [*] by [*]; and in each case that binds to BEER. Antibody Product also includes any product incorporating any such Antibody. 

“Antibody Raw Material” means the bulk Antibody Product, manufactured and quality control tested in accordance with
Article 6 (including, if appropriate, [*] and suitable for use in the manufacture of Antibody Product in Finished Form. 

“BEER” means any protein or a portion thereof comprising the polypeptide sequence of [*] and any polypeptide sequence
having [*] and any [*]. 
 “Business Day” means a day on which banking institutions in both New York, New York,
USA, and London, England are open for business. 
 “Celltech [*] Patent Rights” means the patent
applications and patents set forth in Part A of Schedule F and all Patent Rights that issue from or claim priority from those Patent Rights and foreign counterparts thereof. 
 “Celltech [*] Patent Rights” means the Patent Rights set forth in Part B of Schedule F and all Patent Rights that issue from or claim priority from those Patent Rights and foreign
counterparts thereof 
 “Celltech Initial Countries” means (a) the United Kingdom, France, Germany, Spain,
Italy, Norway, Switzerland and any country in addition to those named which, as of the date of first Regulatory Approval for Commercialisation of an Antibody Product is a member state of the European Union; and (b) Australia and New Zealand.

 “Celltech Know-How” means, other than [*] Know-How and [*] Know-How,
all Information and Materials relating to Antibodies or BEER which are [*] for the [*] of Antibody Products to the extent the same are [*] whether [*]. 
 “Celltech Patent Rights” means, other than [*] Patent Rights, [*] Patent Rights and [*] Patent Rights, (i) all Patent Rights to the extent the same are [*] and which claim [*]
Know-How and 

  
 4









 
(ii) all Patent Rights of [*] to the extent the same are [*]; and in each case which if not licensed herein would be infringed by [*] Antibody Products. [*] Patent Rights include [*] Patent
Rights. 
 “Celltech [*] Know-How” means all Information and Materials characterized, conceived,
developed, derived, discovered, generated or identified solely by employees of or consultants to Celltech in the course of the [*] of Antibody Products [*] and, in each case, any [*] of [*]. 

“Celltech [*] Patent Rights” means those Patent Rights of [*] which specifically disclose and claim [*] Know-How.

 “Celltech Technology” means, collectively, [*] Know-How, [*] Know-How, [*] Patent Rights, [*] Patent Rights,
[*] Patent Rights, and Celltech’s interest in [*] Know-How and Celltech’s interest in [*] Patent Rights. 

“Celltech Territory” means each or all countries (a) in the Celltech Initial Countries and (b) in the
Territory in which Celltech is designated the Territorial Commercial Lead pursuant to Article 5.1. 
 “Celltech
Trademarks” means the Trademarks including house marks and house dress [*] from time to time [*] and used on or in connection with Antibody Products but excluding the [*] Trademarks. 

“Collaboration Committee” means the committee formed pursuant to Article 9.1. 

“Commercialisation” or “Commercialise” means any and all activities (whether before or after Regulatory
Approval) directed to the marketing, Detailing and Promotion of an Antibody Product after Regulatory Approval for commercial sale has been obtained and shall include pre-launch and post-launch marketing, manufacturing for commercial sale, Promoting,
Detailing, distributing, offering to sell and selling an Antibody Product, importing an Antibody Product for sale, conducting Marketing Clinical Studies (but not Development clinical studies), and interacting with Regulatory Authorities regarding
the foregoing. When used as a verb, “Commercialising” means to engage in Commercialisation and “Commercialised” shall have a corresponding meaning. 

  
 5









 “Commercialisation Expense” shall have the meaning as set forth in Schedule
B. 
 “Commercialisation Plan” means the comprehensive plan and overall strategy, and any updates thereto, and
consolidated budget for the Commercialisation of the Antibody Products to be prepared pursuant to Article 5.8. 

“Commercially Reasonable Efforts” means efforts and resources commonly associated with good business practice and
standards in the research-based pharmaceutical industry to research, develop or commercialise (as appropriate) a product of similar market potential at a similar stage in its product life, taking into account efficacy, the competitiveness of
alternative products and product candidates in the marketplace (excluding other products owned or controlled or marketed by a Party or any of its Affiliates), the patent and other proprietary position of the product, the likelihood of regulatory
approval given the regulatory structure involved, the profitability of the product including the royalties payable to licensors of patent rights, alternative Third Party products and product candidates and other relevant factors. Commercially
Reasonable Efforts where appropriate shall be determined on a market-by-market basis for a particular product, and the level of effort may change over time, reflecting changes in the status of the product and the market involved. 

“Confidential Information” means all Information disclosed in good faith for the purposes of this Agreement which is
designated as confidential in writing by the disclosing Party, whether by letter or by the use of an appropriate stamp or legend, prior to or at the time any such Information is disclosed by the disclosing Party to the other Party. Notwithstanding
anything in the foregoing to the contrary, Information which is disclosed in good faith for the purposes of the Agreement, whether orally, electronically, visually or in writing without an appropriate letter, stamp or legend, shall constitute
Confidential Information of a Party (a) if the disclosing Party within thirty (30) days after such disclosure, delivers to the other Party a written document or documents describing the Information and referencing the place and date of
such oral, visual, electronic or written disclosure and the names of the persons to whom such disclosure was made or (b) if such Information is of the type that is customarily considered to be confidential


  
 6









 
information by persons engaged in activities that are substantially similar to the activities being engaged in by the Parties. Any Information of a Party disclosed at a meeting of the
Collaboration Committee, Joint Research Committee, Joint Development Committee or the Joint Commercialisation Committee (or any sub-committee or project team of the foregoing) or disclosed through a report to any such committee shall constitute
Confidential Information of such Party unless otherwise specified. The terms of this Agreement shall be considered Confidential Information of each Party. 
 “Contract Year” means (a) with respect to the first Contract Year, the period beginning on the Effective Date and ending on 31 December 2002 (the “First Contract
Year”), and (b) with respect to each subsequent Contract Year, the twelve (12) month period beginning on the day following the end of the First Contract Year and each succeeding twelve (12) month period thereafter.

 “Control” or “Controlled” means with respect to any (a) Material or Information or
(b) intellectual property right, in each case the possession (whether by ownership, licence or other right, other than pursuant to this Agreement) by a Party or its Affiliates of the ability to grant to the other Party access and/or a licence
(or sublicence) as provided herein under such item or right without violating the terms of any agreement or other arrangement with any Third Party existing before or after the Effective Date and existing as of the date such Party obtains such
ownership, licence or other right in such Material, Information or intellectual property. 
 “Cost of Goods”
shall have the meaning set forth in Schedule B. 
 “Detail” means an interactive face-to-face contact
(including a live video presentation) of a Representative with (a) a medical professional with prescribing authority or (b) an office nurse with influence over the pharmaceutical treatment of a patient, provided that in the case of
(b) such contacts shall not be considered a Detail to the extent they exceed [*] percent ([*]%) of the interactive face-to-face contacts performed by a Party during the Contract Year. To constitute a Detail such interactive face-to-face contact
(i) shall be with a medical professional or office nurse designated by the Territorial Commercial Lead as a target call audience in its Lead Territory, (ii) shall occur at the office of such medical professional or office nurse, at
hospitals or 

  
 7









 
at other locations (excluding exhibits, displays and other forms of communication not involving face-to-face contact by such sales representative), and (iii) during such contact Regulatory
Authority-approved indicated uses, safety, effectiveness, contraindications, side effects, warnings and/or other relevant characteristics of an Antibody Product, shall be described in a fair and balanced manner consistent with the laws and
regulations of the relevant part of the Territory, using either or both of the Product Labelling or the Promotional Materials, in an effort to increase physician prescribing preferences of such Antibody Product for its approved indicated uses. A
sample drop does not constitute a Detail. When used as a verb, “Detailing” means performing Details and “Detailed” shall have a corresponding meaning. 

“Development” or “Develop” means all clinical and other activities undertaken to obtain Regulatory
Approval of an Antibody Product after the filing of an IND for an Antibody Product and up to and including the obtaining of Regulatory Approval for commercial sale of such Antibody Product, and including any supplementary Development forming part of
Late Stage Development in the Field in the Territory. For the avoidance of doubt, these activities shall include clinical drug development activities, including, among other things: test method development and stability testing, toxicology,
formulation, process development, manufacturing, manufacturing scale-up, development-stage manufacturing, quality assurance/quality control development, statistical analysis and report writing, product approval and registration, and regulatory
affairs related to the foregoing. When used as a verb, “Developing” means to engage in Development and “Developed” shall have a corresponding meaning. 

“Dollar” means a United States dollar, and “$” shall be interpreted accordingly. 

“Drug Approval Application” means an application for any Regulatory Approval required before commercial sale or use of
an Antibody Product as a drug or to treat a particular indication in a regulatory jurisdiction, including: (a) (i) a Biologics Licence Application (“BLA”) pursuant to 21 C.F.R. 601.2 (or any successor application or
procedure) submitted to the FDA and (ii) any counterpart of a U.S. BLA in any other country in the Territory; and (b) all supplements and amendments that may be filed with respect to the foregoing. 

“Early Stage Development” means all post-IND Development up to and including conclusion of Phase II Studies. 


  
 8









 “FAMC” shall have the meaning set forth in Schedule E. 

“FDA” means the United States Food and Drug Administration or a successor agency thereto. 

“Field” means [*]. 
 “Finished Form” means the final finished form of an Antibody Product suitable for use by patients including Antibody Raw Material in combination with excipients, vials or other containers
suitable for delivery, delivery devices, packaging and labelling. 
 “First Commercial Sale” means the first
shipment of any Antibody Product sold on arm’s-length terms to a non-sublicensee Third Party by a Party, its Affiliates or its sublicensees, in any country in the Territory after the first Regulatory Approval for Commercialisation has been
achieved for such Antibody Product in such country in any indication. Sales for test marketing, sampling and promotional uses, clinical trial purposes or compassionate or similar use shall not constitute a First Commercial Sale. 

“Force Majeure” means any occurrence beyond the reasonable control of a Party that prevents or substantially interferes
with the performance by a Party of any of its obligations hereunder. 
 “FTE” means a full-time equivalent
person year of scientific or technical work, full-time being [*]. 
 “FTE Cost” means, for any quarter, the FTE
Rate multiplied by the sum of the number of days (calculated by adding the full and partial percentage of days) actually spent in that quarter by FTEs of a Party working directly on Research and Development of Antibody Products under the terms of
this Agreement (as per their time sheets) divided by [*]. 
 “FTE Rate” means the sum of the [*] FTE Rate (as
calculated herein below) and the [*] FTE Rate (as calculated herein below). The [*] FTE Rate is [*] Dollars ($[*]) per FTE. This [*] FTE Rate shall be adjusted annually beginning with 1st April 2003 in accordance with [*]. The [*] FTE Rate is
[*] Dollars ($[*]) and shall be adjusted annually beginning on April 1, 2003 at the same time as the [*] FTE Rate, by the then-most recently published annual increase in the [*] (as determined by the average annual [*] from the prior year as
quoted from the [*])). 

  
 9









 “GAAP” means United States generally accepted accounting principles.

 “IND” means (a) (i) an Investigational New Drug Application (as defined in the U.S. Federal Food,
Drug and Cosmetic Act, as amended from time to time, and the regulations promulgated thereunder) that is required to be filed with the FDA before beginning clinical testing of an Antibody Product in human subjects, or any successor application or
procedure and (ii) any counterpart of a U.S. Investigational New Drug Application in any other country in the Territory; and (b) all supplements and amendments that may be filed with respect to the foregoing. 

“Information” means tangible or intangible know-how, trade secrets, inventions (i.e., conceived or reduced to practice,
constructively or actually), methods, knowledge, conclusions, skill, experience, test data and results (including chemical, biological, biochemical, pharmaceutical, pharmacological, toxicological and research, pre-clinical and clinical data, assay,
control and manufacturing processes, test data and results), analytical and quality control methods and data, results or descriptions, software and algorithms or other information (whether or not patentable) regarding technology, techniques,
practices, products, business information or objectives. 
 “Joint Commercialisation Committee” means the
committee formed pursuant to Article 5.4. 
 “Joint Development Committee” means the committee formed
pursuant to Article 3.7.2. 
 “Joint Know-How” means all Information or Materials that are conceived or
developed [*] after [*] and, in each case, [*] of [*]. 
 “Joint Patent Rights” means Patent Rights in any
country within the Territory which claim [*] Know-How and which identify [*] as inventors. 
 “Joint Research
Committee” means the committee formed pursuant to Article 3.7.1. 
 “Late Stage Development” means
Development following completion of Phase II Studies up to and including filing of a Drug Approval Application for an Antibody Product in any jurisdiction and including any supplementary Development necessary or required by a Regulatory Authority
(a) in order to obtain a Regulatory Approval; or (b) as required as a condition or maintenance, as the case may be, of a Regulatory Approval; in each case necessary for the commercial sale and/or use of an Antibody Product in
that jurisdiction. 

  
 10









 “Lead Territory” means Amgen Territory and/or Celltech Territory as the
case may be. 
 “Licence Agreement” means that certain agreement attached hereto as Schedule G. 

“Licence Fees” shall have the meaning set forth in Schedule B. 

“Marketing Clinical Studies” means, in any jurisdiction, those clinical studies following Early Stage Development of an
Antibody Product, including pharmacoeconomic studies, pharmacoepidemiology studies, investigator-sponsored clinical studies, Phase IIIB, Phase IV and other such studies useful for the Commercialisation of an Antibody Product, including those studies
required to expand the label of an Antibody Product in the approved indication, but excluding those studies undertaken as part of Late Stage Development of an Antibody Product. 

“Materials” means biological and chemical materials including, Antibodies, Antibody Products, screens, animal models,
cell lines, cells, vectors, nucleic acids, receptors and reagents. 
 “Net Sales” shall have the meaning set
forth in Schedule D. 
 “Osteoporosis Indication” means the [*]. 

“Other Expense” shall have the meaning set forth in Schedule B. 

“Other Indications” means all uses of Antibody Products in the Field other than in the Osteoporosis Indication.

 “Party” means Amgen or Celltech; “Parties” means Amgen and Celltech. 

“Patent Rights” means all (a) existing issued, unexpired patents (with the term “patent” being deemed to
encompass an inventor’s certificate), including any reissue, re-examination, renewal or extension (including any supplementary protection certificate) of any such patent, and any confirmation patent or registration patent or patent of addition
based on any such patent and (b) existing patent applications and patent applications hereafter filed, including any continuations, 

  
 11









 
continuations-in-part, divisionals, provisionals, converted provisional, continued prosecution application, or any substitute applications, any patent issued with respect to any such patent
applications, any reissue, re-examination, renewal or extension (including any supplementary protection certificate) of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent; and all
foreign counterparts of any of the foregoing. 
 “[*] Antibody” means an Antibody which is [*] of any
[*] and claimed by any of the [*] Patent Rights. 
 “Phase II Study” means a clinical trial that is designed to
establish the safety and preliminary efficacy of a drug for its intended use, and to define warnings, precautions and adverse reactions that are associated with the drug in the dosage range to be prescribed and that satisfy the requirements of 21
CFR 312.21(b) (or its successor regulation), or its equivalent in any other jurisdiction. 
 “Pivotal Study”
means a clinical trial that, if the defined end-points are met, is designed (and agreed to in advance by a Regulatory Authority(ies) having jurisdiction in the country(ies) in which the trial is to be conducted, based upon existing data in the same
patient population as of the start of such clinical trial) to definitively establish that an Antibody Product drug is safe and efficacious for its intended use, and to define warnings, precautions and adverse reactions that are associated with the
Antibody Product in the dosage range to be prescribed, and provide pivotal data supporting Regulatory Approval of such Antibody Product and that satisfies the requirements of 21 CFR 321.21(c) (or its successor regulation), or its equivalent in any
other jurisdiction. 
 “Position of Detail” means a Primary Detail, a Secondary Detail or a Tertiary Detail as
the case may be. 
 “Primary Detail” means a Detail in which the predominant portion of time or emphasis is
devoted to the Detailing of Antibody Product, and the Antibody Product is the first product presentation made. 

“Product Contribution” shall have the meaning set forth in Schedule B. 

  
 12









 “Product Labelling” means (a) the Regulatory Authority-approved full
prescribing information for an Antibody Product, including any required patient information and (b) all labels and other written, printed or graphic matter upon any container, wrapper or any package insert or outsert utilised with or for an
Antibody Product. 
 “Product Trademark” means any trademarks and trade names (and trademark applications
(whether or not registered), and any renewals, extensions or modifications thereto in the Territory) together with all goodwill associated therewith, trade dress and packaging which (a) are Controlled by either Party and (b) are applied to
an Antibody Product or any Promotional Materials and (c) distinguishes that Antibody Product; but excluding any house marks or house dress or any reserve trademarks and trade names (and trademark applications and any resulting trademarks) which
are Controlled by a Party and are filed with a trademark office for use with an Antibody Product but which shall not have been applied to an Antibody Product. 
 “Promote” or “Promotion” or “Promoting” or “Promotional” means, with respect to an Antibody Product, those activities and obligations other than Detailing
undertaken by a Party to encourage sales of such Antibody Product including, journal advertising, direct mail programs, direct-to-consumer advertising, education, convention exhibits, and other forms of advertising and promotion. 

“Promotional Materials” means all sales representative training materials and all written, printed, graphic, electronic,
audio or video matter including, journal advertisements, sales visual aids, direct mail, direct-to-consumer advertising, Internet postings, product inserts, broadcast advertisements, and sales reminder aids (e.g., scratch pads, pens and other such
items) intended for use or used by a Party in connection with any Promotion or Detailing of an Antibody Product, except Product Labelling. 
 “Regulatory Approval” means any and all approvals (including any applicable supplements, amendments, pre- and
post-approvals, governmental price and reimbursement approvals and approvals of applications for regulatory exclusivity), licences, registrations, or authorisations of any federal, national, multinational,
state, provincial or local regulatory agency, department, bureau, commission, council or other governmental entity necessary for the manufacture, distribution, use, storage, import, export, transport, Promotion, marketing and sale of an Antibody
Product in a country or jurisdiction. 

  
 13









 “Regulatory Authority” means any governmental or regulatory authority
involved in granting Regulatory Approvals of any Antibody Product including, in the United States, the FDA. 

“Regulatory Filings” means, collectively, INDs, Drug Approval Applications, establishment licence applications
(“ELAs”) and drug master files (“DMFs”) or any other similar filings (including any equivalents in other jurisdictions and further including any related correspondence and discussions) and applications for
regulatory exclusivity, and all data contained therein, as may be required by the FDA or equivalent Regulatory Authorities in other jurisdictions, for the Development or Commercialisation of an Antibody Product. 

“Representative” shall have the meaning set forth in Schedule B. 

“Research” means all research and pre-clinical activities up to and including the filing of any IND for an Antibody
Product. When used as a verb “Research” means to engage in Research, and “Researched” and “Researching” shall have a corresponding meaning. 

“Research and Development Cost” means for all activities performed following the Effective Date for the Research and
Development of Antibody Products (a) all out-of-pocket costs and expenses incurred on an arm’s-length basis (calculated in accordance with GAAP) and paid to Third Party subcontractors (or accrued therefor) by Amgen or Celltech or their
Affiliates, (b) the FTE Cost of such activities, and (c) the cost of Materials used in such activities. For the avoidance of doubt, Research and Development Costs excludes [*] made by [*] to [*] pursuant to [*]. 

“Research Plan” means the plan of Research activities to be performed by the Parties and attached hereto as Schedule A,
and as may be modified from time to time pursuant to Article 3.7.1(c). 
 “Secondary Detail” means a Detail in
which the second-most predominant portion of time or emphasis is devoted to the Detailing of Antibody Product, it being understood that, in most but not all Secondary Details, Antibody Product shall be the second product presentation made.


  
 14









 “Term” means the term of this Agreement as set forth in Article 14.1. 

“Territorial Commercial Lead” means, with respect to a particular country, the Party designated pursuant to Article 5.1
to lead Commercialisation of Antibody Products in such country. 
 “Territory” means all the countries of the
world. 
 “Tertiary Detail” means a Detail in which Antibody Product is included in the Detail, with lesser prominence than a
Secondary Detail but more prominence than mere inclusion in a product list. 
 “Third Party” means any person,
partnership, joint venture, corporation, trust, estate, unincorporated organisation, government or any department or agency thereof, or any entity other than a Party or any of its Affiliates. 

“Trademark” means any and all corporate names, service marks, logos or trademarks and trademark applications (whether or
not registered) together with all good will associated therewith, and any renewals, extensions or modifications thereto either filed or used. 
 “Wind Down Costs” means all reasonable out-of-pocket costs incurred by either Party in terminating or transferring to the other Party (or its nominee) Research, Development or
Commercialisation activities (including the termination or assignment of relevant related contracts and Materials) as set forth in Article 14.9, following the service of a notice of termination of this Agreement to the extent such activities,
contracts and Materials have been approved by the Collaboration Committee and are not accounted for in Commercialisation Expense or Research or Development Cost. 
 Each of the following definitions are found in the body of this Agreement as indicated: 
  

			
	Defined Terms	  	Page/Article
	“Acquiring Party”	  	Article 17.1
	“Amgen Indemnitees”	  	Article 18.2
	“Amgen Loss(es)”	  	Article 18.2


  
 15










			
	Defined Terms	  	Page/Article
	“Amgen”	  	Pg. 1, paragraph 2
	“Auditing Party”	  	Article 8.5
	“Balance Payment”	  	Article 8.3(b)
	“BLA”	  	Article 1, def. “Drug Approval Application”
	“Celltech Indemnitees”	  	Article 18.1
	“Celltech Loss(es)”	  	Article 18.1
	“Celltech”	  	Pg. 1, paragraph 3
	“[*]”	  	Article 5.7(i)
	“Co-Detailer”	  	Article 5.2(a)
	“Consultation Rights”	  	Article 11.2.2(b)
	“Continuing Party”	  	Article 14.8(a)
	“Country Plan”	  	Article 5.9
	“Defaulting Party”	  	Article 14.4(a)
	“DMFs”	  	Article 1, def. “Regulatory Filings”
	“Effective Date”	  	Pg. 1, paragraph 1
	“ELAs”	  	Article 1, def. “Regulatory Filings”
	“Excepted Matters”	  	Article 3.7.1(e)
	“[*]”	  	Article 15.1
	“Filing Notice”	  	Article 5.2(b)
	“First Contract Year”	  	Article 1, def. “Contract Year”
	“include” or “includes” or “including”	  	Article 19.12
	“intellectual property”	  	Article 14.5
	“Indemnify”	  	Article 18.1
	“Insolvency Event”	  	Article 14.5(b)
	“Joint Activities”	  	Article 5.5(a)(iii)
	“Joint Loss(es)”	  	Article 18.3
	“Late Stage Development Plan”	  	Article 3.4(a)
	“Manufacturing Lead”	  	Article 6.1(a)
	“[*] Patent Rights”	  	Article 11.2.2(a)


  
 16










			
	Defined Terms	  	Page/Article
	“[*] Patent Rights”	  	Article 11.2.2(a)
	“Milestone Event”	  	Article 7.2
	“Milestone Payment(s)”	  	Article 7.2
	“non-Acquired Party”	  	Article 17.1
	“Non-Defaulting Party”	  	Article 14.4(a)
	“Notice of Default”	  	Article 14.4(a)
	“[*]”	  	Article 15.1
	“opt-out right”	  	Article 3.4(a)
	“Performance Default”	  	Article 14.4(a)
	“Quality Responsibilities”	  	Article 6.8
	“Recall”	  	Article 4.8(a)
	“Representation Default”	  	Article 14.4(a)
	“SOPs”	  	Article 4.8(a)
	“Subsequent Products”	  	Article 3.4(a)
	“Supply Agreements”	  	Article 6.1(a)(ii)
	“Termination Date”	  	Article 14.8(b)
	“Third Party Licence Agreement”	  	Article 11.9
	“Transition Date”	  	Article 11.2.9
	“Transition Plan”	  	Article 14.9(b)(iii)


  
 17









 ARTICLE 2 
 SCOPE OF RELATIONSHIP 
  

	2.1	 Exclusive Collaboration.  The Parties agree to collaborate exclusively in the Research, Development and Commercialisation of
Antibody Products in the Field in accordance with the terms of this Agreement and, other than as explicitly permitted under this Agreement, not to undertake or enable any Third Party to undertake any activities for Antibody Products without the
other Party’s prior written consent (which may be withheld for any reason), including to undertake or enable any Third Party to undertake any activities for Antibody Products for any use outside of the Field (including [*]).



  

	2.2	 Provision of Assistance.  Each Party shall co-operate reasonably with the other Party to facilitate the Research, Development and
Commercialisation of Antibody Products in the Field. In addition to other assistance explicitly set forth in this Agreement, during the Term Amgen shall provide Celltech with reasonable technical assistance relating to the use of [*] Know-How, [*]
Know-How and [*] Know-How and Celltech shall provide Amgen with reasonable technical assistance relating to the use of [*] Know-How, [*] Know-How and [*] Know-How, each solely to the extent licensed to the other Party in this Agreement. In addition,
during the Term each Party shall make its employees, consultants and agents reasonably available upon reasonable notice during normal business hours at their respective places of employment to consult with the other Party on issues relating to this
Agreement or any request from any Regulatory Authority concerning an Antibody Product, including requests relating to regulatory, scientific and technical issues. Each Party shall also keep the Joint Research Committee, Joint Development Committee,
Joint Commercialisation Committee and Collaboration Committee, as appropriate, informed as to its progress in the Research, Development and Commercialisation of Antibody Products. A Party shall not be in breach of any obligation under this Agreement
to the extent its inability to perform such obligation is caused by the other Party’s failure to perform any of its obligations under this Agreement. 



  
 18










	2.3	 Decision Making and Obligations.  Control of a final decision-making authority for any aspect of the Research, Development and/or
Commercialisation as set forth in this Agreement shall not relieve the Party with such control from any of its obligations under this Agreement. 


  

	2.4	 Transfer of Materials.  The Parties anticipate that each Party may transfer certain of its Materials to the other Party. Each Party
agrees that it will use such Materials of the other Party only in accordance with the terms and conditions of, and solely for the purposes of the activities conducted pursuant to, this Agreement, and will not transfer such Materials of the other
Party to any Third Party without the consent of the other Party, except as expressly permitted under this Agreement. 


  

	2.5	 Third Party Research Agreements.  The Parties shall, through the Collaboration Committee or its designees, agree upon and
co-ordinate Material transfer agreements and collaboration agreements with Third Parties (excluding Third Party subcontractors) to the extent such agreements relate to the Research or Development of Antibody Products or BEER or involve the use of
Antibody Products or BEER, in a manner so as to conserve the available quantities of the Parties’ Materials and to avoid compromise of the Parties’ abilities to fulfil their obligations and responsibilities under this Agreement, and with a
view toward maintaining access to relevant intellectual property rights. Notwithstanding the above, other than with respect to Antibody Products, neither Party may transfer the other Party’s Materials to any such Third Parties, without the
express written consent of the other Party. 


  

	2.6	 Employee Obligations.  Prior to beginning work relating to any aspect of the subject matter of this Agreement and/or being given
access to the [*] Technology or [*] Technology, each employee, consultant or agent of Celltech and Amgen shall be bound by an employment agreement or other agreement pursuant to which (a) each such person (other than administrative and/or
non-technical personnel) shall (but in the case of a Party’s own Technology, only to the extent such Party’s employees consultants or agents are conducting activities pursuant to this Agreement) be obliged to comply with all of the
obligations of Celltech or Amgen under this Agreement, as appropriate, including: 



  
 19










	 	 
(i) following Celltech’s or Amgen’s (as appropriate) policies and procedures regarding reporting any invention, discovery, process, software program or other intellectual
property right created by such person in the course of his or her employment or retainer with Celltech or Amgen, as appropriate, within [*] Technology or [*] Technology; (ii) assigning to Celltech or Amgen, as appropriate, all of his or her
right, title and interest in and to any such invention, discovery, process, software program or other intellectual property right; (iii) co-operating in the preparation, filing, prosecution, maintenance and enforcement of any Patent Rights
covering the same; and (iv) performing all acts and signing, executing, acknowledging and delivering any and all papers, documents and instruments required for effecting the obligations and purposes of this Agreement and (b) each person
shall be bound by obligations of confidentiality and non-use consistent with the terms of this Agreement. It is understood and agreed that any such agreement need not be specific to this Agreement. 



 

	2.7	 No Parking.  Each Party acknowledges that using Commercially Reasonable Efforts requires it to take ongoing actions that are
consistent with a good faith intention to achieve the objective of Developing an Antibody Product and obtaining Regulatory Approvals to Commercialise such Antibody Product for the [*] (or if the [*] is dropped in accordance with the terms of this
Agreement an [*] chosen in accordance with the terms of this Agreement) in the Field, and to Commercialise such Antibody Product, throughout the Amgen Territory and Celltech Territory. For the avoidance of doubt, Development and Commercialisation in
each instance includes the manufacture and the supply of Antibody Product. If a Party decides that deployment of Commercially Reasonable Efforts does not justify it making continued, ongoing efforts towards this objective it shall promptly notify
the other Party in writing. 



  
 20









 ARTICLE 3 
 RESEARCH AND DEVELOPMENT OF 
 ANTIBODY PRODUCTS 

 

	3.1	 Collaboration Regarding Research and Development. 



 

	3.1.1	 From and after the Effective Date: 


  

	 	(a)	 the Parties shall use diligent and timely efforts to satisfactorily complete Research of the Antibody Products and obtain in one of the [*] for an
Antibody Product an IND in the [*] or, if agreed by the Joint Research Committee pursuant to Article 3.7.1(e), an [*]; 


  

	 	(b)	 In addition to its Development supply obligations as set out in Article 6, Celltech shall use Commercially Reasonable Efforts:



  

	 	(i)	 to satisfactorily complete, in respect of an Antibody Product, those Development activities assigned to it pursuant to Article 3.2.2(b) and Article
3.2.2(c); and 


  
  

	 	(ii)	 following delivery by Amgen to Celltech of a filed data package pursuant to Article 4.1(d), to obtain Regulatory Approval to Commercialise an
Antibody Product supported by, in the indication supported by, such data package, in the Field throughout the Celltech Territory. 


  

	 	(c)	 Amgen shall: 


  

	 	(i)	 use Commercially Reasonable Efforts to satisfactorily complete all Development activities with respect to an Antibody Product (other than those
Development activities assigned to Celltech pursuant to Article 3.2.2(b) and Article 3.2.2(c)); and 


  

	 	(ii)	 use Commercially Reasonable Efforts to obtain Regulatory Approval to Commercialise an Antibody Product; 



  
 21









 in each case for the [*] (or if the [*] is dropped in accordance with the
terms of this Agreement an [*] chosen in accordance with the terms of this Agreement) in the Field throughout the Amgen Territory. 
  

	 	(d)	 Each Party acknowledges that the obligations it undertakes pursuant to this Article 3.1.1 are material obligations. 



 

	3.1.2	 Each Party agrees to conduct its Research activities and Development activities in compliance with all laws, regulations and guidelines that are
applicable to the particular stage of Research or Development for the Antibody Product, including, GLP, GCP and GMP, of the relevant jurisdiction as the same may be amended from time to time. 



 

	3.1.3	 Neither Party will approve, oppose or take any action under this Agreement which is contrary to its preliminary or final conclusions that the safety
or toxicity of an Antibody Product then being considered for Development or being Developed pursuant to this Agreement would pose a [*] that is [*] to patients. 



 
  

	3.1.4	 Notwithstanding any other term of this Agreement, [*] shall not, except with the written consent of [*], have an Antibody Product in Late Stage
Development in more than one [*] unless (i) Regulatory Approval for the Commercialisation of an Antibody Product has been obtained in any of the [*] or (ii) such additional [*] was included in the first [*] for such Antibody Product
presented to [*] pursuant to Article [*]. 



  
 22










	3.2	 Activities.  Without limiting the obligations of Article 3.1 the Parties shall undertake the Research and Development activities as
follows: 


  

	3.2.1	 Research 


  

	 	(a)	 The Parties shall conduct all activities for the Research of Antibody Products in accordance with the Research Plan, a copy of which is attached as
Schedule A, as may be amended from time to time by the Joint Research Committee, with the Research objective of filing an IND and initiating clinical studies for at least one Antibody Product. 



 

	 	(b)	 As part of the Research, Celltech shall use diligent and timely efforts to: 



 

	 	(i)	 supply Amgen with [*] Antibody in amounts in line with the Research Plan as of the Effective Date and such additional amounts as may be reasonably
requested by Amgen (which request will recognize timing constraints for supply imposed by Celltech’s existing capacity to provide), and in each case to specifications and timing agreed by the Joint Research Committee, for use by Amgen in [*]
studies; 


  

	 	(ii)	 supply Amgen with such quantities of [*] as requested by Amgen and as Celltech shall have the existing capacity to provide, and to specifications
and timing agreed by the Joint Research Committee, for use by Amgen in [*] studies; and 


  

	 	(iii)	 provide Amgen with any Information [*] which [*] reasonably considers to be [*] to the [*] safety and/or toxicity of Antibody Products (being
considered for Development or being Developed). 


  

	 	(c)	 As part of the Research, Amgen shall use diligent and timely efforts to: 



 

	 	(i)	 conduct [*] studies required to select an Antibody Product clinical candidate and file an IND therefor in one of the [*]. For the avoidance of
doubt, nothing in this Agreement shall preclude Amgen from filing INDs in such other countries as it sees fit; 


  

	 	(ii)	 conduct studies to identify, test and select [*] and, if applicable, [*] for use in the Development of Antibody Products; and



  

	 	(iii)	 provide [*] with any [*] arising from the studies referred to in (i) and (ii), and with any [*] which [*] reasonably considers to be [*] to the
[*] safety and/or toxicity of Antibody Products (being considered for Development or being Developed). 



  
 23










	 	(d)	 If (i) Celltech has not achieved Milestone 1 as set out in Schedule A by the [*] of the [*]; or (ii) if Celltech achieves [*] but
subsequently fails to achieve Milestone 3 as set out in Schedule A within [*] of Amgen notifying Celltech in writing (pursuant to Article 3.2.1(g) below) of [*] Antibody as determined by the [*] study results; the Parties (upon the written request
of [*]) shall for a period of [*] of [*] with respect to unachieved Milestone 1 or unachieved Milestone 3 (as applicable) discuss the possibility of extending such time period for an additional, mutually agreed period. Each Party acknowledges that
it shall be [*] as to whether or not to agree to such an extension of any such time period. 


  

	 	(e)	 Within [*] of expiry of each date referred to in Article 3.2.1(d) or any extension to such dates agreed to by the Parties, Amgen shall notify
Celltech in writing that Amgen will either: 


  

	 	(i)	 assume the right and obligation to Research, Develop, and supply either itself or through agreement with a Third Party the [*] referred to in
Milestone 1 and/or (as appropriate) the [*] referred to above in Article 3.2.1(d); or 


  

	 	(ii)	 terminate this Agreement. 


 If Amgen does not serve such a notice it will be deemed to have exercised the option set out in Article 3.2.1(e)(i). 

  
 24










	 	(f)	 Where Amgen has exercised the option set out in Article 3.2.1(e)(i) the following shall apply and this Agreement shall be deemed to be amended as
follows: 


  

	 	(i)	 all Research and Development Costs incurred by either Party after the exercise of such option shall be shared equally by the Parties;



  

	 	(ii)	 Amgen shall have no obligation to pay any Milestone Payments pursuant to Article 7.2 not already paid or due to be paid at the time that Amgen
exercises such option; 


  

	 	(iii)	 Amgen shall cease to have any rights to use or exploit any of the [*] Patent Rights and any other [*] Technology that [*] to any invention claimed
by any of the [*] Patent Rights, and Celltech shall cease to have any obligation to provide Amgen with any Information concerning the [*] Patent Rights, or to provide Amgen with assistance or guidance in using or understanding the [*] Technology
covered by the same, but without prejudice to the rights [*] has to other [*] Technology as granted hereunder; 


  

	 	(iv)	 Celltech’s obligations to conduct Research activities shall terminate save for those under Articles 3.2.1(b)(ii) and (iii) and its
obligations with respect to the manufacture and supply of Antibody Raw Material (including those pursuant to Articles 3.2.2(c) and Article 6) shall terminate and Amgen shall assume all such responsibilities; and 



 

	 	(v)	 Amgen’s Research obligations shall, for a period not to exceed [*] from the date Amgen exercised the option pursuant to Article 3.2.1(e), be
amended by the substitution of “Commercially Reasonable Efforts” for “diligent and timely efforts” wherever it appears. Celltech shall provide Amgen with reasonable co-operation in connection with its Research activities. If
Amgen has not commenced [*] on an Antibody Product clinical candidate within [*] of exercise of the option referred to in Article 3.2.1(e)(i), this Agreement shall terminate automatically and without notice. If Amgen has commenced such [*] before
such date, from the commencement of such [*] Amgen shall again be obliged to use diligent 



  
 25










	 	 
and timely efforts where it was previously obliged to use diligent and timely efforts. Save for the change in the level of effort required by Amgen during such period, Amgen’s Research and
Development obligations as set out in this Agreement shall continue to apply; 


 provided
however if at that time the Parties mutually agree in writing to develop an Antibody Product claimed by any of [*] Patent Rights the provisions of Articles 3.2.1(f)(i) through (v) shall not apply and this Agreement shall remain in force
unamended. 
  

	 	(g)	 Amgen shall provide the Joint Research Committee with the results of the [*] studies conducted as set out in the Research Plan, within [*] of
completion of those studies. The Joint Research Committee shall determine the characteristics required of the [*] for Milestone 3 within [*] of its receipt of the results of the [*] studies and Amgen shall promptly notify Celltech in writing of such
characteristics. Should the Joint Research Committee subsequently decide to change such characteristics, Amgen shall notify Celltech of such change within [*] of the Joint Research Committee decision and the [*] referred to in Article 3.2.1(d) (with
respect to the achievement of Milestone 3) shall commence on the date of Celltech’s receipt of such subsequent notice. 


  

	3.2.2	 Development 


  

	 	(a)	 Other than as specifically set forth in this Article 3.2.2 and Article 6, Amgen shall be responsible for all activities of Development of Antibody
Products, and shall have the right to make all strategic and tactical decisions with respect to the Development of Antibody Products subject always to its obligations under this Agreement. Amgen shall be responsible for all Development tasks (other
than those which Celltech undertakes pursuant to Article 3.2.2(b) or Celltech is responsible for pursuant to Article 3.2.2(c) and Article 6, below), including: 



 

	 	(i)	 determining in which [*] to conduct clinical studies provided that Amgen may not select an [*] in substitution of the [*] except in
accordance with Article 3.2.2(e); 



  
 26










	 	(ii)	 submitting all necessary Regulatory Filings for initiation of clinical studies; 



 

	 	(iii)	 identifying key Development objectives, expected associated resources, risk factors, timelines, Go/No Go decision points and relevant decision
criteria; 


  

	 	(iv)	 forecasting clinical manufacturing production requirements; 



 

	 	(v)	 carrying out all aspects of (e.g., designing studies and protocols for and conducting) clinical studies (but excluding [*]), as well as establishing
new dosage forms, new formulations or other enhancements of approved Antibody Products including (1) establishing/contracting with clinical sites, investigators and CROs; (2) enrolling clinical study patients; (3) organising
investigator meetings, scientific meetings, advisory panel workshops and regulatory meetings; and (4) analysing, summarising clinical study results; 



 

	 	(vi)	 performing any other additional pre-clinical research in support of the clinical development of Antibody Products; 



 

	 	(vii)	 subject to Article 4, reporting to Regulatory Authorities on study design, study outcome, other regulatory communications and filings; and



  

	 	(viii)	 maintaining a database of clinical trial data accumulated from clinical studies of all Antibody Products, all safety data, and any adverse reaction
information acquired for all Antibody Products during Development or Commercialisation. 



  
 27










	 	(b)	 With respect to any Antibody Product and indication which is in [*], Celltech may undertake supplemental [*] activities for that indication in the
Celltech Territory where it reasonably considers that such studies are [*] in order to obtain any Regulatory Approvals within the Celltech Territory. Such studies shall be carried out in a manner consistent with the objectives of [*] for that
indication as determined by the Joint Development Committee (which objectives shall recognise Celltech’s right to conduct such studies). 


  

	 	(c)	 Celltech shall be responsible for providing Amgen with guidance and Information Controlled by Celltech and obtained from Celltech’s experience
in the development of [*], including pre-clinical and clinical safety data and other information Controlled by Celltech, in each case to the extent Celltech in good faith considers the same to be [*] to the Development of Antibody Products.



  

	 	(d)	 Each Party shall conduct its Development responsibilities regarding Antibody Product(s) pursuant to this Article 3.2.2 in a manner consistent with
its obligations under Article 3.1. 


  

	 	(e)	 Should Amgen reasonably determine that it no longer wishes to continue to pursue Research or Development activities of an Antibody Product for the
[*] and that it wishes instead to Develop Antibody Product for an [*] it shall promptly notify the Joint Research Committee (if the Antibody Product is still the subject of Research activities); or the Joint Development Committee if the Antibody
Product has ceased to be in Research and is the subject of Development activities. Such notice shall set out Amgen’s reasons in detail, and include reasonable supporting evidence. If Celltech disputes that the [*] should be dropped, or disputes
the choice of an [*] and suggests a different [*] it shall notify the relevant Committee in writing setting out its reasons in detail, and including reasonable supporting evidence. If the Joint Research Committee or Joint Development Committee (as
appropriate) cannot agree (and [*] has [*]) the decision as to whether the [*] should be dropped and an [*] substituted in its 



  
 28










	 	 
place shall be escalated for consideration by the Collaboration Committee. Within the Collaboration Committee, in the case of a dispute arising out of the Research Committee, [*] shall have [*]
and, in the case of a dispute arising out of the Development Committee, [*] shall have [*] on this issue. If, following such consideration the relevant Committee determines that the [*] shall be dropped and an [*] substituted in its place then such
[*] shall be substituted for the [*] for the purposes of this Agreement. Neither Party shall unreasonably withhold or delay its consent to any [*] proposed by a Party pursuant to this Article. Each Party shall, if requested to do so, provide written
reasons to the relevant Committee supporting its choice of an [*], or its rejection of the same. 


  

	3.3	 Sharing of Information. 


  

	3.3.1	 Without prejudice to its other obligations, each Party shall disclose to the other Party all Information Controlled by it and which it reasonably
considers to be [*] to any Antibody Product as soon as practicable after it is [*] or its [*] is [*]. The Parties shall [*] in the data dossiers used to support applications for Regulatory Approvals and in the database referred to in Article
3.2.2(a)(viii). 


  

	3.3.2	 In addition to being informed of the progress of the Research and Development via the Joint Research Committee (pursuant to Article 3.7.1) and the
Joint Development Committee (pursuant to Article 3.7.2), each Party shall have the right to obtain through the Joint Research Committee or Joint Development Committee (as appropriate), copies of final reports and a reasonable number of interim
reports (in existence) of any studies carried out pursuant to Research and Development conducted under this Agreement and the Joint Research Committee and Joint Development Committee shall have no right to refuse any such request. If, after
receiving any such report (or in the event no such report exists), a Party reasonably requires additional Information generated during Research and Development by either Party from pre-clinical studies and clinical trials of each Antibody Product,
to exercise its rights or fulfil its obligations under this Agreement the other Party shall in response to a request, use Commercially Reasonable Efforts to provide such 



  
 29










	 	 
additional Information but only to the extent such additional Information is Controlled by it. The Party requesting such Information shall, if the Information provided by the other Party is
incomplete, have the right to access such Information during regular business hours and on reasonable notice. 


  

	3.3.3	 Each Party shall provide reasonable assistance to the other Party in understanding the data dossiers, database and reports referred to in this
Article 3.3, provided that such Party shall use such data, dossiers, databases and reports only for the purpose of exercising its rights or fulfilling its obligations under this Agreement. 



 
  

	3.3.4	 Notwithstanding the obligations in this Agreement to provide Information, co-operation and assistance, [*] shall not be obliged to provide to [*]
any of the same in relation to the [*] Patent Rights or any invention claimed by any of the [*] Patent Rights or any [*] Technology specific to any such inventions, except in compliance with its obligations under Article 6.7.



  

	3.4	 Celltech Opt-Out Right. 


  

	 	(a)	 Celltech shall have the option (the “opt out right”) to terminate this Agreement with respect to any Antibody Product which
proceeds to Late Stage Development (as well as all other Antibody Products (“Subsequent Products”) excluding any Antibody Product which has previously been subject to the procedure under this Article 3.4 and for which Celltech shall
have previously elected in accordance with this Article 3.4 to remain subject to the terms of this Agreement), as set out in this Article 3.4. Celltech may exercise such opt-out right by providing written notice to Amgen at any time within [*] of
Celltech’s receipt from Amgen of (i) a detailed report of the results of the Phase II Studies of such Antibody Product; (ii) Amgen’s proposed plan for Late Stage Development (“Late Stage Development Plan”) for such
Antibody Product together with Amgen’s confirmation of its intention to proceed with such plan if Celltech were not to exercise its opt-out right; (iii) Amgen’s good-faith estimate of the Research and Development Costs




  
 30










	 	 
of such Late Stage Development Plan and (iv) if the [*] has been dropped in accordance with Article 3.2.2(e) the Late Stage Development Plan will identify any intention Amgen has to develop
the [*]. For the avoidance of doubt, with respect to any such intention set forth in such Late Stage Development Plan, other than as set forth in a revised Late Stage Development Plan provided pursuant to Article 3.4(b) below, Amgen shall not be
obliged to inform Celltech of any change to Amgen’s intention after providing such Late Stage Development Plan pursuant to this Article 3.4(a). The report, plan and estimate provided to Celltech pursuant to this Article shall be the same
standard, quality and completeness as those utilised by Amgen in its internal deliberations and decision making concerning whether to proceed with Development of such Antibody Product. 



 

	 	(b)	 If at any stage during the conduct of activities pursuant to a Late Stage Development Plan, but prior to obtaining the first Regulatory Approvals to
Commercialise such Antibody Product in the Amgen Territory, 


  

	 	(i)	 the Joint Development Committee has decided (in accordance with the terms of this Agreement) to drop the indication set out in the Late Stage
Development Plan and has selected a new indication (subject to Article 3.2.2(e) where the initial indication is the [*]); and 


  

	 	(ii)	 Amgen decides to advance such Antibody Product into Late Stage Development for such new indication; and 



 

	 	(iii)	 the cost of Late Stage Development of such Antibody Product is expected to exceed the good-faith estimate of Research and Development Costs received
by Celltech pursuant to Article 3.4(a) by [*] ([*]%) or more; then 


 Amgen shall provide
Celltech with written notice that it wishes to perform Late Stage Development activities pursuant to a revised Late Stage Development Plan. With such notice Amgen shall provide Celltech with: 

 

	 	(iv)	 a detailed report of the results of the studies undertaken in Late Stage Development completed at the time of such notice together with preliminary
results of any other such studies that are still in progress and for which interim or final results are available; 



  
 31










	 	(v)	 Amgen’s proposed revised Late Stage Development Plan for such Antibody Product; 



 

	 	(vi)	 Amgen’s good faith estimate of the Research and Development Costs of such revised Late Stage Development Plan; and



  

	 	(vii)	 the revised Late Stage Development Plan will identify any intention Amgen has to develop the [*] (For the avoidance of doubt, with respect to any
such intention set forth in such revised Late Stage Development Plan Amgen shall not be obliged to inform Celltech of any change to Amgen’s intention after providing such revised Late Stage Development Plan pursuant to this Article 3.4(b)).



 The report, plan and estimate provided to Celltech pursuant to this Article shall be the
same standard, quality and completeness as those utilised by Amgen in its internal deliberations and decision making concerning whether to proceed with the Development of such Antibody Product in the new indication. Within [*] of receiving such
notice, Celltech may again exercise its opt out right with respect to such Antibody Product by written notice to Amgen. 
  

	 	(c)	 At the date Celltech provides its written notice to Amgen that it is exercising its opt-out right pursuant to Articles 3.4(a) or 3.4(b), as
appropriate, Celltech shall provide Amgen with a document signed by an authorized officer of Celltech on its behalf either indicating in such document that (i) the written representations and warranties of Celltech set out in Articles 16.1,
16.2 and 16.3 are true and correct as if made as of the date of such document and as if referring to the Licence Agreement and not this Agreement or (ii) such written representations and warranties of Celltech are not true and correct and the
reasons why such 



  
 32










	 	 
representations and warranties are not true and correct; provided that failure to provide Information that is subject to a Third Party confidentiality obligation shall not make the
representation and warranty under Article 16.2(c) or 16.3(c) untrue or incorrect. 


  

	 	(d)	 Within [*] after receipt of Celltech’s written notice to Amgen under Article 3.4(c), Amgen shall provide Celltech with a document signed by an
authorized officer of Amgen on its behalf either indicating in such document that (i) the written representations and warranties of Amgen set out in Articles 16.1 and 16.2 are true and correct as if made as of the date of such document and as
if referring to the Licence Agreement and not this Agreement or (ii) such written representations and warranties of Amgen are not true and correct and the reasons why such representation and warranties are not true and correct; provided
that failure to provide Information that is subject to a Third Party confidentiality obligation shall not make the representation and warranty under Article 16.2(c) untrue or incorrect. 



 

	 	(e)	 If Celltech shall not have exercised its opt-out right under Articles 3.4(a) or 3.4(b) with respect to an Antibody Product, this Agreement shall
remain in full force and effect with respect to all Antibody Products. However, Celltech’s opt out right shall apply to any other Antibody Product that Amgen proposes to advance or advances to Late Stage Development, and Articles 3.4(a) and
(b) shall apply mutatis mutandis to all such Antibody Products. 


  

	 	(f)	 In the event Celltech shall exercise its opt-out right pursuant to Article 3.4(a) or (b) for any Antibody Product, the Licence Agreement shall
immediately come into full force and effect for such Antibody Product (as well as all Subsequent Products). This Agreement shall terminate in relation to such Antibody Product (as well as all Subsequent Products), but remain in full force and effect
with respect to any Antibody Product which has previously been subject to the procedures set out in Article 3.4(a) and which Celltech shall not have previously exercised its opt-out right. If Celltech exercises its opt-out right, Celltech shall have
no liability for any Research and Development Costs of Late Stage Development, whether or not incurred prior to expiry of the opt-out period. 



  
 33










	3.5	 Budgets.  The budgets for each Contract Year during Research and Development shall be specified by each Party and submitted to the
other Party (via the Joint Research Committee or Joint Development Committee, respectively) in a format to be agreed by the Parties but which must include line item estimates of Research and Development Costs by function. The budgets shall be
updated by the Joint Research Committee or Joint Development Committee (as appropriate) at least once annually on a timeline that meets the budget planning requirements of both Parties, but in no event less than [*] before the end of the preceding
Contract Year; provided however, it is acknowledged and agreed that such budgets may need to be modified from time-to-time between annual updates, based upon the results of clinical studies and other unanticipated events. In any Contract
Year, each Party shall promptly inform the other Party upon such Party determining that it is likely to exceed or underspend by more than [*] ([*]%) its respective total budget in that Contract Year. In addition, if in any Contract Year a Party
exceeds its budget by more than [*]%, the Party who has so exceeded its budget shall, at the request of the other Party, provide to the Joint Research Committee or Joint Development Committee (as appropriate) and to the Collaboration Committee (if
the matter is escalated to the Collaboration Committee) a full explanation for exceeding its budget (as requested). Each Committee may, [*], reduce the amount of any overspend to be included in the Research and Development Costs as it considers
equitable in the circumstances. If either the Joint Research Committee or Joint Development Committee do not [*] on how to deal with such overspend, the matter shall be escalated to the Collaboration Committee for consideration. The members of any
such Committee (as appropriate) may elect to reduce or not reduce such overspend [*], and unless the relevant Committee [*] to reduce the overspend, [*]. 



  
 34










	3.6	 Costs. Amgen and Celltech shall share all costs for the Research and Development of Antibody Products on the following basis:



  

	3.6.1	 Research Costs 


 Other than as provided below with respect to amounts paid to Third Parties, Celltech and Amgen shall each bear its own Research and Development Costs in carrying out its Research activities. The cost of
supplying Amgen with Antibodies for Research shall be considered as Research and Development Costs to be borne by Celltech. All out-of-pocket Research and Development Costs paid to Third Parties shall be paid to any such Third Parties by the Party
engaging the services of such Third Parties and, as between Amgen and Celltech, shall be shared on the basis of [*]:[*] Amgen: Celltech. Such Third Party costs shall include the cost of supply of GMP Antibody for Research by a Third Party on behalf
of Celltech as required by Amgen for the purposes of pre-clinical or formulation studies. 
  

	3.6.2	 Early Stage Development Costs 


 All Research and Development Costs cumulatively incurred (whether FTE Cost incurred directly by Amgen or Celltech or amounts payable to Third Parties engaged by Celltech or Amgen) for Early Stage
Development of Antibody Products shall be shared, as follows: 
  

	 	(a)	 up to [*] Dollars ($[*]) of such cumulative Research and Development Costs, on the basis of [*]:[*] Amgen:Celltech; 



 

	 	(b)	 over [*] Dollars ($[*]) of such cumulative Research and Development Costs on the basis of [*]:[*] Amgen:Celltech. 



For the avoidance of doubt, (i) any cost incurred for an Early Stage Development activity shall be a Research and
Development Cost of Early Stage Development, even if such activity occurs before the filing of an IND or after any Late Stage Development activity has commenced; and (ii) (without limiting the foregoing) the cost of manufacture of Antibody
Product required for the purposes of Early Stage Development shall be deemed Research and Development Costs of Early Stage Development even if such Antibody Product is manufactured before the filing of an IND. 

  
 35










	3.6.3	 Late Stage Development Costs 


 All Research and Development Costs cumulatively incurred (whether FTE Cost incurred directly by Amgen or Celltech or amounts payable to Third Parties engaged by Celltech or Amgen) for Late Stage
Development of Antibody Products shall be shared as follows: 
  

	 	(a)	 up to [*] Dollars ($[*]) of such cumulative Research and Development Costs, on the basis of [*]:[*] Amgen:Celltech; and



  

	 	(b)	 over [*] Dollars ($[*]) of such cumulative Research and Development Costs, on the basis of [*]:[*] Amgen:Celltech. 



The costs of manufacture, including scale-up and validation of Antibody Raw Material and Antibody Product in Finished
Form, shall be deemed Research and Development Costs of Late Stage Development to the extent only that Antibody Raw Material and Antibody Product in Finished Form so produced is not used for Commercialisation and otherwise shall be a Cost of Goods.

  

	3.6.4	 Quarterly Reconciliation of Research and Development Costs 



 

	 	(a)	 At least [*] prior to the end of each Calendar Quarter, each Party shall submit to the other Party: (i) a report of the actual Research and
Development Costs incurred by such Party in the first [*] of such quarter; and (ii) an estimate of Research and Development Costs to be incurred in the [*] of such quarter. 



 

	 	(b)	 Within [*] following the end of each Calendar Quarter, Amgen shall submit to Celltech a written report setting forth in reasonable detail (to the
extent made or incurred by Amgen) its Research and Development Costs for such quarter showing, on a line item basis, variances from the budget for that quarter, together with an estimate of Research and Development Costs for the remainder of that
Contract Year. 


  

	 	(c)	 Within [*] following the end of each Calendar Quarter, Celltech shall submit to Amgen a written report setting forth in reasonable detail (to the
extent made or incurred by Celltech) its Research and Development Costs for such quarter 



  
 36










	 	 
showing, on a line item basis, variances from the budget for that quarter, together with an estimate of Research and Development Costs for the remainder of that Contract Year.



  

	 	(d)	 Within [*] following the end of each Calendar Quarter, Amgen shall submit to Celltech a written consolidated report setting forth in reasonable
detail the calculation of all Research and Development Costs and the calculation of any net amount owed by Celltech to Amgen or by Amgen to Celltech, as the case may be, in order to ensure the appropriate sharing of Research and Development Costs in
accordance with the provisions of Article 3.6.1 or 3.6.2 or 3.6.3 as appropriate. The net amount payable shall be paid by Amgen or Celltech, as the case may be, within [*] after receipt of such written report. If the invoiced amount exceeds the
initial budget forecast for such quarter (as provided in Article 3.5) by more than [*] ([*]%), the paying Party may elect to carry the difference between the budgeted amount and the invoiced amount over to the next Calendar Quarter. The election to
carry the difference over must be provided within [*] after the date such above-referenced written report is provided by Amgen to Celltech. If, as a result of carrying over such difference to a subsequent quarter, the total amount payable in that
subsequent quarter exceeds the initial budget forecast for that quarter by more than [*] ([*]%), the difference between the budgeted amount and the invoiced amount (including the carryover from the previous quarter) may be carried over to the next
quarter. Such carry over may be continued quarter-by-quarter to the end of the Contract Year when it shall be paid in full within ten (10) Business Days of the receipt of the above-referenced report by Celltech from Amgen at the end of the
Contract Year. 


  

	3.6.5	 Pre-Launch Commercialisation Cost.  Each Party shall provide the Joint Development Committee with a good faith preliminary estimate
of its pre-launch Commercialisation Costs of an Antibody Product on or about the date Amgen provides written notice to Celltech that it intends to proceed with Late Stage Development activities with respect to such Antibody Product.




  
 37










	3.7	 Governance of Research and Development. 


  

	3.7.1	 Research 


  

	 	(a)	 Promptly after the Effective Date the Parties shall form a Joint Research Committee to co-ordinate the Research activities of the Parties. The Joint
Research Committee shall consist of equal numbers (not more than three) from each Party. Either Party may (with the consent of the other Party not to be unreasonably withheld or delayed) invite additional participants from either Party to provide
expert opinions for some or all of the meetings. 


  

	 	(b)	 Meetings of the Joint Research Committee shall be held at least every three (3) months and shall be held more frequently if reasonably
requested by either Party. Meetings which are held in person shall be held alternately at Amgen and Celltech locations (with the first meeting to be held at a Celltech location). Meetings may take place by videoconference or similar means if agreed
by both Parties. Promptly following the Effective Date the Joint Research Committee shall hold an organisational meeting to establish its operational requirements. At each scheduled Joint Research Committee meeting each Party shall present a
detailed report showing any progress on its Research activities since the previous scheduled meeting of the Committee. 


  

	 	(c)	 The Joint Research Committee generally shall have the responsibility of managing, directing and overseeing Research including the following
responsibilities: 


  

	 	  (i)	 modifying the Research Plan, as appropriate; 


  

	 	 (ii)	 co-ordinating the Research activities of both Parties in accordance with the Research Plan, so as to identify Antibody Products suitable for
Development; 


  

	 	(iii)	 agreeing Antibody Product candidates (including whether to select a [*] Antibody and/or [*] Antibody) for filing of an IND; and



  

	 	(iv)	 agreeing key decisions required in order to progress the Research and the appropriate criteria to be met in reaching such decisions.




  
 38










	 	(d)	 [*] shall appoint from amongst its representatives a chairperson of the Joint Research Committee with the responsibility to arrange meetings in
accordance with this Agreement and to prepare and distribute the minutes of all key decisions made by the Joint Research Committee. Such minutes shall be distributed by the chairperson within ten (10) Business Days of each Joint Research
Committee meeting. Minutes shall be approved or disapproved and revised if necessary at the next meeting. 


  

	 	(e)	 A primary objective of the Joint Research Committee is to reach unanimous decisions, with the representatives of each Party who are members of the
Joint Research Committee collectively having one (1) vote, arrived at through open discussions amongst the representatives of each of the Parties. In the event of a tied vote, the [*] shall, after giving due consideration to the views expressed
by both Parties, have [*] in all matters, except the following (“Excepted Matters”): 


  

	 	(i)	 changes in the direction of Research and Development from the [*] to an [*] as the initial indication for which to file an IND;



  

	 	(ii)	 [*]. [*] will not, having regard to the potential impact of any proposed change on [*], unreasonably withhold or delay its consent to any reasonable
change proposed by [*]; 


  

	 	(iii)	 changes in the Research Plan that represent a major change in the scope or direction of the Research Plan. [*] will not, having regard to the
potential impact of any proposed change on [*], unreasonably withhold or delay its consent to any reasonable change proposed by [*]; or 


  

	 	(iv)	 any changes to the then-approved [*] as set out in [*]. 



  
 39









 In the event of a tied vote on an Excepted Matter, the Joint Research
Committee shall promptly submit such issue to the Collaboration Committee for resolution. If the Collaboration Committee is unable to resolve such dispute within [*] of submission (in writing) to the Collaboration Committee, such Excepted Matters
shall be resolved using the disputes procedure outlined in Article 15. 
  

	3.7.2	 Development 


  

	 	(a)	 Upon the decision of the Joint Research Committee to file the first IND application for an Antibody Product, the Parties shall form a Joint
Development Committee. The Joint Development Committee shall consist of equal numbers (not more than three) from each Party. Either Party may (with the consent of the other Party, not to be unreasonably withheld or delayed) invite additional
participants from either Party to provide expert opinions for some or all of the meetings. Meetings of the Joint Development Committee shall be held at least every six (6) months and shall be held more frequently if reasonably requested by
either Party. If agreed between the Parties at any time, the Joint Development Committee may assume any residual responsibilities of the Joint Research Committee, and the latter may then be disbanded. 



 

	 	(b)	 Meetings of the Joint Development Committee which are held in person shall be held alternately at Amgen and Celltech locations (with the first
meeting to be held at an Amgen location). Meetings may take place by videoconference or similar means if agreed by both Parties. At each scheduled Joint Development Committee meeting each Party shall present a detailed report showing any progress on
its Development activities since the previous scheduled meeting of the Committee. 


  

	 	(c)	 The responsibilities of the Joint Development Committee shall be to (i) co-ordinate the Development activities of both Parties; (ii) share
information about Development activities and the results thereof; and (iii) establish procedures for the collection, sharing and reporting of adverse event information pursuant to Article 4.6 and relating to the Antibody Products obtained after
Regulatory Approval thereof. 



  
 40










	 	(d)	 [*] shall appoint from amongst its representatives a chairperson of the Joint Development Committee with the responsibility to arrange meetings in
accordance with this Agreement and to prepare and distribute the minutes of all key decisions made by the Joint Development Committee. Such minutes shall be distributed by the chairperson within fifteen (15) Business Days of each Joint
Development Committee meeting. Minutes shall be approved or disapproved and revised if necessary at the next meeting. 


  

	 	(e)	 A primary objective of the Joint Development Committee is to reach unanimous decisions, with the representatives of each Party who are members of
the Joint Development Committee collectively having one (1) vote, arrived at through open discussions amongst the representatives of each of the Parties. In the event of a tied vote, [*] shall, after giving due consideration to the views
expressed by both Parties, have [*] in all matters provided that to the extent the matter concerns a Research activity [*] shall not have [*] in respect of the Excepted Matters set out in Article 3.7.1(e). 



ARTICLE 4 

REGULATORY 
  

	4.1	  Rights and Responsibilities through [*]. 



 

	 	(a)	 The Parties shall fully consult and co-operate with each other on all matters relating to and in communications with Regulatory Authorities and
shall use Commercially Reasonable Efforts to obtain Regulatory Approval for Commercialisation of each Antibody Product and indication in [*] at the earliest possible opportunity. In particular, until Celltech assumes exclusive control for regulatory
matters in any country in the Celltech Territory the Parties will co-ordinate all communications with Regulatory Authorities in countries in the 



  
 41










	 	 
Celltech Territory to ensure consistent and clear communication with the Regulatory Authorities in those countries. In addition, each Party will discuss in advance with the other Party any
planned communication with any Regulatory Authority in the Celltech Territory, where such communication may affect the activities of the other Party. 


  


	 	(b)	 When designing and implementing [*] studies Amgen will consult with Celltech and accommodate the requirements of the Celltech Territory within
Amgen’s [*] studies, to the extent that is practicable. To the extent any such requirements are not accommodated within such Amgen studies, Celltech may conduct such studies as supplemental [*] studies in accordance with Article 3.2.2(b).



  

	 	(c)	 Subject to Article 4.1(a) and (b), in each jurisdiction Amgen shall be primarily responsible for all regulatory matters (including communications
with Regulatory Authorities) concerning each Antibody Product and each indication with such Antibody Product up to delivery to Celltech of the filed data package in accordance with Article 4.1(d). Notwithstanding the previous sentence, during
Development prior to completion of a said data package Celltech shall have the right to communicate with Regulatory Authorities in the Celltech Territory solely for the purposes of Article 4.1(c) (i)-(iv) below: 



 

	 	(i)	 determining appropriate filing strategies for Drug Approval Applications within the Celltech Territory and matters concerning such Drug Approval
Applications; 


  

	 	(ii)	 planning, designing and conducting supplemental [*] activities as permitted by Article 3.2.2(b) 



 

	 	(iii)	 planning, designing and conducting Marketing Clinical Studies; and 



 

	 	(iv)	 with respect to process Development, manufacture and supply of Antibody Raw Material, unless Amgen is the only Manufacturing Lead.




  
 42










	 	(d)	 Amgen shall provide Celltech with a copy of and reasonable opportunity to comment on the data package suitable for a Drug Approval Application for
each Antibody Product in each indication intended to be submitted by Amgen to the FDA. Amgen shall provide Celltech with a copy of such data package when filed and with any subsequent data packages filed in such indication.



  

	4.2	 Rights and Responsibilities of Territorial Commercial Leads.  On an indication-by-indication basis, as reasonably required, each
Territorial Commercial Lead shall have the right to monitor, review and direct all aspects of all regulatory matters to the extent the same concern the activities and studies for which it is responsible pursuant to Article 4.1 with respect to each
such Antibody Product, including making all strategic and tactical decisions with respect thereto. Each Territorial Commercial Lead shall have the right and responsibility for the filing of a Drug Approval Application in its own name, including the
conformation of the data package provided by Amgen to the requirements of each jurisdiction within its Lead Territory and for seeking Regulatory Approvals for such Antibody Products in its Lead Territory. Notwithstanding the above, pursuant to
Article 4.1, Amgen shall remain responsible for all regulatory matters for all Antibody Products for any indication which is not yet the subject of [*]. 



 

	4.3	 Additional Rights and Responsibilities of Manufacturing Lead.  The Manufacturing Lead in the case of Antibody Raw Material and
Amgen in the case of Antibody Products in Finished Form (as appropriate) shall be responsible for obtaining all necessary Regulatory Approvals to enable it to supply the same as specified in Article 6. 



 

	4.4	 Co-operation.  Notwithstanding anything to the contrary in this Agreement, each Party shall have the right to receive from the
other Party, and each Party shall provide to the other Party, all regulatory data or information which Amgen or the Territorial Commercial Lead is required to submit to a Regulatory Authority (as it is required by law, rule, regulation or a
Regulatory Authority having jurisdiction in any part of the Territory to have access) in sufficient time to comment on and consult with each other with respect to the same. 



  
 43










	4.5	 Access to INDs.  At the request of Celltech and for the purposes set out in Article 4.1(c), Amgen shall grant Celltech a right of
access and reference to (and name it a party of record on) all INDs in such country in the Celltech Territory and shall promptly notify Regulatory Authorities in such country of (and as soon as is reasonably practicable thereafter take all actions
reasonably necessary to effect or evidence) the right of access and reference to (and naming Celltech as a party of record on) such INDs. 


  

	4.6	 Adverse Event Reporting; Customer Complaints. 



 

	 	(a)	 Each Party shall maintain a record of all non-medical and medical product-related complaints and reports of adverse events that it receives with
respect to any Antibody Product. Each Party shall notify the other Party of any complaint received by it and, within three (3) days of the initial receipt, shall provide the other Party with a copy of such complaint(s) and adverse event
reports. Amgen shall maintain such adverse reaction information in the database described in Article 3.2.2(a). 


  

	 	(b)	 Except as set forth in Article 4.6(c) below, each Party shall be responsible for reporting to Regulatory Authorities any adverse experience and
safety issues for such Antibody Product arising out of its activities and studies, in compliance with the requirements of the laws, rules and regulations in its Territory, and shall promptly thereafter provide the other Party with a copy of such
report. If possible, with respect to the Celltech Territory, the other Party shall have an opportunity to review and the Parties shall consult with each other, prior to submission of any such report. 



 

	 	(c)	 Following the delivery of the filed data package for an Antibody Product to Celltech pursuant to Article 4.1(d), each Territorial Commercial Lead
shall be responsible for reporting to Regulatory Authorities, in each country within its Lead Territory, any adverse experience and safety issues for such Antibody Product in the relevant jurisdiction in compliance with the requirements of all
applicable laws and regulations in such country and shall promptly thereafter 



  
 44










	 	 
provide the other Party with a copy of such report. Notwithstanding anything to the contrary in this Agreement, the Territorial Commercial Lead shall have the right to receive from the other
Party (and the other Party shall provide to the Territorial Commercial Lead) any regulatory data or information Controlled by the other Party which the Territorial Commercial Lead, as the holder of any Drug Approval Application or Regulatory
Approval in its Lead Territory, requires by law, rule, regulation or a Regulatory Authority having jurisdiction in its Lead Territory to have access, or which the Territorial Commercial Lead reasonably requires in order to carry out its
responsibilities pursuant to this Agreement. 


  

	4.7	 Communications. 


  

	 	(a)	 In addition to the responsibilities in Article 4.6(c), each Party shall have primary responsibility for all correspondence and for any official
communications with Regulatory Authorities in the Territory in respect of the activities and studies for which it is responsible. Each Party shall reasonably co-operate with the other Party regarding any direct communications with the Regulatory
Authorities. 


  

	 	(b)	 Both Parties shall have the right to [*] with Regulatory Authorities having jurisdiction in any part of the Celltech Territory where any matter
which may affect the activities or studies of the other Party is to be discussed. 


  

	 	(c)	 Without prejudice to the other provisions of this Article 4, following delivery of the filed data package to Celltech pursuant to Article 4.1(d),
the Territorial Commercial Lead for such country shall have exclusive responsibility for all correspondence in respect of the Antibody Product covered by such data package and for any official communications with Regulatory Authorities in such
country regarding its rights and responsibilities under this Article 4 (including submitting Regulatory Filings, seeking Regulatory Approvals, filing annual reports, and filing of Promotional Materials) consistent with all applicable laws and
regulations of any such country. Except as may be required by applicable laws and regulations, or requested by the Territorial Commercial Lead or any 



  
 45










	 	 
Regulatory Authority having jurisdiction in such country, the other Party shall not communicate regarding any Antibody Product with any Regulatory Authority having jurisdiction in such country.
The other Party shall keep the Territorial Commercial Lead informed of any such required communications. 


  

	 	(d)	 Regarding the manufacture of any Antibody Raw Material and/or Antibody Product, both Parties shall have the right to [*] with Regulatory Authorities
having jurisdiction in the Territory wherein issues regarding the manufacturing of such Antibody Raw Material and/or Antibody Product in Finished Form contained in any Regulatory Filings is to be discussed, where the Party responsible for
communications is different from the Party responsible for said manufacturing issues or where required by law or regulation. Notwithstanding the above, and unless Amgen is the Manufacturing Lead, Celltech shall have exclusive responsibility for all
correspondence and for any official communications with Regulatory Authorities in the Territory in connection with the supply of Antibody Raw Material and as reasonably required to meet its obligations with respect to any such supply under this
Agreement. The Manufacturing Lead with respect to Antibody Raw Material, and Amgen with respect to Antibody Product in Finished Form, shall have the right, to the extent permitted by Regulatory Authorities, to file a drug master file with a
Regulatory Authority to make their respective proprietary manufacturing information (e.g., the CMC section contained in any Regulatory Filings) and formulation information available directly to the Regulatory Authority, in order to help preserve the
proprietary nature thereof; provided however, that the other Party shall have the right of access and reference to the extent required, as a result of its responsibilities hereunder, by law, rule, regulation or a Regulatory Authority having
jurisdiction in the Territory. 


  

	 	(e)	 Each Party shall promptly notify and provide the other Party with a copy of any correspondence or other reports or complaints submitted to or
received by the first Party from any Regulatory Authority or other Third Party claiming that any Promotional Materials are inconsistent with the Product Labelling or are otherwise in violation of any applicable laws and regulations of any country in
the Territory. 



  
 46










	4.8	 Recalls. 


  

	 	(a)	 The Parties shall exchange their internal standard operating procedures as to product recalls (“SOPs”) reasonably promptly after
the first filing of a Drug Approval Application for an Antibody Product and reasonably promptly after such SOPs are approved or modified thereafter. In the event that, in a country, the Territorial Commercial Lead for such country determines that an
event, incident or circumstance has occurred which may result in the need for a “recall” or “market withdrawal” or “stock recovery” (as such terms are defined in U.S. regulations in 21 CFR 7.3 or another similar
national, state or local law or regulation), hereinafter collectively referred to as a “Recall”, of Antibody Product or any lot(s) thereof, such Party shall promptly notify the other Party in writing. 



 

	 	(b)	 The Territorial Commercial Lead shall have the right to determine whether and upon what terms and conditions to Recall the Antibody Product within
its Lead Territory; provided however, if the Territorial Commercial Lead shall elect not to conduct a Recall of the Antibody Product, and solely if the other Party is responsible for the manufacture of Antibody Raw Material or Antibody
Product in Finished Form, and the manufacture of Antibody Raw Material or Antibody Product in Finished Form is the basis of such proposed Recall, the other Party shall have the right to conduct such Recall if, in its good faith opinion, regulatory
requirements or public safety considerations so require. Prior to making any Recall decision in any part of its Territory, each Party shall consult with the other Party. The Territorial Commercial Lead shall be responsible for discussions with
Regulatory Authorities within the applicable country regarding all aspects of the Recall decision and the execution thereof. Any costs or expenses of any Recall in any part of the Territory shall be a Commercialisation Expense. Celltech and Amgen
shall each maintain complete and accurate records of any Recall it has the right to control pursuant to this Article 4.8 for such periods as may be required by legal requirements, but in any event for no less than [*].




  
 47










	4.9	 Applications for Regulatory Exclusivity.  The Parties recognise that exclusivity rights granted or provided for under regulatory
laws of the countries of the Territory may be commercially significant to Antibody Products. To the extent permitted by law, as between the Parties, the Territorial Commercial Lead for a country shall have the exclusive right to file for, request
and maintain any regulatory exclusivity rights for Antibody Products in such country (including regulatory exclusivity rights based upon an orphan drug designation of an Antibody Product) and to conduct and prosecute any proceedings or actions to
enforce such regulatory exclusivity rights. 


 ARTICLE 5 

COMMERCIALISATION OF ANTIBODY PRODUCTS 
  

	5.1	 Territorial Commercial Lead.  The Parties shall Commercialise each Antibody Product in the Territory, with one Party (on a
country-by-country basis) being the Territorial Commercial Lead for all Antibody Products in each such country as follows: 


  

	 	(a)	 Amgen shall be the Territorial Commercial Lead in the Amgen Initial Countries; 



 

	 	(b)	 Celltech shall be the Territorial Commercial Lead in the Celltech Initial Countries; 



 

	 	(c)	 With respect to additional countries in the Territory outside the Amgen Initial Countries and the Celltech Initial Countries, at a time [*] prior to
the planned filing date for the first Drug Approval Application of an Antibody Product, the Joint Commercialisation Committee shall designate (such designation [*]), between the Parties, the Territorial Commercial Lead in such additional countries
(and such countries shall be included within the Lead Territory of the Territorial Commercial Lead), in accordance with the following principles. If at the time the Joint Commercialisation Committee considers the issue: 



 

			
	 (i)
  
	 	 only one Party wishes to be the Territorial Commercial Lead, that Party shall be designated the Territorial
Commercial Lead; if neither Party wishes to be the Territorial Commercial Lead, neither Party shall be designated the Territorial Commercial Lead; if both Parties wish to be the Territorial Commercial Lead, then;




  
 48









 
			
	 (ii)
  
	 	 if only one Party has a [*] that is [*] of the Antibody Product in that country, the Party with such [*] shall be
designated the Territorial Commercial Lead in that country;



  

			
	 (iii)
  
	 	 if both Parties have a [*] the Antibody Product in that country, the Party best able to exploit the Antibody
Product to best advantage in that country (having regard to [*] of the [*]) shall be designated the Territorial Commercial Lead;



  

			
	 (iv)
  

 
	 	 if neither Party has a [*] the Antibody Product the Joint Commercialisation Committee shall consider whether
either Party has immediate and funded plans to establish a [*] for that country and any other relevant factors that indicate one Party may be better suited to exploit Antibody Products to best advantage in that country, including management of a
Third Party subcontractor pursuant to Article 5.3;



 provided that, the Joint Commercialisation Committee shall designate the
Territorial Commercial Lead for countries outside the Amgen Initial Countries and Celltech Initial Countries such that the [*] of all Antibody Products from such countries used in the [*] for which such [*], is [*]. 

 

	 	(d)	 If the Joint Commercialisation Committee shall fail, for any reason, to designate the Territorial Commercial Lead in any country where both Parties
wish to be the Territorial Commercial Lead, the matter shall be referred to the Collaboration Committee who shall make such designation in accordance with the terms of Article 5.1(c). 



  
 49










	 	(e)	 In the event a Territorial Commercial Lead is not designated in a country at the time specified in Article 5.1(c) because, at that time, neither
Party wished to be the Territorial Commercial Lead in such country, the Joint Commercialisation Committee shall upon receipt of a notice from a Party expressing the wish to be the Territorial Commercial Lead in such country designate such Party as
the Territorial Commercial Lead in such country, provided that the Joint Commercialisation Committee shall give the other Party a reasonable period (not to [*]) to also serve such a notice. If both Parties serve such a notice, the Joint
Commercialisation Committee shall designate the Territorial Commercial Lead in accordance with Article 5.1(c). 


  

	 	(f)	 The Territorial Commercial Lead shall use Commercially Reasonable Efforts to maximise the Product Contribution of each Antibody Product in its Lead
Territory. 


  

	5.2	 Co-Detailer. 


  

	 	(a)	 In the event a Party is not the Territorial Commercial Lead in a country, such Party shall have the right to deploy a supportive co-Detailing sales
force in such country. If such Party exercises that right, in accordance with Article 5.2(c) below, such Party shall be termed the “Co-Detailer” in such country. 



 

	 	(b)	 The Territorial Commercial Lead shall notify the other Party in writing of the date on which it expects to file the first Drug Approval Application
for each Antibody Product in each country in its Lead Territory at least [*] prior to each such filing (“Filing Notice”). 


  

	 	(c)	 If a Party is not the Territorial Commercial Lead in such country, it shall have the right to notify the Territorial Commercial Lead within [*] of
the Filing Notice for such country and such Antibody Product. The notice shall identify the country or countries identified in such Filing Notice where the Party that is not the Territorial Commercial Lead exercises its right to deploy a supportive
co-Detailing sales force in such country. The Territorial Commercial Lead shall have the sole right 



  
 50










	 	 
and responsibility to Commercialise in accordance with Article 5 such Antibody Product in any country not identified in the notice (or if no notice is served, in all countries in its Lead
Territory) and the Party that is not the Territorial Commercial Lead shall have no further right to co-Detail in such country. 


  

	5.3	 Third Parties.  The Territorial Commercial Lead may determine that the services of a Third Party are required or desirable to
Commercialise an Antibody Product in any country in its Lead Territory. The Territorial Commercial Lead shall be free to enter into an agreement with such Third Party on arm’s-length terms; provided that such terms shall be consistent
with the terms of this Agreement so as to preserve the rights of the other Party in such country including the right (if any) of such Party to co-Detail pursuant to Article 5.2, and provided that in the reasonable estimation of the
Territorial Commercial Lead, in such country, [*] in the absence of such agreement. The Territorial Commercial Lead shall, in entering into such agreement, be entitled to grant such Third Party any licences or sublicences to [*] Technology or [*]
Technology required by the Third Party solely to Commercialise an Antibody Product in such country. The Net Sales from and the costs incurred by a Party in such Third Party arrangement shall be included in calculating the Product Contribution for
such Antibody Product in such country. 


  

	5.4	 Joint Commercialisation Committee Formation.    Immediately following [*], the Parties shall establish a Joint
Commercialisation Committee to facilitate the Commercialisation of Antibody Products on a global basis. The Joint Commercialisation Committee shall be comprised of an equal number of Celltech and Amgen representatives (not to exceed three
(3) from each Party), with each Party having one vote. The Joint Commercialisation Committee shall meet at times to be agreed and, commencing no later than [*] before the expected date for the first filing of the first Drug Approval
Application, at least quarterly. In addition, the Joint Commercialisation Committee shall appoint a chairperson and otherwise follow the organisational and meeting procedures set forth in Article 9 with respect to the Collaboration Committee.




  
 51










	5.5	 Joint Commercialisation Committee and Territorial Commercial Lead Responsibilities. 



 

	 	(a)	 Each Territorial Lead has the right and responsibility to Commercialise Antibody Product in the manner it deems appropriate, but subject always to
its obligations under this Agreement including those set out in this Article. If the Joint Commercialisation Committee determines that any Commercialisation activities should be conducted jointly or on a co-ordinated basis, such activities shall be
co-ordinated through the Joint Commercialisation Committee. The Parties now agree that it is likely they will wish to co-ordinate the following matters, and that unless and until one Party objects to the Joint Commercialisation Committee determining
any or all such matters, and subject always to Article 5.7, the Joint Commercialisation Committee shall be responsible for: 


  

	 	(i)	 co-ordination of the Commercialisation of Antibody Products throughout the Territory in accordance with the Commercialisation Plan;



  

	 	(ii)	 addressing strategic issues with relevance throughout the Territory (e.g., branding, regulatory issues, product positioning);



  

	 	(iii)	 deciding any activities that the Parties shall undertake jointly in order to Commercialise Antibody Products on a worldwide basis (e.g. pre-launch
activities, market research, launch, and post–launch marketing and promotion) (“Joint Activities”); 


  

	 	(iv)	 co-ordinating Marketing Clinical Studies; 


  

	 	(v)	 co-ordinating the packaging, labelling and language to be included in the package insert; 



 

	 	(vi)	 co-ordinating commercial manufacturing production requirements; 



 

	 	(vii)	 selecting, obtaining and maintaining generic names and Product Trademarks and domain names incorporating any of the same or otherwise referencing
Antibody Products; 



  
 52










	 	(viii)	 developing and updating a Commercialisation Plan pursuant to Article 5.8; and 



 

	 	(ix)	 resolving any complaint by a Party that the activities of the other Party are adversely affecting the Commercialisation of Antibody Product in the
Lead Territory of the Party making the complaint; 


 provided however, and subject to
Article 5.7, in the event that the Joint Commercialisation Committee is unable to agree on any such matters within its authority, that particular matter shall at the written request of either Party, be removed from the responsibility of the Joint
Commercialisation Committee and the Territorial Commercial Lead shall (to the extent such matters concern its Lead Territory only) determine such matters for its Lead Territory. 

 

	 	(b)	 The Territorial Commercial Lead shall be responsible in each country in its Lead Territory for determining the Commercialisation of Antibody Product
in a manner consistent with the Commercialisation Plan (if any), including: 


  

	 	(i)	 tactical issues, for example, sales force allocation and disposition; 



 

	 	(ii)	 determining Promotional Materials suitable for each such country; and 



 

	 	(iii)	 preparing and implementing a Country Plan (as defined in Article 5.9 below) and monitoring budgets and forecasts for each such country; and



  

	 	(iv)	 booking sales of Antibody Products, taking orders, distributing Antibody Product, handling returns, and contracting and administering accounts.



  

	5.6	 Decision Making.  A primary objective of the Joint Commercialisation Committee shall be to reach unanimous decisions (with each
Party having one (1) vote), arrived at through open discussions amongst the representatives of each of the Parties. All decisions of the Joint Commercialisation Committee shall be made by the unanimous decision of Celltech and Amgen (subject to
Article 5.7), with the representatives of each Party who are members of the Joint Commercialisation Committee collectively having one vote in any 



  
 53










	 	 
matter. The Parties agree that all decisions regarding the Commercialisation of an Antibody Product will be made in the interests of securing the best value from the Antibody Product on a global
basis. 


  

	5.7	 Dispute Resolution.    If the Joint Commercialisation Committee shall have a disagreement with respect to any issue
(including those set forth in Article 5.1(c) and 5.5(a), or should a Party wish to remove any matter set out in Article 5.5(a) from the responsibility of the Joint Commercialisation Committee, such issue shall be promptly submitted in writing to the
Collaboration Committee for resolution. If the Collaboration Committee is unable to agree on the resolution of such dispute within [*] of such written submission to the Collaboration Committee: 



 

	 	(i)	 the matter, if an issue set forth in [*], shall be promptly submitted in writing to [*]. If following discussion between them, the [*] are unable to
agree a resolution of the matter within [*] after the matter has been submitted to them, the Territorial Commercial Lead for any country shall determine such issue with respect to any [*]; or 



 

	 	(ii)	 the matter, if relating to any other issue, shall be determined by [*]. 



 
  

	5.8	 Commercialisation Plan. 


 Pursuant to Article 5.5(a), the Joint Commercialisation Committee shall develop a Commercialisation Plan for each Antibody Product which shall: 

 

	 	(i)	 outline the overall strategy for the Commercialisation of each Antibody Product throughout the Territory; 



 

	 	(ii)	 adopt a budget for any Joint Activities; 


  

	 	(iii)	 consolidate the budgets of each Territorial Commercial Lead; and 



 

	 	(iv)	 address any other issue where the Parties wish to adopt a co-ordinated approach throughout the Territory. 



  
 54









 The Commercialisation Plan shall be first developed and approved by the
Joint Commercialisation Committee no later than [*] before it is expected to file the first Drug Approval Application for an Antibody Product and shall be updated and approved as deemed necessary but at least annually, in time for the annual budget
cycle of each of the Parties. 
  

	5.9	 Country Plans.  In each country, the Territorial Commercial Lead for such country, in consultation with the Co-Detailer (if any) of
that country, shall develop a commercialisation plan and budget (“Country Plan”) for such country setting out the work activities, including the number of Details and the Position of Detail to be carried out in such country in the
following year, in a manner consistent with the Commercialisation Plan, but taking into account the specific circumstances appropriate to the Commercialisation of such Antibody Product in such country. The Country Plan shall be developed to a
standard and timing consistent with other products marketed by the Territorial Commercial Lead in that country. In the event of any dispute between the Territorial Commercial Lead and the Co-Detailer on any matter relating to the Commercialisation
of an Antibody Product in that country, the Territorial Commercial Lead shall, after taking due consideration of the views expressed by the other Party, determine the resolution of such matter. Any dispute regarding whether or not a Country Plan is
consistent with the Commercialisation Plan shall, at the request of either Party, be determined by the Joint Commercialisation Committee, subject to Article 5.7. 



 

	5.10	 Implementation of Commercialisation Plan and Country Plan.      Once the Commercialisation Plan has been
approved by the Joint Commercialisation Committee, or if the Joint Commercialisation Committee fails to approve a Commercialisation Plan, the Territorial Commercial Lead with respect to its Lead Territory shall be free to Commercialise an Antibody
Product in each country in such Lead Territory, in such manner that they reasonably deem appropriate in accordance with the Country Plan for such country; provided however, that neither Party shall undertake any activity that is




  
 55










	 	 
inconsistent with such Commercialisation Plan (if any) or with its obligation to use Commercially Reasonable Efforts to maximise the value of the Antibody Product on a global basis.



  

	5.11	 Co-Detailing.   The Co-Detailer’s right to support the Territorial Commercial Lead in a country shall include the
following terms and conditions. 


  

	 	(a)	 The Co-Detailer’s sales force shall be deployed as determined by the Territorial Commercial Lead (e.g., whether or not such supportive sales
force representatives shall double call on customers already called on by sales force representatives of the Territorial Commercial Lead). 


  

	 	(b)	 The Co-Detailer’s sales force shall jointly Detail with the sales force of the Territorial Commercial Lead under a single Product Trademark in
accordance with the Country Plan including being trained by and using the field sales force materials (including Promotional Materials) of the Territorial Commercial Lead and systems compatible with the systems of the Territorial Commercial Lead.



  

	 	(c)	 On an Antibody Product-by-Antibody Product and indication-by-indication basis, the planned level of Detailing effort conducted by the
Co-Detailer’s sales force for an Antibody Product in an indication shall be [*] ([*]%) (or such lesser percentage as the Co-Detailer may agree) of the planned level of Detailing effort of the [*] for that Antibody Product and indication in any
Contract Year. 


  

	 	(d)	 Subject to (c) above the Territorial Commercial Lead shall determine the minimum level of effort and resources the Co-Detailer is directed to
commit to individual field activities under this Article 5.11, provided the Co-Detailer shall not be required to provide overall effort and resources that exceed the generally proportional level of effort and resources of the Territorial Commercial
Lead, having regard to the relative number of sales representatives deployed by the Co-Detailer in relation to the total number of sales representatives deployed by both Parties in such country, pursuant to the Country Plan for such country.




  
 56










	 	(e)	 Except with the prior written consent of the Territorial Commercial Lead, all sales representatives of the Co-Detailer Detailing an Antibody Product
shall be [*]. Notwithstanding Article 5.11(g) below, if any sales representative of the Co-Detailer is not competent or qualified to carry out the Co-Detailer’s responsibilities pursuant to this Article 5.11, the Territorial Commercial Lead (at
its discretion, after consultation with the Co-Detailer) may require the Co-Detailer to remove such sales representative from the Detailing of all Antibody Products. 



 

	 	(f)	 If an Antibody Product is returned to the Co-Detailer, it shall promptly be shipped to the facility responsible for shipment of Antibody Products in
the country in question, to the attention of a department or another location as may be designated by the Territorial Commercial Lead. 


  

	 	(g)	 Neither Party shall have any responsibility for the hiring, firing or compensation of the other Party’s employees or for any employee benefits.
No employee or representative of a Party shall have any authority to bind or obligate the other Party to a Third Party for any sum or in any manner whatsoever, without said first Party’s written approval. 



 

	 	(h)	 Upon the other Party’s request and to the extent permitted by law, regulation or Regulatory Authorities in such a country, the other
Party’s corporate name and logo shall be included on Promotional Materials and Product Labelling in positions of equivalent prominence and frequency with the corporate name and logo of the Territorial Commercial Lead. In order to maintain the
value of the other Party’s corporate name and logo, when using the other Party’s corporate name and logo, the Territorial Commercial Lead shall maintain such reasonable quality standards as it maintains for its own corporate name and logo
and shall comply with the other Party’s then-current policies regarding use of its corporate name and logo (as applied to products marketed by the other Party in that country); provided however, that such policies are consistent with the
first sentence of this Article 5.11(h). Prior to the use thereof, the Territorial Commercial Lead shall provide to the other Party a prototype of any Promotional 



  
 57










	 	 
Materials or Product Labelling which contains the other Party’s corporate name and logo, so that the other Party may review the manner in which its corporate name and logo are used therein.
The other Party shall notify the Territorial Commercial Lead within thirty (30) days after delivery of such prototype as to whether the other Party approves or disapproves of the manner of such use and, in the case of disapproval, the specific
reasons therefor and an acceptable alternative. In the event the other Party fails to so notify the Territorial Commercial Lead within such thirty (30) day period, the other Party shall be deemed to have approved the manner of such use.



  

	5.12	 Commercialisation Budget.  


  

	 	(a)	 Prior to the First Commercial Sale and before the end of each Contract Year following the First Commercial Sale, at a time to be agreed by the Joint
Commercialisation Committee, but consistent with the annual budget cycles of each Party, each Party shall provide the Joint Commercialisation Committee with a budget of expected Commercialisation Expenses and forecasted revenue (calculated as set
forth in Schedule B) for the ensuing Contract Year for that Party’s Lead Territory. Such budget shall be in a form to be agreed by the Joint Commercialisation Committee and shall, unless agreed otherwise by the Joint Commercialisation
Committee, be prepared by each Party as a consolidation of the individual budgets for each country in such Party’s Lead Territory. For the avoidance of doubt, each budget prepared by a Territorial Commercial Lead will be provided to the Joint
Commercialisation Committee for its information but not for its approval. The Joint Commercialisation Committee shall also agree a budget for and agree on an allocation of responsibilities between the Parties for any Joint Activities on which the
Parties agree for the ensuing year. 


  

	 	(b)	 The Joint Commercialisation Committee shall review on a quarterly basis the Commercialisation Expenses actually incurred against the budget for such
expenses in the applicable calendar year and will consider for approval any appropriate changes to such budget. If in the course of the quarterly review, the 



  
 58










	 	 
Joint Commercialisation Committee should determine for any Antibody Product that the actual amounts incurred are, in the aggregate, likely to be greater than [*] ([*]%) of the amount budgeted,
the Joint Commercialisation Committee shall review the reasons for such potential overrun and determine whether such overrun is appropriate. If the Joint Commercialisation Committee determines that such overrun is appropriate, the Joint
Commercialisation Committee shall approve a revised Commercialisation budget. If the Joint Commercialisation Committee determines that such overrun is not appropriate, the Joint Commercialisation Committee shall initiate (within [*]) such actions as
required to remedy the situation. If the Joint Commercialisation Committee is unable to agree on any matter relating to said overrun, [*]. 


  

	5.13	 Public Statements Regarding Antibody Products.  Each Party shall be responsible for disseminating accurate information regarding
any Antibody Product to its sales representatives based on Product Labelling and Promotional Materials. In exercising their rights pursuant to this Article 5, Celltech and Amgen shall ensure that no claims or representations in respect of the
Antibody Products or the characteristics thereof (e.g., safety or efficacy) are made by or on behalf of it (by members of its sales force or otherwise) which do not represent an accurate summary or explanation of the Product Labelling of the
Antibody Product in the country in question. 


  

	5.14	 Medical and Other Inquiries.  The Territorial Commercial Lead shall be responsible for responding to all medical questions or
inquiries relating to the Antibody Products sold in countries in its respective Lead Territory, except that the Co-Detailer, in the course of carrying out its activities under Article 5.11(c), may respond to any such question or inquiry which can be
answered by reference to the Product Labelling and package insert in the applicable country. The Territorial Commercial Lead shall designate a medical liaison to whom the Co-Detailer shall instruct its medical affairs group, as well as its sales
forces engaged in the Detailing of Antibody Products, to direct medical questions or inquiries relating to the Antibody Products. The Territorial Commercial Lead shall keep such records and make such reports as are reasonably necessary to document
such communications in compliance with all applicable regulatory requirements. 



  
 59










	5.15	 Compliance with Laws. 


  

	 	(a)	 Each Party agrees to comply with all applicable laws, regulations and rules with respect to the Commercialisation of Antibody Products and in all
material respects to conform its practices and procedures with the recommended industry practices and procedures applicable to the relevant part of the Territory, as the same may be amended from time to time. Each Party shall use Commercially
Reasonable Efforts to conduct its business operations and shall use Commercially Reasonable Efforts to cause each of its employees, representatives and agents to do nothing which such Party knows or reasonably should know would jeopardise the good
will or reputation of the other Party or the Antibody Products. 


  

	 	(b)	 Neither Party shall be required to undertake any activity relating to the Commercialisation of Antibody Products that it believes, in good faith,
may violate any law. 


  

	 	(c)	 To the extent that a Party’s sales force engages in the distribution of samples of Antibody Products pursuant to any activities conducted
pursuant to this Agreement, that Party shall ensure that all such activities are conducted in a manner which conforms to this Agreement, the Country Plan and all applicable laws. 



 

	 	(d)	 In addition to its responsibilities under Article 4.7(e), the other Party shall promptly notify the Territorial Commercial Lead of and provide the
Territorial Commercial Lead with a copy of any correspondence or other reports with respect to the Detailing or Promotion of Antibody Products submitted to or received from any Regulatory Authority or industry association in the relevant part of the
Territory. Each Party shall in all material respects conform its practices and procedures relating to educating the medical community in the relevant part of the Territory with respect to Antibody Products to any applicable Regulatory Authority or
industry association regulations, policies and guidelines, as the same 



  
 60










	 	 
may be amended from time to time, and the other Party shall promptly notify the Territorial Commercial Lead of and provide the Territorial Commercial Lead with a copy of any correspondence or
other reports submitted to or received from any such Regulatory Authority or industry association with respect to Antibody Products. 


  

	5.16	 Detailing Reports. 


  

	 	(a)	 For information purposes, each Party shall, at country level, provide the other Party with current reports giving detailed information on [*]. Such
Detailing reports and any other relevant sales force information related to such Antibody Product shall be provided to the other Party [*]. 


  

	 	(b)	 No later than forty-five (45) days after the conclusion of each Calendar Quarter after First Commercial Sale of an Antibody Product in each
country, each Party shall submit to the other Party a report, based upon such Party’s internal Detailing report data, setting forth the [*] or otherwise as required by the Country Plan. Except as set forth in Article 5.16(c) below, for purposes
of this Agreement the number of Details and Position of Detail for an Antibody Product performed by the first Party for a given Calendar Quarter shall be based on such first Party’s internal Detailing report data. 



 

	 	(c)	 Each Party agrees, if requested by the other Party, to make available to independent accountants nominated by the other Party (subject to the
approval of the Party receiving the request, such approval not to be unreasonably withheld or delayed), upon reasonable advance notice, such books and records necessary to verify the accuracy of such report in respect of any Calendar Quarter ending
not more than [*] prior to the date of such request. Upon expiration of [*] following the end of any Contract Year, the report reflecting such Party’s Details for such Antibody Product for such Contract Year shall be binding on the other Party,
and such Party shall be released from any liability or accountability to the other Party with respect to the number of Details given during such Contract Year unless 



  
 61










	 	 
prior to such expiration the other Party has notified the first Party of an issue regarding such audit report (arising from such inspection) pursuant to this Article 5.16(c).



  

	 	(i)	 If, after an audit, the other Party has a good faith concern with the accuracy of the [*] of Details reflected by the first Party’s internal
Detailing report data, based on the other Party’s assessment of such data when compared to available Third Party audit data, sampling data (if applicable) or other relevant data relating to the first Party’s Detailing of such Antibody
Product, then the other Party shall so advise the first Party of such concern, and promptly thereafter the other Party and the first Party’s representatives shall consider in good faith whether the [*] of Details reflected by the first
Party’s internal Detailing report data are accurate and, if not, whether an adjustment to the [*] of Details of such Antibody Product performed by the first Party for such Calendar Quarter is appropriate. 



 

	 	(ii)	 If such representatives referred to in Article 5.16(c)(i) are unable to resolve the matter, either Party may (by notice to the other Party) have the
dispute referred to the [*] of each Party, or their designees, for attempted resolution by good faith negotiations for a period of not more than [*] after such notice is received or such other period of time as may be mutually agreed upon by the
Parties to determine whether an adjustment to the [*] of the first Party’s Details for Antibody Product in such Calendar Quarter is appropriate. 


  


	 	(iii)	 If the Parties are unable to resolve the matter after such negotiation as provided in Article 5.16(c)(ii), then such dispute regarding the [*] of
the first Party’s Details for Antibody Product in such Calendar Quarter shall be referred for final resolution to an independent market research firm or another expert, mutually acceptable to the Parties. The fees that such market research firm
or other expert, shall be paid in connection with such 



  
 62










	 	 
resolution shall be charged to the Product Contribution account as a Commercialisation Expense. The settlement of such dispute by such market research firm or other expert shall, after each Party
has been given the reasonable opportunity to present written evidence, be binding upon the Parties, and shall be to the exclusion of any court of law with respect to proceedings based solely on such dispute (it being understood that such matter is
not within the Collaboration Committee’s authority). 


  

	5.17	 Post-Regulatory Approval Activities.  The Territorial Commercial Lead shall have the right to conduct all activities for Marketing
Clinical Studies in its Lead Territory. 


 ARTICLE 6 

MANUFACTURE AND SUPPLY 
  

	6.1	 Manufacturing. 


  

	 	(a)	 Celltech shall use Commercially Reasonable Efforts to procure the supply of Antibody Raw Material for Development and Commercialisation and, in so
doing, shall be responsible for using Commercially Reasonable Efforts to: 


  

	 	(i)	 identify one or more suitable Third Party suppliers of Antibody Raw Material; 



 

	 	(ii)	 negotiate the terms of and enter into agreements (“Supply Agreements”) with one or more of such Third Party suppliers for the
supply of Antibody Raw Material to meet the Development and Commercialisation requirements of the Parties as set forth in Article 6.4; and 


  

	 	(iii)	 manage the relationship with and require any such Third Party supplier(s) to fulfill the responsibilities of the Manufacturing Lead as set forth in
this Agreement. 


 Such Third Party supplier or suppliers is herein referred to as the
“Manufacturing Lead” for Antibody Raw Material, unless a Party assumes 

  
 63









 
manufacture of Antibody Raw Material pursuant to Article 6.7 below, in which case such Party shall be responsible for the supply of Antibody Raw Material and shall be designated the
“Manufacturing Lead”. 
  

	 	(b)	 Amgen shall use Commercially Reasonable Efforts to procure the supply (itself and/or through a Third Party subcontractor) of Antibody Product in
Finished Form. To the extent Amgen uses a Third Party subcontractor to supply Antibody Product in Finished Form the terms of Articles 6.1(a)(i)-(iv) and 6.2(b), as they relate to agreement with any such Third Party subcontractor, shall apply
mutatis mutandis to the supply of Antibody Product in Finished Form. 


  

	6.2	 Manufacture of Antibody Products for Development.  



 

	 	(a)	 With respect to each Antibody Product selected to be advanced to [*], the Manufacturing Lead shall be responsible for [*] and for [*], Antibody Raw
Material for use in all pre-clinical studies, formulation, development studies and clinical studies in the Territory, in quantities (as forecast by Amgen) and with the specifications agreed between the Parties. 



 

	 	(b)	 Development Supply Agreements shall have terms and conditions as are customary in transactions of this type and reasonable under all of the
circumstances. The terms and conditions of such Development Supply Agreements shall include the cost and specification of the Antibody Raw Material, the quality standards and the method of forecasting demand to be used during Development.



  

	 	(c)	 Amgen shall be responsible for [*] Antibody Product in Finished Form, including [*], for all pre-clinical studies, formulation, development studies
and clinical studies in the Territory, in quantities (as forecast by the Parties) and with the specifications agreed between the Parties. 



  
 64










	6.3	 Manufacture of Antibody Product(s) for Commercialisation.  



 

	 	(a)	 With respect to each Antibody Product receiving Regulatory Approval for Commercialisation, the Manufacturing Lead shall be responsible for [*]
Antibody Raw Material for commercial use in the Territory (in quantities as forecast in the Commercialisation Plan and with specifications set forth in the Regulatory Approval of such Antibody Raw Material). Commercialisation Supply Agreements shall
have terms and conditions as are customary in transactions of this type and reasonable under all circumstances. The terms and conditions of such Commercialisation Supply Agreements shall include the cost and specification of the Antibody Raw
Material, commercial quality standards and the method of forecasting demand to be used during Commercialisation. 


  

	 	(b)	 Amgen shall be responsible for [*] Antibody Product in Finished Form and [*] Antibody Product in Finished Form in quantities (as forecast in the
Commercialisation Plan) and with specifications set forth in the Regulatory Approval of such Antibody Product. 


  

	 	(c)	 The Parties shall agree procedures and terms for the transfer of title in Antibody Products to the Territorial Commercial Lead prior to the sale
thereof in its Lead Territory. 


  

	6.4	 Third Party Manufacturers.  Celltech shall not enter into any Supply Agreement with a Third Party for Antibody Raw Material as
specified in this Article 6 without first obtaining the consent of Amgen to such agreement (such consent not to be unreasonably withheld or delayed). Celltech shall use Commercially Reasonable Efforts to ensure that, in addition to the terms set
forth in Articles 6.2 and 6.3 (as appropriate), such Supply Agreement shall contain terms that, in the event that either Celltech or Amgen assumes exclusive responsibility for manufacture and supply of Antibody Raw Material pursuant to Article 6.7,
will grant Celltech the right to (a) terminate such agreement on reasonable notice with respect to Antibody Raw Materials, (b) have transferred to Amgen or Celltech (as appropriate) and to receive assistance reasonably required by Amgen or
Celltech (as appropriate) to effect transfer of the Third Party’s Information relating to the manufacture and analysis of Antibody Raw Material in sufficient detail for Amgen or Celltech (as




  
 65










	 	 
appropriate) to implement the [*] of such [*], including Information contained in the [*] of any applicable Regulatory Filings and the results of any stability studies performed on Antibody Raw
Material, (c) have provided Amgen or Celltech (as appropriate) such Information pertaining to the manufacture and analysis of Antibody Raw Material as Amgen or Celltech (as appropriate) shall reasonably request; (d) if requested by Amgen
or Celltech (as appropriate), obtain reasonable assistance in the manufacture of trial batches of Antibody Raw Material to enable Amgen or Celltech (as appropriate) to determine its ability to manufacture Antibody Raw Material; (e) audit in
accordance with Article 6.6; (f) obtain copies of any direct communications by or to the Manufacturing Lead from Regulatory Authorities having jurisdiction in the Territory regarding and concerning the manufacture of any Antibody Product and
(g) name Amgen as a permitted assignee or sublicensee. 


 Once Amgen has given such
consent, Amgen shall be deemed to have accepted the terms of such Third Party Supply Agreement. Both Parties shall comply and operate in accordance with the terms of any such Supply Agreement accepted by Amgen and entered into by Celltech. To the
extent the same relates to Antibody Product, all (i) out-of–pocket costs, expenses and liabilities (calculated on an arm’s-length basis in accordance with GAAP), (ii) FTE Cost and (iii) cost of Materials used, which are
incurred by Celltech in discharging its obligations pursuant to this Article 6 shall be Research and Development Costs if incurred for Development and a Commercialisation Expense if incurred for Commercialisation, and all amounts recovered from any
Third Party supplier shall be credited to Product Contribution revenues, provided however, that if the costs, liabilities and/or amounts recovered are also applicable to products other than Antibody Products, then only an equitable portion of such
costs, liabilities and/or amounts recovered shall be so allocated. The sharing of liabilities under any Third Party Supply Agreement is without prejudice to Article 18. In the event that Amgen obtains supply of Antibody Product in Finished Form from
a Third Party, costs, liabilities and/or amounts recovered shall also be allocated to Research and Development Costs or Commercialisation Expenses mutatis mutandis. 

  
 66










	6.5	 Standards of Supply.  Antibody Raw Material, in the case of the Manufacturing Lead, and Antibody Products in Finished Form, in the
case of Amgen, shall be manufactured in accordance with current GMP in manufacturing processes and facilities as described in the applicable Regulatory Filings submitted to and approved by the Regulatory Authority. 



 

	6.6	 Audit.   Each Party, to the extent it is not the Manufacturing Lead, shall have the right to conduct reasonable quality
assurance audits with respect to all facilities, operations and laboratories (and any records related thereto) of the other Party or its subcontractors (provided that, where the Manufacturing Lead is a Third Party, only to the extent
permitted by the relevant Supply Agreement), where applicable manufacturing activities are conducted, as is reasonably necessary to verify the Manufacturing Lead’s conformance (or Amgen’s conformance with respect to Antibody Product in
Finished Form) with cGMP, cGLP, cGCP and other regulatory requirements. Such audits shall be conducted upon reasonable notice during reasonable business hours. 



 

	6.7	 Manufacturing Option.  


  

	 	(a)	 At any time during Development or Commercialisation and subject to any commitments already made to any Third Party supplier either Party may seek to
manufacture and supply Antibody Raw Material by providing written notice to the other Party and the Collaboration Committee that it wishes to assume manufacture and supply of the Antibody Raw Material for the Territory or its Lead Territory. Within
[*] after receipt of such request, the other Party shall have the right to provide reciprocal notice of its desire to manufacture and supply Antibody Raw Material. 



Thereafter, the Collaboration Committee shall promptly meet to consider any and all requests and determine ([*]) whether
one or both of the Parties should have the right and obligation to manufacture and supply Antibody Raw Material, applying the following criteria: 
  

	 	(i)	 the FAMC resulting from the requesting Party’s manufacturing is likely to be less than the actual or probable FAMC as invoiced by the Third
Party manufacturer or, if both Parties desire to assume such responsibility, the probable FAMC as between the Parties; 



  
 67










	 	(ii)	 other benefits, such as stability of supply or quality of product, are like to accrue to both Parties as a result of manufacture of Antibody Raw
Material by the requesting Party or Parties; 


  

	 	(iii)	 a Third Party manufacturer for Development or Commercialisation supplies has not been identified or such Third Party manufacturer is unable or
unwilling to enter into a Supply Agreement on terms reasonably satisfactory to both Parties; 


  

	 	(iv)	 the desirability of a second (or further) source of supply of Antibody Raw Material; 



 

	 	(v)	 that the Third Party manufacturer is in material breach of its supplier obligations and that as a result of such breach, the requesting Party or
Parties should assume manufacture and supply of Antibody Raw Material; or 


  

	 	(vi)	 the cost and difficulty of enforcing the relevant Supply Agreement to enable one or both Parties to manufacture and supply Antibody Product.



  

	 	(b)	 If the Collaboration Committee determines that, after applying the foregoing criteria, in total it would be beneficial to the interests of both
Parties that the requesting Party or Parties manufacture and supply Antibody Raw Material, the selected Party or Parties shall have the right and obligation to manufacture and supply Antibody Raw Material for either the Territory or its Lead
Territory as determined by the Collaboration Committee. Upon selection of a Party, then 


  

	 	(i)	 If Amgen is the selected Party, Celltech shall itself transfer any Information Controlled by Celltech, and Celltech shall use the level of effort
determined by the Collaboration Committee to enforce (or, at the request of Amgen and to the extent permitted by the terms of the Supply 



  
 68










	 	 
Agreement assign to Amgen the right to enforce) the terms and conditions of the Third Party Supply Agreement entered into by Celltech pursuant to Article 6.4 including (but only to the extent
permitted by the Supply Agreement with such Third Party) the provision to Amgen of any Information and assistance reasonably required by Amgen from such Third Party pertaining to the manufacture and analysis of Antibody Raw Material with the
objective of Amgen being enabled to implement the [*] of [*], including Information contained in the [*] of any applicable Regulatory Filings and the results of any stability studies performed by or on behalf of Celltech; and



  

	 	(ii)	 If Amgen is the selected Party, Celltech shall, at the request of Amgen, use the level of effort determined by the Collaboration Committee to
enforce (or, to the extent permitted by the Supply Agreement with such Third Party assign to Amgen the right to enforce) the terms and conditions of the Third Party Supply Agreement entered into by Celltech pursuant to Article 6.4 (but only to the
extent such terms are included in any such Supply Agreement, and only to the extent such Supply Agreement relates to Antibody Raw Material) including termination of the Third Party Supply Agreement on reasonable notice (but only if the Collaboration
Committee has determined Amgen shall have the exclusive right and obligation to manufacture and supply Antibody Raw Material); and 


  

	 	(iii)	 The Parties (as appropriate) shall continue to work with the Third Party supplier in order to achieve the manufacturing transition or second
sourcing with minimal disruption, and to ensure adequate supplies of Antibody Raw Material during the transitional process; and 


  

	 	(iv)	 The Party or Parties assuming the obligation to manufacture and supply Antibody Raw Material Party shall use Commercially Reasonable Efforts to put
all necessary manufacturing processes in place so as to be able to meet Development or Commercialisation requirements (as appropriate) of Antibody Raw Material (of a quality and quantity required of the Manufacturing Lead); and




  
 69










	 	(v)	 The Party assuming the obligation to manufacture and supply Antibody Raw Material shall have the right to include the cost of [*] as Research and
Development Costs if such transfer takes place during Development or as a Commercialisation Expense if such transfer takes place during Commercialisation (but only to the extent any such costs relate to Antibody Raw Material).



  

	 	(c)	 All amounts paid to the Third Party in connection with the supply of Antibody Raw Material and any Third Party Supply Agreement (including all
amounts paid in connection with the provision of Information and assistance), and all costs incurred by the Parties in enforcing the terms of any Supply Agreement, shall be a Research and Development Cost if incurred for Development and a
Commercialisation Expense if incurred for Commercialisation. All amounts recovered from the Third Party by way of damages as a result of any breach by the Third Party supplier in the supply of Antibody Raw Material shall be revenues included in the
calculation of the Product Contribution. 


  

	6.8	 Quality Responsibility.    The Parties acknowledge that, in order to meet regulatory requirements prior to the
commencement of any supply of Antibody Raw Material or Antibody Product in Finished Form, appropriate quality assurance agreements relating to such supply must be entered into between the Parties and between each Party and its Third Party
manufacturers. The Parties will negotiate such quality assurance agreements in good faith having regard to the document entitled “Quality Responsibilities” and dated March 12, 2002. If the Parties are unable to conclude any
such agreement then the matter shall be referred at the request of either Party to the Collaboration Committee. 



  
 70









 ARTICLE 7 
 CONSIDERATION 
  

	7.1	 Up-front Fees.    In consideration of the rights granted hereunder by Celltech, Amgen shall pay Celltech a
non-refundable, non-creditable licence fee of [*] ($[*]) within [*] after the Effective Date. 


  

	7.2	 Milestone Payments.    As further consideration for the rights granted hereunder by Celltech, Amgen shall make
non-creditable, non-refundable payments (“Milestone Payment(s)”) to Celltech within [*] after the first occurrence of each of the corresponding events listed below (each, a “Milestone Event”), in the amount
provided: 


  

					
	  	    	 Milestone Event	  	Milestone Payment Amount
			
	(a)	    	[*].	  	[*] ($[*])
			
	(b)	    	[*].	  	[*] ($[*])
			
	(c)	    	[*].	  	[*] ($[*])
			
	(d)	    	[*].	  	[*] ($[*])
			
	(e)	    	[*].	  	[*] ($[*])

 Each Milestone Payment shall be payable only once, no matter how many times the
corresponding Milestone Event is achieved by one or more Antibody Product(s). 

  
 71









 ARTICLE 8 
 COMPENSATION 
  

	8.1	 Product Contribution.    The Parties shall split 50:50 the Product Contribution from Commercialisation of Antibody
Products throughout the Territory whether such Product Contribution is a profit or a loss. For the avoidance of doubt, any Commercialisation Expenses incurred prior to Regulatory Approval of an Antibody Product shall be charged to the Product
Contribution and be borne by the Parties on a 50:50 basis. 


  

	8.2	 Calculation and Duration of Product Contribution.    The Product Contribution shall be payable in respect of sales
in the Territory, on an Antibody Product-by-Antibody Product basis, for so long as there are sales by either Party or their sublicensees or distributors of that Antibody Product in the Territory. The Product Contribution shall be calculated on a
quarterly basis for each Antibody Product in accordance with Schedule B. 


  

	8.3	 Quarterly Reconciliation of Product Contribution. 



 

	 	(a)	 Within [*] following the end of each Calendar Quarter, each Party shall submit to the other Party a written report (in reasonable detail specified
by the categories set out in Schedule B and with supporting documentation) which shall show separately with respect to each Antibody Product and each country in the Territory, to the extent made or incurred by each Party the following: (i) a
calculation of the Product Contribution showing all Net Sales achieved and recoveries from legal actions and any other relevant revenues, Cost of Goods, Commercialisation Expenses (per category), Other Expenses and Licence Fees incurred;
(ii) the variation from the budgeted Product Contribution for that quarter (identifying in the same any variance which is attributable to fluctuations in currency exchange rates); and (iii) an estimate for the Product Contribution for the
remainder of the Contract Year. 


  

	 	(b)	 Within [*] following the end of each Calendar Quarter, Amgen shall submit to Celltech a written consolidated report setting forth in reasonable
detail the 



  
 72










	 	 
calculation of total Product Contribution for each Antibody Product in each country in the Territory for that Calendar Quarter and the calculation of any net amount owed by Celltech to Amgen or
by Amgen to Celltech, as the case may be in order to ensure the appropriate sharing of Product Contribution in accordance with Article 8.1, and the net amount payable (the “Balance Payment”) shall be paid by Amgen or Celltech (as
the case may be) within [*] after receipt of such written report. If the Product Contribution is a negative number and the Balance Payment is [*] ([*]%) or greater in excess of the budgeted Balance Payment for that quarter (after taking into account
any change in applicable exchange rates used in calculating the Balance Payment for that quarter and the budgeted Balance Payment), the paying Party may elect to carry over to the next quarter the difference between the budgeted Balance Payment and
the invoiced Balance Payment, and such carried sum shall be included in the calculation of the amount of the Balance Payment for the next quarter. The election to roll over must be provided within [*] after receipt of the above-referenced written
report. 


  

	 	(c)	 In the event of a dispute with respect to any amounts under this Article 8.3, the disputing Party shall provide written notice to the Joint
Commercialisation Committee within [*] after receipt of the written report in question, specifying such dispute and explaining the basis of the dispute. The Joint Commercialisation Committee shall promptly thereafter meet and negotiate in good faith
a resolution to such dispute. The resolution of such dispute shall [*]. In the event that the Parties are unable to resolve such dispute within [*] after written notice by the disputing Party, the matter shall be resolved in the manner set forth in
Article 15. Notwithstanding the above, such dispute shall not affect a Party’s obligation to pay all undisputed amounts (and all undisputed amounts shall be paid in accordance with Article 8.3(b)) or a Party’s right to audit the records of
the other Party in accordance with Article 8.5. 


  

	 	(d)	 Interest shall accrue from the due date for payment as set out in Article 8.3(b) on all amounts due and payable but unpaid, including any amounts
withheld which 



  
 73










	 	 
are subsequently agreed or determined to be payable. All withheld amounts, together with interest, shall be paid within [*] of any such agreement or determination. 



 

	8.4	 Payments; Tax Matters. 


  

	 	(a)	 All payments to be made under this Agreement shall be made in U.S. Dollars by bank wire transfer in immediately available funds to a bank account
designated from time to time in writing by the Party receiving the funds. 


  

	 	(b)	 Net Sales or other revenues received or payments due in currencies other than Dollars shall first be calculated in the relevant foreign currency and
then converted to Dollars against the currency in question on the rate of exchange applicable on the last Business Day of the Calendar Quarter in respect of which the funds are payable using the currency exchange rates quoted by Bloomberg
Professional, a service of Bloomberg L.P., during the period of such Net Sales, or in the event Bloomberg Professional is not available then The Wall Street Journal. Budgets and intra-budget forecasts of future Net Sales and
expenses in currencies other than Dollars shall be converted into Dollars at budget rates to be agreed between the Parties at the Joint Commercialisation Committee. 



 

	 	(c)	 All amounts due under this Agreement shall be paid exclusive of any Value Added Tax (which, if applicable shall be payable by a Party in addition
upon receipt of a valid Value Added Tax invoice). Each Party agrees to inform the other Party forthwith if it concludes that there is a Value Added Tax law or practice, or a change in such law or practice, which requires it to account for Value
Added Tax on any payments due pursuant to this Agreement at any time after the Effective Date, with a view to the Parties using their best endeavours to agree on the manner in which subsequent payments shall be made to reduce or eliminate the
liability of the Parties to pay Value Added Tax. 


  

	 	(d)	 All amounts due under this Agreement shall be paid in full without deduction for any applicable taxes, levies, imposts, duties and fees of whatever
nature imposed 



  
 74










	 	 
by or under the authority of any government or public authority, except for tax legally required to be deducted or withheld. Where any sum due to be paid to a Party under this Agreement is
subject to any withholding or similar or other tax, the Parties shall take all reasonable steps to do all such acts and things and to sign all such deeds and documents as will enable them to take advantage of any applicable double taxation
agreements to reduce the rate of withholding or similar taxes with the object of paying the sums due under deduction of a reduced rate of withholding tax or on a gross basis. In the event there is no double taxation agreement or the reduced rate of
withholding tax under the relevant double taxation agreement is greater than [*] ([*]%), the Party making payment shall pay such withholding or similar tax, deduct the relevant amount from the payment due to the other Party, and secure and send to
the other Party proof of such withholding or similar tax in a form in accordance with the relevant taxation authority as evidence of such payments. Each Party agrees to inform the other Party forthwith if it concludes that there is any law or
practice or any change in such law or practice which requires it to deduct or withhold tax in respect of any payments due pursuant to this Agreement at any time after the Effective Date with a view to the Parties using their best endeavours to agree
on the manner in which subsequent payments shall be made to reduce or eliminate the liability of both Parties to deduct or withhold any amount on account of tax. 



 

	 	(e)	 Any payment of any amount under this Agreement not received by the due date specified herein shall accrue interest thereafter on the sum due and
owing from the date payment is due until the date payment is received at the rate equal to [*]. 


  

	8.5	 Records; Audits. Each of Celltech and Amgen and their respective Affiliates shall keep and maintain complete and accurate records and books
of account documenting in detail sufficient to track and determine, in a manner consistent with GAAP, all revenues, expenses and all other data necessary for the Product Contributions and other sums payable pursuant to this Agreement and in
compliance with the terms of the Agreement. Such records shall be retained for a period of the later of (a) a [*] period following the 



  
 75










	 	 
year in which any payments were made hereunder; (b) the expiration of the applicable tax statute of limitations (or any extensions thereof); or (c) such longer period as may be required
by law. Each Party and their respective Affiliates shall permit independent accountants of internationally recognised standing retained by the other Party (the “Auditing Party”) and reasonably acceptable to the other Party, upon
reasonable prior written notice, to have access to its and its Affiliates’ records and books and premises for the sole purpose of determining the appropriateness of costs charged by or accrued to the Party being audited and the correctness of
amounts due and payable under this Agreement for any year ending no more than [*] prior to the date of such request; provided however, that the books and records for any particular Contract Year shall only be subject to one audit. Such
examination shall be conducted during regular business hours and no more than once in each calendar year. The report of such accountant shall be limited to a certificate verifying, or not verifying, as the case may be, any report made or payment
submitted by the audited Party during such period. In the event the accountant shall be unable to verify the correctness of any such payment, the accountant’s report shall specify why such payment is unverifiable and the amount of any
discrepancy. The audited Party shall receive a copy of each such report concurrently with receipt by the Auditing Party and the Parties shall use good faith efforts to resolve any discrepancies. All information contained in any such report shall be
deemed Confidential Information hereunder. If such examination reveals that such costs or payments have been misstated, any adjustment shall be promptly refunded or paid, as appropriate. The Auditing Party shall pay the fees and expenses of the
accountant engaged to perform the audit, unless such audit reveals a net discrepancy of [*] ([*]%) or more for the period examined which is to the disadvantage of the Auditing Party, in which case the Party who misreported shall pay all reasonable
costs and expenses incurred by the Auditing Party in the course of making such determination. Upon the expiration of [*] following the end of any Contract Year, the calculation of any such amounts payable with respect to such year shall be
binding and conclusive upon a Party entitled to such audit and the other Party or its Affiliates shall be released from any liability or accountability with respect to such amounts for such year. 



  
 76









 ARTICLE 9 
 COLLABORATION 
  

	9.1	 Collaboration Committee Formation. As soon as practicable following the Effective Date, the Parties shall establish a Collaboration Committee
to oversee the Research, Development and Commercialisation of all Antibody Products. The Collaboration Committee shall be comprised of an equal number (not more than four) of Celltech and Amgen representatives and shall include senior officers or
managers from each Party. The Collaboration Committee shall follow the organisational and meeting procedures set forth in Article 9.3. 


  

	9.2	 Collaboration Committee Responsibilities. 



The Collaboration Committee shall be responsible for: 

 

	 	(a)	 managing the relationship between the Parties; 


  

	 	(b)	 resolving issues in the Joint Research, Joint Development and Joint Commercialisation Committees that are [*], or that are expressed to be matters
to be considered or determined by the Collaboration Committee; and 


  

	 	(c)	 performing such other functions as are expressly set out in this Agreement as matters for the Collaboration Committee or are consistent with the
terms of this Agreement to further the purposes of the collaboration as set forth in Article 2, as determined by the Parties. 


  

	9.3	 Decision Making; Administrative Matters. 



 

	 	(a)	 All decisions of the Collaboration Committee shall be made by the unanimous decision of Celltech and Amgen, with the representatives of each Party
who are members of the Collaboration Committee collectively having one vote in any matter requiring the approval of the Collaboration Committee. The Parties agree that all decisions regarding the Research, Development or Commercialisation of an
Antibody Product will be made in the interests of maximising the value of the Antibody Product on a global basis. 



  
 77










	 	(b)	 If the Collaboration Committee is unable to reach unanimous agreement on any issue within its authority pursuant to Article 9.2, the Parties shall
attempt to resolve such dispute in accordance with the provisions of Article 15. 


  

	 	(c)	 The Collaboration Committee shall establish its own procedural rules for its operation, consistent with the terms of this Article 9.3(c). A
chairperson for the Collaboration Committee shall be appointed from among its members. The chairperson shall be appointed on an annual basis and shall alternate each year between a Celltech representative and an Amgen representative, with Celltech
being responsible for designating the chairperson for the First Contract Year after the Effective Date. The chairperson shall be responsible for calling meetings of the Collaboration Committee and for leading the meetings. A Collaboration Committee
member of the Party hosting a meeting of the Collaboration Committee shall serve as secretary of that meeting. The secretary of the meeting shall prepare and distribute (within ten (10) Business Days following each meeting) to all members of
the Collaboration Committee the minutes of the meeting. Such minutes shall provide a description in reasonable detail of the discussions held at the meeting and a list of any actions, decisions or determinations approved by the Collaboration
Committee. The minutes of each Collaboration Committee meeting shall be approved or disapproved, and revised as necessary, at the next meeting. Final minutes of each meeting shall be distributed to the members of the Collaboration Committee by the
chairperson. 


  

	 	(d)	 The Collaboration Committee shall meet at least every six (6) months and in addition within [*] of a request by either Party to have such a
meeting. Such meetings shall be held at such times as are mutually agreed upon by the Collaboration Committee. Meetings may take place by video conference or telephone conference or such other means as the Collaboration Committee shall decide,
provided that all members of the Collaboration Committee shall meet in person at least [*]. Meetings held in person shall alternate between Amgen and Celltech locations. The first meeting shall be held at Celltech’s facilities.




  
 78










	 	(e)	 If a Party’s representative is unable to attend a meeting, such Party may designate an appropriate alternate representative to attend such
meeting in place of the absent representative. In addition, each Party may (at its discretion and with the consent of the other Party) invite additional employees, consultants or scientific advisors to attend the Collaboration Committee meetings.



 ARTICLE 10 
 GRANT OF RIGHTS 
  

	10.1	 Patent Licences. 


  

	 	(a)	 Amgen hereby grants to Celltech (i) a sole royalty-free licence (co-exclusive with Amgen), under the [*] Patent Rights, [*] Patent Rights, [*]
Know-How, [*] Know-How [*] and [*] Know-How; and (ii) a non-exclusive royalty-free licence under the [*] Patent Rights and other [*] Know-How to Research, Develop, Commercialise, make, have made, use, sell, have sold, offer to sell or resell,
import, export, distribute or otherwise transfer physical possession of or otherwise transfer title in Antibody Products in the Field in the Territory, solely in compliance with the terms and conditions of this Agreement. For the avoidance of doubt,
the grant of a licence under [*] Patent Rights and [*] Know-How is not intended to require the transfer by Amgen to Celltech of Materials and Information beyond that explicitly set forth in this Agreement. 



 

	 	(b)	 Celltech hereby grants to Amgen (i) a sole royalty-free licence (co-exclusive with Celltech), under the [*] Patent Rights, [*] Patent Rights,
[*]Patent Rights, [*] Know-How, [*] Know-How [*] and [*] Know-How; and (ii) a non-exclusive royalty-free licence under [*] Patent Rights and other [*] Know-How to Research, Develop, Commercialise, make, have made, use, sell, have sold, offer to
sell or resell, import, export, distribute or otherwise transfer physical 



  
 79










	 	 
possession of or otherwise transfer title in Antibody Products in the Field in the Territory, solely in compliance with the terms and conditions of this Agreement. For the avoidance of doubt, the
grant of a licence under [*]Patent Rights and [*] Know-How is not intended to require the transfer by Celltech to Amgen of Materials and Information beyond that explicitly set forth in this Agreement. 



 

	 	(c)	 Certain licence rights granted to a Party under this Article 10.1 may include a sublicence of Patent Rights and/or know-how of Third Parties under
Third Party licences. Notwithstanding anything to the contrary in this Agreement, the Party receiving a sublicence of such Third Party licences shall, in exercising such sublicence rights, subject to and so far as the terms are applicable to its
activities, comply with the provisions of such Third Party licences relating to Antibody Products to the extent the granting Party has notified in writing the terms of such Third Party licence to the Party receiving a sublicence of such Third Party
licences. Each Party shall promptly provide to the other Party a copy of any notice of breach received by it under any such Third Party licence. 


  

 

	10.2	 Trademark; Copyright Licences.  


  

	 	(a)	 Amgen hereby grants to Celltech a non-exclusive, royalty-free licence to use and display the Amgen Trademarks (subject to the provisions of Article
5.11(h)) and a sole royalty-free licence (co-exclusive with Amgen), to use and display the Product Trademarks, in connection with Antibody Products in the Territory. Celltech hereby grants to Amgen a non-exclusive, royalty-free licence to use and
display (subject to the provisions of Article 5.11(h)) the Celltech Trademarks and a sole royalty-free licence (co-exclusive with Amgen) to use and display Product Trademarks in connection with Antibody Products in the Territory. All licences
granted under this Article 10.2(a) are sublicensable pursuant to the terms of Article 19.10. 



  
 80










	 	(b)	 Each Party hereby grants to the other Party a sole royalty-free licence (co-exclusive with the Party), with the right to sublicence solely pursuant
to the terms of Article 19.10, under the Party’s entire right, title and interest in any intellectual property rights in Promotional Materials and additional Antibody Product-specific materials to reproduce, distribute copies of, prepare
derivative works of and publicly perform and display such Promotional Materials or additional Antibody Product-specific materials solely in connection with Antibody Products in the Field in the Territory and in accordance with this Agreement.



  

	 	(c)	 The Joint Commercialisation Committee shall determine a Product Trademark that shall be applied to each Antibody Product in the Territory. In the
event that the Joint Commercialisation Committee is unable to agree on such a Product Trademark, and if the matter is not determined in accordance with Article 5.7, the Territorial Commercial Lead shall be free to choose and in any event the
Territorial Commercial Lead shall own, the Product Trademark in its respective Lead Territory. 


  

ARTICLE 11 

INTELLECTUAL PROPERTY RIGHTS 
  

	11.1	 Ownership. 


  

	11.1.1	 As between the Parties, Amgen shall own all right, title and interest in and to all [*] Technology (other than [*] Know-How and all [*] Patent
Rights), subject to the rights and licences granted to Celltech hereunder. 


  

	11.1.2	 As between the Parties, Celltech shall own all right, title and interest in and to all [*] Technology (other than [*] Know-How and all [*] Patent
Rights), subject to the rights and licences granted to Amgen hereunder. 



  
 81










	11.1.3	 As between the Parties, all right, title and interest in and to all [*] Know-How and all [*] Patent Rights shall be [*] by [*]. Subject to the
rights and licences granted hereunder, each Party shall have [*]. 


  

	11.1.4	 Other than as expressly set forth in this Agreement, neither Party shall have any right in and to any intellectual property owned or controlled by
the other Party and neither Party shall have an obligation to grant the other Party any rights therein. 


  

	11.1.5	 Other than as expressly set forth in Articles 11.2, 11.4 and 11.6, neither Party shall have the right to prepare, file, prosecute, maintain, defend,
settle and/or enforce Patent Rights or Product Trademarks Controlled by the other Party, such activity being the exclusive right (but not the obligation) of the Party Controlling the same. 



 

	11.2	  Prosecution and Defence. 


  

	11.2.1	 Promptly after the Effective Date, Celltech shall provide Amgen with copies of all material documents in Celltech’s possession pertaining to
[*] Patent Rights [*]. During the term of this Agreement, each Party shall as soon as practicable provide the other Party (as appropriate) with all material documents and any other document Controlled by a Party reasonably requested by the other
Party (such request to identify the specific documents required), pertaining to [*] Patent Rights, [*] Patent Rights, [*] Patent Rights and [*] Patent Rights. 



 

	11.2.2  (a)	 Amgen shall have the first right (but not the obligation) to have mutually acceptable outside counsel (i) at any time prepare, file, prosecute,
maintain and defend the Product Trademarks in the Amgen Territory and [*] Patent Rights outside the Celltech Territory; (ii) prior to, on and following the Transition Date (as defined in Article 11.2.9 below) prepare, file, prosecute and
maintain any [*] Patent Rights and the [*] Patent Rights that are [*] to any Antibody Products (“[*] Patent Rights”) in the Amgen Territory; (iii) on and following the Transition Date, defend any [*] Patent Rights and [*]
Patent Rights in the Amgen Territory; and (iv) for the avoidance of doubt only, prior to the Transition Date defend any [*] Patent Rights that are [*]to any Antibody Products (“[*] Patent Rights”) in the Celltech Territory.




  
 82










	 	(b)	 Celltech shall have the right to review and comment on any papers pertaining to proposed applications, responses, interferences and oppositions
before the filing thereof by such counsel with any patent or trademark office (e.g., national, regional or international) (“Consultation Rights”), regarding [*] Patent Rights, [*] Patent Rights and Product Trademarks in the Amgen
Territory. Celltech shall also have Consultation Rights regarding [*] Patent Rights and [*] Patent Rights outside the Amgen Territory. If such outside counsel concludes that taking, or failing to take, any specific action(s) would be inconsistent
with its instructions under Article 11.2.4, then Amgen shall not take, or shall take (as the case may be), such specific action(s) unless the prior express written consent of Celltech shall have been obtained. Amgen shall have the right to
propose an alternative strategy for Celltech’s consideration. To that end, Amgen shall instruct such outside counsel to furnish Celltech with a reasonably complete draft of each submission to a patent or trademark authority regarding any such
[*] Patent Rights, [*] Patent Rights, [*] Patent Rights, [*] Patent Rights and Product Trademarks no later than [*] prior to the date such submission is proposed to be made, or if given less than [*] to respond as soon as practicable, and will
consider any of Celltech’s reasonably timely comments thereon. Additionally, Amgen shall instruct such outside counsel to provide Celltech with a copy of each submission made to and document received from a patent or trademark authority
regarding any such [*] Patent Rights, [*] Patent Rights, [*] Patent Rights, [*] Patent Rights and Product Trademarks reasonably promptly after making such filing. 



 

	 	(c)	 Amgen shall have the right, at any time and at its sole option, to elect not to proceed with and/or to abandon the preparation, filing, prosecution,
maintenance and/or defence of any Patent Right or any Product Trademark it is permitted to pursue under Article 11.2.2(a), provided that it shall give Celltech notice of such




  
 83










	 	 
intention at least [*] before a final due date which would result in the abandonment, cancellation or lapse of an issued patent or pending patent application or abandonment, cancellation or lapse
of such granted trademark or pending trademark application. In such case, Celltech, at its option, may assume the right to prepare, file prosecute, maintain and/or defend any such Patent Right or Product Trademark. Amgen shall have Consultation
Rights in respect of any such Patent Right and Product Trademark and if such outside counsel concludes that taking, or failing to take, (as the case may be) any specific action(s) would be inconsistent with its instructions under Article 11.2.4,
then Celltech shall not take, or shall take (as the case may be), such specific action(s) unless the prior express written consent of Amgen has been obtained. Celltech shall have the right to propose an alternative strategy for Amgen’s
consideration. To that end, Celltech shall instruct such outside counsel to furnish Amgen with a reasonably complete draft of each submission to a patent or trademark authority regarding any such Patent Rights and Product Trademark no later than [*]
prior to the date such submission is proposed to be made, or if given less than [*] to respond as soon as practicable, and will consider any of Amgen’s reasonably timely comments thereon. Additionally, Celltech shall instruct such outside
counsel to provide Amgen with a copy of each submission made to and document received from a patent or trademark authority regarding any such Patent Rights and Product Trademark reasonably promptly after making such filing.



  

	 	(d)	 A decision by Amgen not to exercise its right pursuant to Article 11.2.2(a) to prepare, file, prosecute, maintain and/or defend any Patent
Right or any Product Trademark as permitted by the terms of that Article shall not affect any of Amgen’s licence or other rights under this Agreement. 



 

	11.2.3  (a)	 Celltech shall have the first right (but not the obligation) to have mutually acceptable outside counsel (i) at any time prepare, file,
prosecute, maintain and defend the Product Trademarks in the Celltech Territory and [*] Patent Rights in the Celltech Territory; (ii) prior to, on and following the Transition Date prepare,




  
 84










	 	 
file, prosecute and maintain any [*] Patent Rights in the Celltech Territory; (iii) on and following the Transition Date, defend any [*] Patent Rights in the Celltech Territory; and
(iv) for the avoidance of doubt only, prior to the Transition Date defend any [*] Patent Rights and [*] Patent Rights in the Amgen Territory. 


  

	 	(b)	 Amgen shall have Consultation Rights regarding [*] Patent Rights and [*] Patent Rights outside the Amgen Territory. Amgen shall also have
Consultation Rights regarding [*] Patent Rights, [*] Patent Rights and Product Trademarks in the Celltech Territory. If such outside counsel concludes that taking, or failing to take, any specific action(s) would be inconsistent with its
instructions under Article 11.2.4, then Celltech shall not take, or shall take, (as the case may be) such specific action(s) unless the prior express written consent of Amgen shall have been obtained. Celltech shall have the right to propose an
alternative strategy for Amgen’s consideration. To that end, Celltech shall instruct such outside counsel to furnish Amgen with a reasonably complete draft of each submission to a patent or trademark authority regarding any such [*] Patent
Rights, [*] Patent Rights, [*] Patent Rights, [*] Patent Rights and Product Trademarks no later than [*] prior to the date such submission is proposed to be made, or if given less than [*] to respond as soon as practicable, and will consider any of
Amgen’s reasonably timely comments thereon. Additionally, Celltech shall instruct such outside counsel to provide Amgen with a copy of each submission made to and document received from a patent or trademark authority regarding any such [*]
Patent Rights, [*] Patent Rights, [*] Patent Rights, [*] Patent Rights and Product Trademarks reasonably promptly after making such filing. 


  

	 	(c)	 Celltech shall have the right, at any time and at its sole option, to elect not to proceed with and/or to abandon the preparation, filing,
prosecution, maintenance and/or defence of any Patent Right or Product Trademark it is permitted to pursue under Article 11.2.3(a), provided that it shall give Amgen notice of such intention at least [*] before a final due date which would
result in the abandonment, cancellation or lapse of an issued patent or pending patent application or 



  
 85










	 	 
abandonment, cancellation or lapse of such granted trademark or pending trademark application. In such case Amgen, at its option, may assume the right to prepare, file, prosecute, maintain and/or
defend any such Patent Right or Product Trademark. Celltech shall have Consultation Rights in respect of any such Patent Right and Product Trademark and if such outside counsel concludes that taking, or failing to take, any specific action(s) would
be inconsistent with its instructions under Article 11.2.4, then Amgen shall not take, or shall take (as the case may be), such specific action(s) unless the prior express written consent of Celltech has been obtained. Amgen shall have the right to
propose an alternative strategy for Celltech’s consideration. To that end, Amgen shall instruct such outside counsel to furnish Celltech with a reasonably complete draft of each submission to a patent or trademark authority regarding any such
Patent Rights and Product Trademark no later than [*] prior to the date such submission is proposed to be made, or if given less than [*] to respond as soon as practicable, and will consider any of Celltech’s reasonably timely comments thereon.
Additionally, Amgen shall instruct such outside counsel to provide Celltech with a copy of each submission made to and document received from a patent or trademark authority regarding any such Patent Rights and Product Trademark reasonably promptly
after making such filing. 


  

	 	(d)	 A decision by Celltech not to exercise its right pursuant to Article 11.2.3(a) to prepare, file, prosecute, maintain and/or defend any Patent Right
or any Product Trademark as permitted by the terms of that Article shall not affect any of Celltech’s licence or other rights under this Agreement. 



 

	11.2.4	 Outside counsel retained under this Article 11 shall be instructed to act in the best interests of both Parties under this Agreement and such
counsel shall also be instructed to secure claims of the broadest possible scope without jeopardising validity. 


  

	11.2.5	 The Parties shall closely co-ordinate the defence of any attack on the validity and/or any enforcement (against a Third Party developing or
commercialising an Antibody that binds to BEER) of the [*] Patent Rights, [*] Patent Rights, [*] Patent Rights and/or the 



  
 86










	 	 
[*] Patent Rights through the Collaboration Committee (including the right of the Party not responsible for such defence or enforcement to review and comment on any papers relating thereto which
are material to the conduct of such defence or enforcement). Notwithstanding anything to the contrary in this Article 11, prior to the Transition Date, neither Party shall have any right to enforce or defend the validity of Patent Rights Controlled
by the other Party, which right shall be exclusively that of the Party Controlling the Patent Rights. The Party responsible for such defence or enforcement shall not take (nor fail to take) any action with respect to any such defence and/or
enforcement which would, in the opinion of the retained outside counsel, be inconsistent with the instructions given to outside counsel under Article 11.2.4. 



 

	11.2.6	 Celltech agrees to use reasonable efforts to ensure that with respect to any patent application forming part of the [*] Patent Rights and [*] Patent
Rights which it shall initially file in the Celltech Initial Countries in accordance with Article 11 will be filed in a form sufficient to establish the date of original filing as a priority date for the purposes of a subsequent filing in the Amgen
Initial Countries. Amgen agrees to use reasonable efforts to ensure that with respect to any patent application forming part of the [*] Patent Rights and [*] Patent Rights which it shall initially file in the Amgen Initial Countries in accordance
with Article 11 will be filed in a form sufficient to establish the date of original filing as a priority date for the purposes of a subsequent filing in the Celltech Initial Countries. 



 

	11.2.7	 Each Party agrees to co-operate with the other Party in the preparation, filing, prosecution, maintenance and defence of intellectual property
rights as set forth in this Article 11.2, including the signing of any necessary legal papers, and to provide the other Party with data or other information in support thereof, and to use best efforts to ensure the co-operation of any of their
respective personnel as might reasonably be requested in any such matters. 


  

	11.2.8	 Notwithstanding any other provision of this Article 11, neither Party shall have an obligation, which is in violation of, or not permitted by, the
terms of a Third Party agreement, to prosecute or maintain, or take or defend any action in respect of, nor shall 



  
 87










	 	 
either Party have any right, in violation of the terms of a Third Party agreement, to take or defend any action in respect of, any Patent Right which is owned by a Third Party and licensed to
such Party under such Third Party agreement. 


  
  

	11.2.9	 For the purposes of this Article 11, “Transition Date” means the date of [*]. 



 

	11.3	 Patent and Trademark Expenses.  


  

	11.3.1	 Amgen shall have the right to charge (i) up to the date of Regulatory Approval to Commercialise the first Antibody Product, as a Research and
Development Cost; and (ii) thereafter, to the Product Contribution account as a Commercialisation Expense; all of Amgen’s external costs, expenses and fees (as documented by written invoices for legal and expert services and receipts for
filing and maintenance fees paid) to have outside counsel prepare, file, prosecute and maintain and/or defend [*] Patent Rights, [*] Patent Rights, [*] Patent Rights, [*] Patent Rights and Product Trademarks in accordance with Article 11 during the
Term. 


  

	11.3.2	 Celltech shall have the right to charge (i) up to the date of Regulatory Approval to Commercialise the first Antibody Product, as a Research
and Development Cost; and (ii) thereafter, to the Product Contribution account as a Commercialisation Expense; all of Celltech’s external costs, expenses and fees (as documented by written invoices for legal and expert services and
receipts for filing and maintenance fees paid) to have outside counsel prepare, file, prosecute and maintain, and/or defend [*] Patent Rights, [*] Patent Rights, [*] Patent Rights, [*] Patent Rights and Product Trademarks in accordance with Article
11 during the Term. 


  

	11.4	 Enforcement.  


  

	11.4.1	 Amgen shall have the sole right but not the obligation to bring any suit or action (or to otherwise seek payment and/or claim) against a Third Party
developing or commercialising an Antibody product which binds BEER, and Celltech agrees to be 



  
 88










	 	 
joined as a plaintiff to any such suit or action if Amgen so requests: (i) for infringement of a claim within the [*] Patent Rights outside of the Celltech Territory; (ii) on or
following the Transition Date, for infringement of a claim within the [*] Patent Rights and/or [*] Patent Rights in the Amgen Territory; and/or (iii) regarding any Product Trademark in the Amgen Territory. Amgen shall, subject to prior
consultation with Celltech, have the right to determine the strategy and to exclusively control the conduct and all aspects of any such proceedings including the right to settle or compromise such proceedings (by, for example, granting any such
Third Party a sublicence, covenant not to sue or other rights to the Patent Rights or Product Trademark being enforced); provided however, that in any such settlement or compromise Amgen will not admit the invalidity of any claim within [*]
Patent Rights, [*] Patent Rights, [*] Patent Rights and/or [*] Patent Rights without the prior written approval of Celltech. 


  

	11.4.2	 Celltech shall have the sole right but not the obligation to bring any suit or action (or to otherwise seek payment and/or claim) against a Third
Party developing or commercialising an Antibody product which binds BEER, and Amgen agrees to be joined as a plaintiff to any such suit or action if Celltech so requests: (i) on or following the Transition Date, for infringement of a claim
within the [*] Patent Rights in the Celltech Territory; (ii) for infringement of a claim within the [*] Patent Rights in the Celltech Territory; and/or (iii) regarding any Product Trademark in the Celltech Territory. Celltech shall,
subject to prior consultation with Amgen, have the right to determine the strategy and to exclusively control the conduct and all aspects of any such proceedings including the right to settle or compromise such proceedings (by, for example, granting
any such Third Party a sublicence, covenant not to sue or other rights to the Patent Rights or Product Trademark being enforced); provided however, that in any such settlement or compromise Celltech will not admit the invalidity of any claim
within [*] Patent Rights, [*] Patent Rights, [*] Patent Rights and/or such [*] Patent Rights without the prior written approval of Amgen. 


  

	11.4.3	 Neither Party shall bring any action in the Lead Territory of the other Party to enforce any Patent Rights Controlled by the non-lead Party against
a Third Party in respect of such Third Party developing or commercialising an Antibody product which binds BEER, without the lead Party’s prior written consent. 



  
 89










	11.4.4	 Both Parties shall be entitled to charge to the Product Contribution account as a Commercialisation Expense all out-of-pocket costs and expenses
(including outside attorneys’ fees) incurred by such Party in preparing for and/or enforcing Patent Rights or Product Trademarks Controlled by it against a Third Party in respect of the Development or Commercialisation of an Antibody product
that binds BEER, and/or in bringing any suit under this Article 11.4. Recoveries in any actions under this Article 11.4 shall be credited to the Product Contribution account. 



 

	11.5	 Infringement Defence. 


  

	 	(a)	 The Territorial Commercial Lead shall have the first right to defend any actual, alleged or threatened claim or action in its Lead Territory which
names the Territorial Commercial Lead and/or the Territorial Commercial Lead and the other Party and which claims (i) the infringement of Third Party Patent Rights or know-how through Researching, Developing, Commercialising, making, having
made, using, selling, having sold, offering to sell or resell, importing, exporting, distributing or otherwise transferring physical possession of or otherwise transferring title in or to an Antibody Product or (ii) that any Product Trademark
infringes any Third Party Trademark or its use constitutes any unfair trade practice, trade dress imitation, passing off of counterfeit goods or like offence. If the Territorial Commercial Lead shall decide not to defend such an action, the other
Party, to the extent it is named, may defend any such claim or action. The Party defending such claim or action shall have the right to determine the strategy and to exclusively control the conduct and all aspects of any such proceedings;
provided however that the Party defending such claim or action shall not settle or compromise such proceedings that affect the other Party’s rights or interests, without the prior written consent of the other Party (which consent shall
not be unreasonably withheld or delayed). When named, the Party not defending such claim or action shall be entitled to participate in and to have counsel selected by it participate in any action in which the other Party is a named party.




  
 90










	 	(b)	 If either Party defends such claim or action, both Parties shall be entitled to charge if and to the extent the costs of such defence are incurred
during Research or Development as a Research and Development Cost and if and to the extent the costs of such defence are incurred during Commercialisation to the Product Contribution account (as a Commercialisation Expense) all external costs and
expenses (including outside attorneys’ fees) incurred in preparing for and/or carrying out the activities described in this Article 11.5. In addition, any payment that either or both Parties are obliged to make on past and/or future sales of
Antibody Product(s) as a result of a settlement or judgment in such a suit shall also be treated as a Commercialisation Expense. 


  

	11.6	 Trademarks.  Each Territorial Commercial Lead may, but shall not be obligated to, elect to defend the Product Trademarks against
any challenges in its applicable Lead Territory and to enforce the Product Trademarks against any actual, alleged or threatened infringement by Third Parties or against any unfair trade practices, trade dress imitation, passing off of counterfeit
goods or like offences in the applicable Lead Territory. In the event the Territorial Commercial Lead shall so elect, the Territorial Commercial Lead shall determine the strategy and the other Party shall reasonably assist and co-operate in any such
enforcement or defence. All out-of-pocket costs and expenses incurred by either Party in defending or taking any such action shall be charged to the Product Contribution account as a Commercialisation Expense. 



 

	11.7	 Patent Markings.  To the extent practical, each Territorial Commercial Lead shall mark the Antibody Product(s) sold in its
Territory with all applicable patent numbers of Patent Rights of the Parties to the extent permitted by law in those countries of its Lead Territory in which such markings have notice value as against infringers of patents.




  
 91










	11.8	 Co-operation. 


  

	 	(a)	 Each Party shall promptly notify the other upon becoming aware of (i) any actual, alleged or threatened Third Party claim or action against
Celltech and/or Amgen for infringement of any Third Party Trademark through the Development or Commercialisation of an Antibody Product; or of any Third Party Patent Rights through Researching, Developing, Commercialising, making, having made,
using, selling, having sold, offering to sell or resell, importing, exporting, distributing or otherwise transferring physical possession of or otherwise transferring title in or to Antibody Products in the Field in the Territory; or (ii) any
Third Party infringement of the Product Trademarks, or any Patent Rights of either Party relating to an Antibody that binds to BEER, or (iii) in respect of any Antibody Product, any unfair trade practices, trade dress imitation, passing off of
counterfeit goods or like offences. 


  

	 	(b)	 With respect to a Party bringing or defending a suit as permitted under this Article 11 the other Party shall assist and co-operate with the Party
bringing or defending such suit, and if the Party bringing or defending such suit finds it necessary or desirable to join the other Party as a party in such suit, the other Party shall execute all papers or perform such other acts as may reasonably
be required by the Party bringing or defending such suit. 


  

	 	(c)	 A Party bringing or defending suit as permitted under this Article 11 shall notify the other Party of all substantive developments with respect to
such enforcement or defensive actions including, all material filings, court papers and other related documents, substantive settlement negotiations and offer of settlement. 



 

	 	(d)	 Without prejudice to the other terms of this Article 11, all actual, alleged or threatened claims, actions and defences referred to in this Article
11 (including any settlement and conduct of same) shall be co-ordinated through the Collaboration Committee. 



  
 92










	11.9	 Third Party Licences. The Parties acknowledge that they have entered into licence agreements with Third Party owners of potentially blocking
intellectual property and that it may be necessary or desirable to enter into such further licences (individually herein called a “Third Party Licence Agreement”). The Parties agree to treat such Third Party Licence Agreements as
follows: 


  
  

	 	(a)	 Following the Effective Date, if a Party desires to enter into a new Third Party Licence Agreement, it shall inform the Collaboration Committee and,
prior to determining whether to enter into such Third Party Licence Agreement, shall give due consideration to any reasonable comments by the other Party relating thereto, including, comments that entering into such Third Party Licence Agreement [*]
of the other Party. If the Collaboration Committee cannot unanimously agree whether or not such a Third Party Licence Agreement should be entered into, the matter shall be promptly submitted in writing to the [*] of both Parties. If following
discussion between them, the [*] are unable to agree a resolution of the matter within [*] after the matter has been submitted to them the Territorial Commercial Lead may determine the matter for the countries within its Lead Territory.



  

	 	(b)	 Any fees or other payments due Third Parties under Third Party Licence Agreements prior to the first Regulatory Approval for Commercialisation of an
Antibody Product shall be Research and Development Costs, provided however, that if the rights under such Third Party Licence Agreement are also applicable to products other than Antibody Products, then only an equitable portion of such fees
or other payments shall be allocated to the Antibody Product as Research and Development Costs. 


  

	 	(c)	 Any fees or other payments due to a Third Party under a Third Party Licence Agreement after the first Regulatory Approval of an Antibody Product
shall be Licence Fees, provided however, that if the rights under such Third Party Licence Agreement are also applicable to products other than Antibody Products, then only an equitable portion of such fees or other payments shall be
allocated to the Antibody Product as Licence Fees. 



  
 93









 ARTICLE 12 
 CONFIDENTIALITY AND NON-USE 
  

	12.1	 Confidential Information.    Except as otherwise provided in this Article 12, (a) the Parties shall maintain in
confidence and use only for purposes specifically authorised under this Agreement any Confidential Information of the other Party pursuant to this Agreement; (b) Celltech shall keep confidential all [*] Know-How which is [*] to [*], and/or
which is [*] to [*] to [*]and all [*] Know-How and [*] Know-How which is [*] to Antibody Products and/or [*] (whether generated prior to or during the term of this Agreement) and, provided however, where such [*] Know-How may have [*] outside
[*], or where such [*] Know-How or [*] Know-How may have [*] outside Antibody Products and/or [*], Celltech shall be free to use and exploit the same and to disclose the same to Third Parties subject always to obligations of confidentiality; and
(c) Amgen shall keep confidential all [*] Know-How which is [*] to [*] and/or which is [*] to Antibodies to [*], and all [*] Know-How and [*] Know-How which is [*] to Antibody Products and/or [*] (whether generated prior to or during the term
of this Agreement) and, provided however, where such [*] Know-How may have [*] outside [*], or where such [*] Know-How or [*] Know-How may have [*] outside Antibody Products and/or [*], Amgen shall be free to use and exploit the same and to
disclose the same to Third Parties subject always to obligations of confidentiality. 


  

	12.2	 Disclosure.  


  

	12.2.1	 To the extent it is reasonably necessary or appropriate to fulfil its obligations or exercise its rights under this Agreement, a Party may disclose
such Confidential Information of the other Party as it is otherwise obliged under Article 12.1 not to disclose: 


  

	 	(a)	 to its Affiliates and to its (whether actual or potential) sublicensees, consultants, outside contractors and clinical investigators, on a
need-to-know basis and on the condition that such entities or persons agree to keep the Confidential Information confidential for the same time periods and to the same extent as such Party is required to keep such Confidential Information
confidential; 



  
 94










	 	(b)	 to Regulatory Authorities to the extent that such disclosure is reasonably necessary to obtain authorisations to conduct clinical studies or to
file, obtain and maintain Regulatory Approvals and to Commercialise the Antibody Products; 


  

	 	(c)	 to the extent that such disclosure is reasonably necessary in connection with preparing, filing, prosecuting, defending and/or maintaining the other
Party’s Patent Rights in accordance with Article 11; or 


  

	 	(d)	 in prosecuting or defending litigation as explicitly authorised under this Agreement; and in establishing rights or enforcing obligations under this
Agreement; provided that it shall (i) give reasonable advance notice to the other Party of such disclosure requirement; (ii) provide a copy of the proposed disclosure to the other Party; and (iii) at the request of the other
Party, use Commercially Reasonable Efforts in assisting the other Party to secure confidential treatment of such Confidential Information required to be disclosed, including co-operating with the other Party to obtain a protective order of the other
Party’s Confidential Information. 


  

	12.2.2	 Notwithstanding Article 12.1, Amgen may disclose [*] Know-How and [*] Know-How and Celltech may disclose [*] Know-How and [*] Know-How and each
Party may disclose the [*] Know-How which is subject to an obligation of confidentiality under Article 12.1 in any of the following circumstances: 


  

	 	(a)	 where such disclosure would [*]; 


  

	 	(b)	 to its Affiliates, and to its (whether actual or potential) sublicensees, consultants, outside contractors and clinical investigators, on a
need-to-know basis and on the condition that such entities or persons agree to keep the Confidential Information confidential for the same time periods and to the same extent as such Party is required to keep such Confidential Information
confidential; 



  
 95










	 	(c)	 to Regulatory Authorities to the extent that such disclosure is reasonably necessary to obtain authorisations to conduct clinical studies or to
file, obtain and maintain regulatory approvals and to commercialise products other than Antibody Products; 


  

	 	(d)	 without prejudice to Article 11, to the extent that such disclosure is reasonably necessary in connection with preparing, filing, prosecuting,
maintaining and/or defending Patent Rights; or 


  

	 	(e)	 in prosecuting or defending litigation and in establishing rights or enforcing obligations under this Agreement or in complying with applicable
laws, regulations, court or administrative orders, the rules of any relevant stock exchange or the U.S. Securities and Exchange; provided however, in the case of [*] Know-How which is [*] to [*] and/or which is [*] to Antibodies to [*],[*]
Know-How which is [*] to [*] and/or which is [*] to Antibodies to [*],[*] Know-How and [*] Know-How only, to the extent practicable it shall (i) give reasonable advance notice to the other Party of such disclosure requirement; (ii) provide
a copy of the proposed disclosure to the other Party; and (iii) at the request of the other Party, use Commercially Reasonable Efforts to secure confidential treatment of such [*] Know-How which is [*] to [*] and/or which is [*] to Antibodies
to [*],[*] Know-How which is [*] to BEER and/or which is [*] to Antibodies to [*],[*] Know-How and [*] Know-How required to be disclosed, including seeking a protective order of such [*] Know-How which is [*] to [*] and/or which is [*] to Antibodies
to [*],[*] Know-How which is [*] to [*] and/or which is [*] to Antibodies to [*],[*] Know-How and [*] Know-How. 


  

	12.3	 Exceptions.  The obligation not to disclose Confidential Information under this Article 12 shall not apply to any part of such
Confidential Information that: 


  

	 	(a)	 is or becomes published or otherwise becomes publicly known other than by acts of the Party obligated not to disclose such Confidential Information
or its Affiliates or permitted Third Parties pursuant to Article 12.2.1(a) or 12.2.2(b) in breach of this Agreement; 



  
 96










	 	(b)	 was disclosed to the receiving Party or its Affiliates or sublicensees by a Third Party, provided that such Confidential Information was not
obtained by such Third Party from the disclosing Party under an obligation of confidentiality; 


  

	 	(c)	 prior to disclosure under this Agreement, was already in the possession of the receiving Party or its Affiliates or sublicensees, provided
that such Confidential Information was not obtained from the disclosing Party under an obligation of confidentiality; 


  

	 	(d)	 can be shown by written documents to have been independently developed by the receiving Party or its Affiliates without breach of any of the
provisions of this Agreement or access to any Confidential Information provided by the disclosing Party; or 


  

	 	(e)	 is required to be disclosed by the receiving Party to comply with applicable laws, or with a court or administrative order or the rules of any
relevant stock exchange, or the U.S. Securities and Exchange Commission provided however, that this Article 12.3(e) shall not permit a Party to disclose the other Party’s Confidential Information for the purpose of obtaining Patent
Rights and, further provided however, the receiving Party shall, if practicable, notify the disclosing Party in writing (and if practicable provide a copy of the proposed disclosure) prior to any such disclosure and shall use reasonable
efforts to secure confidential treatment thereof prior to its disclosure (whether by protective order or otherwise). 


  

	12.4	 Terms of Agreement. 


 Except as permitted by the foregoing provisions or as otherwise required by law or the rules of any relevant stock exchange or the U.S. Securities and Exchange Commission, the Parties shall not disclose
any terms or conditions of this Agreement to any Third Party without the prior consent of the other Party; provided however, that each Party shall 

  
 97









 
be entitled to disclose the terms of this Agreement without such consent on a need-to-know basis to its financial and legal advisors and potential investors or other financing sources on the
condition that such entities or persons agree to keep such terms confidential for the same time periods and to the same extent as such Party is required to keep such terms confidential. Each Party shall give the other Party a reasonable opportunity
to review all filings with the United States Securities and Exchange Commission or any stock exchange describing the terms of this Agreement prior to submission of such filings, and shall give due consideration to any reasonable comments by the
non-filing Party relating to such filing, including the provisions of this Agreement for which confidential treatment should be sought. 
  

	12.5	 Public Announcements.   Following the Effective Date, the Parties shall issue one or more press releases regarding this
Agreement, the timing and content of which shall be mutually agreed. Except to the extent required by law or the rules of a relevant stock exchange or as otherwise permitted in accordance with this Article 12, neither Party shall make any further
public announcements concerning this Agreement or the subject matter hereof without the prior written consent of the other, which shall not be unreasonably withheld or delayed. The Parties agree to consult with each other reasonably and in good
faith with respect to the text and timing of any press releases prior to the issuance thereof. 


  

	12.6	 Residual Information.  Each Party acknowledges that personnel of the Parties and their Affiliates who participate in the
collaboration set forth in this Agreement also participate in the research, development and commercialisation of other pharmaceutical products unrelated to this Agreement and that each Party’s personnel shall have access to Confidential
Information of the other Party. Each Party further acknowledges that such personnel will retain and use residual information derived from the collaboration and that use of such residual information by such personnel shall not constitute a breach of
this Article 12 to the extent such personnel did not know (and could not reasonably be expected to know) it was the confidential Information of the other Party or otherwise subject to a confidentiality or restricted use obligation; provided
however, that notwithstanding the above, no rights are granted to practice under the other Party’s Patent Rights and such personnel shall not use the written Confidential Information of the other Party. Each Party shall implement
appropriate procedures to identify to its personnel Information which is the subject of confidentiality or restricted use obligations. 



  
 98










	12.7	 Third Party Obligations.  Other than with respect to Article 16.4(e), neither Party is obliged to disclose to the other any
Information if to do so would put the disclosing Party in breach of an existing or future obligation owed to a Third Party. Without limitation to the foregoing, Amgen acknowledges that Celltech is not obliged to disclose to Amgen, and will not
disclose to Amgen, any Information, data or know-how concerning Celltech’s products [*] whether arising out of Celltech’s [*] or otherwise. 


 ARTICLE 13 
 PUBLICATIONS 

 

	13.1	 Procedure.  The Collaboration Committee (or its appropriate designees) shall determine the strategy for and co-ordinate the
publication and presentation of results of studies of Antibody Products or which incorporates data generated under this Agreement. Each Party to this Agreement recognises that the publication of papers regarding results of and other information
regarding activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties provided such publications are subject to reasonable controls to protect Confidential Information. In particular, it is
the intent of the Parties to maintain the confidentiality of any Confidential Information included in any patent application until such patent application has been published. Accordingly, each Party will have the right to review and approve any
paper proposed for publication by the other Party, including oral presentations and abstracts, which incorporates data generated under this Agreement and/or includes Confidential Information of the other Party. Before any such paper is submitted for
publication or an oral presentation is made, the publishing or presenting Party will deliver a complete copy of the paper or materials for oral presentation to the other Party at least [*] prior to submitting the paper to a publisher or making the
presentation. The other Party will review any such paper and give its comments to the publishing Party within [*] of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party will make
reasonable efforts to expedite review of such materials and abstracts, and will return such 



  
 99










	 	 
items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than [*] from the date of delivery to the other Party. Failure to
respond within such [*] shall be deemed approval to publish or present. If approval is not given or deemed given, for publications or presentations of other than Marketing Clinical Studies, the matter shall be referred to the Collaboration Committee
together with the reasons for withholding approval. Publications or presentations to the extent relating to Marketing Clinical Studies shall be determined by the Territorial Commercial Lead that conducted such Marketing Clinical Studies, having
considered the comments of the other Party. Notwithstanding the foregoing, the publishing or presenting Party will comply with the other Party’s request to delete references to the other Party’s Confidential Information in any such paper
and, with respect to Marketing Clinical Studies, will withhold publication of any such paper or any presentation of same for an additional [*] in order to permit the Parties to obtain patent protection, if either of the Parties deems it necessary,
in accordance with the terms of this Agreement. 


  

	13.2	 Credit.  Any such publication will include recognition of the contributions of the other Party according to standard practice for
assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. 


 ARTICLE
14 
 TERM AND TERMINATION 
  

	14.1	 Term.  This Agreement shall become effective on the Effective Date and shall remain in full force and effect, unless earlier
terminated pursuant to Article 3.4 or this Article 14, for such time as the Antibody Products are being Researched, Developed or Commercialised by the Parties. 



 

	14.2	 Termination for Convenience.  


  

	14.2.1	 Amgen may terminate this Agreement at any time following presentation of the [*] demonstrating an [*] in the [*] referred to in [*] of [*] but prior
to the expiry of Celltech’s opt out right as set out in Article 3.4 by providing [*] prior written notice of 



  
 100










	 	 
termination to Celltech. Termination shall be effective upon the expiry of the [*] notice period. Should Amgen exercise (or be deemed to exercise) its right to terminate pursuant to Article
3.2.1(e), termination shall be effective upon the receipt of such notice by Celltech. 


 14.2.2 

 

	 	(a)	 After expiry of Celltech’s opt-out right as set out in Article 3.4(a), either Party may terminate this Agreement after completion of the first
[*] of an Antibody Product by providing [*] prior written notice to the other Party. Termination shall be effective upon the expiry of the [*] notice period. 



 

	 	(b)	 Should a Party provide a notice pursuant to Article 2.7 (whether before or after the expiry of Celltech’s opt-out right or [*] of a [*]), such
Party shall be deemed to have served a termination notice pursuant to this Article. 


  

	 	(c)	 Within [*] of receipt of a termination notice pursuant to this Article 14.2.2 the non-terminating Party shall provide a written response to the
terminating Party, setting out in such written response whether: 


  

	 	(i)	 the non-terminating Party wishes to assume the Research, Development and/or Commercialisation of Antibody Products (as appropriate); or



  

	 	(ii)	 the non-terminating Party does not wish to continue to pursue the Research, Development and/or Commercialisation of Antibody Products (as
appropriate). 


 If the non-terminating Party does not send such a written response within
the said [*], it shall be deemed to have made the election set out in 14.2.2(c)(ii). 
  

	14.3	 Mutual Consent.  This Agreement shall terminate upon the mutual written consent of the Parties. Termination shall be
effective upon the date specified in such written consent. 



  
 101










	14.4	 Termination for Default. 


  

	 	(a)	 In the event any material representation or warranty made hereunder by either Party shall have been untrue in any material respect and this has had
a material and adverse effect on the other Party in relation to this Agreement (“Representation Default”), or upon any material breach or material default of a material obligation of this Agreement by a Party (“Performance
Default”), the Party not in default (“Non-Defaulting Party”) must first give the other Party (“Defaulting Party”) written notice thereof (“Notice of Default”), which notice must state the
nature of the Representation Default or Performance Default in reasonable detail and must request the Defaulting Party cure such Representation Default or Performance Default within [*], or if such Default cannot be cured, take such action as will
substantially mitigate the material adverse effect of such Default on the other Party. During any such [*] period after receipt or delivery of a Notice of Default under this Article 14.4(a) for which termination of this Agreement is a remedy, all of
each Party’s respective rights and obligations under this Agreement, including Research, Development, and Commercialisation, shall (to the extent applicable) remain in force and effect. If the Defaulting Party shall dispute the existence,
extent or nature of any default set forth in a Notice of Default, the Parties shall use good faith efforts to resolve the dispute. 


  

	 	(b)	 In the event of a Representation Default or a Performance Default by Celltech that shall not have been cured or mitigated within the [*], as set
forth in Article 14.4(a) above, Amgen, at its option, may immediately terminate this Agreement upon prior written notice to Celltech. Termination shall be effective upon the receipt of such notice by Celltech. 



 

	 	(c)	 In the event of a Representation Default or a Performance Default by Amgen that shall not have been cured or mitigated within the [*], as set forth
in Article 14.4(a) above, Celltech, at its option, may immediately terminate this Agreement upon prior written notice to Amgen. Termination shall be effective upon the receipt of such notice by Amgen. 



  
 102










	14.5	 Bankruptcy.  


  

	 	(a)	 All rights and licences granted under or pursuant to this Agreement by Amgen or Celltech are, and shall otherwise be deemed to be licences of rights
to “intellectual property”. The Parties agree that the Continuing Party (as defined below) shall retain and may fully exercise all of its rights and elections under bankruptcy legislation in the Territory. The Parties further agree
that, in the event of the commencement of a bankruptcy proceeding by or against a bankrupt Party the other Party shall be entitled to a complete duplicate of (or complete access to, as appropriate) any intellectual property which at that date is
known to be necessary or useful to an Antibody Product (then the subject of Research or Development or Commercialisation) and all embodiments of such intellectual property; and same, if not already in the other Party’s possession, shall be
promptly delivered to the other Party (a) upon any such commencement of a bankruptcy proceeding, upon the other Party’s written request therefor (which request must identify the specific intellectual property), unless the non-bankrupt
Party (or a trustee on behalf of the bankrupt Party) elects within [*] to continue to perform all of its obligations under this Agreement or (b) if not delivered under (a) above, upon the rejection of this Agreement by or on behalf of the
bankrupt Party, upon written request therefor by the other Party. 


  

	 	(b)	 Without prejudice to Article 14.5(a) this Agreement may be terminated by a Party upon prior written notice to the other in the event that
(i) the other Party shall make an assignment for the benefit of its creditors, file a petition in bankruptcy, petition or apply to any tribunal for the appointment of custodian, receiver or any trustee for it or a substantial part of its
assets, or shall commence any proceeding under any bankruptcy, reorganisation, arrangement, readjustment of debt, dissolution or liquidation law or statute of any jurisdiction (other than for the purposes of a solvent amalgamation or
reconstruction), whether now or hereafter in effect; or (ii) if there shall have been filed against the other Party any such bona fide petition or application, or any such proceeding shall have been commenced against it, in which an order for
relief is entered or which remains undismissed for a period of ninety (90) days or more; or (iii) if the other Party by any act or 



  
 103










	 	 
omission shall indicate its consent to, approval of or acquiescence in any such petition, application or proceeding or order for relief or the appointment of a custodian, receiver or trustee for
it or any substantial part of its assets, and shall suffer any such custodianship, receivership or trusteeship to continue undischarged for a period of ninety (90) days or more (each an “Insolvency Event”). Termination shall be
effective upon the date specified in such notice. Notwithstanding the foregoing, this Agreement shall not be terminated pursuant to this Article 14.5(b) if, prior to the effective date of termination stated in the written notice from the Party
desiring to terminate this Agreement, the Party experiencing the Insolvency Event demonstrates to the other Party that it is not insolvent. 


  

	14.6	 Additional Termination Right of Celltech.  If in any suit or proceeding where Celltech or any of its Affiliates is a named party
Amgen or any of its Affiliates asserts, or Amgen or any of its Affiliates provides Confidential Information, financial assistance or technical assistance in collusion with a Third Party to assist such Third Party in asserting that any claim within
the [*] Patent Rights or any [*] Patent Rights is invalid, Celltech, at its option, may, within [*] of such assertion, terminate this Agreement upon [*] prior written notice to Amgen (with termination being effective upon expiry of the [*] notice
period); provided however, that nothing contained herein shall prohibit Amgen or any of its Affiliates from asserting the invalidity of any claim within the [*] Patent Rights or any [*] Patent Rights, where such assertion is raised as a
defence against an assertion of such [*] Patent Rights or [*] Patent Rights in such suit or proceeding brought against Amgen or any of its Affiliates or any of its licensees (provided that such suit or proceeding relates to the licensed subject
matter) or its intellectual property rights. If the inclusion of this Article 14.6 would make invalid or unenforceable any other provision of this Agreement, or any of the Patent Rights licensed pursuant to this Agreement, this Article 14.6 shall be
automatically and without notice severed from this Agreement and the remaining provisions of this Agreement shall remain in force. 



  
 104










	14.7	 Opt-Out by Celltech.  In the event Celltech shall provide notice of its election to opt-out of this Agreement pursuant to Article
3.4, this Agreement shall automatically terminate in accordance with that Article 3.4. 


  

	14.8	 Continuing Party; Effective Date of Termination. 



 

	 	(a)	 For the purposes of this Article 14: 


  

	 	(i)	 Celltech under Article 14.2.1; 


  

	 	(ii)	 the Party who wishes to assume, or has agreed to assume, Research, Development and/or Commercialisation of Antibody Product under Articles 14.2.2 or
14.3; 


  

	 	(iii)	 the Non-Defaulting Party under Article 14.4; 


  

	 	(iv)	 the terminating Party under Article 14.5 or Article 14.6; and 



 

	 	(v)	 Amgen under Article 14.7, with respect to each Antibody Product and Subsequent Products included within Celltech’s opt-out under Article 3.4;



 shall be, in each case, the “Continuing Party”; 

 

	 	(b)	 The effective date of termination of this Agreement, as set forth in each instance in Articles 14.2 through 14.7, is hereby referred to as the
“Termination Date”. 



  
 105










	14.9	 Effects of Termination.  In addition to any other remedies which may be available at law or equity upon termination of this
Agreement, the rights and obligations of the Parties shall be as set forth in this Article 14.9. 


  

	 	(a)	 Upon termination of this Agreement howsoever caused, the following rights and obligations shall apply: 



 

	 	(i)	 The following provisions shall remain in full force and effect after the expiration or termination of this Agreement if there is a Continuing Party:
Article 1, [*], Article 8 (in case of any payments relating to the period prior to the Termination Date), Article 11.1, Article 12 , this Article 14.9, Article 14.10, Article 16, Article 18, Article 19, Schedule E, and all ancillary provisions
necessary for the implementation of this Article 14.9. 


  

	 	(ii)	 The following provisions shall remain in full force and effect after the expiration or termination of this Agreement if there is no Continuing
Party: Article 1, [*], Article 8 (in case of any payments relating to the period prior to the Termination Date), Article 11.1, Article 11.5, Article 11.8 (in the case of any infringement defence pursuant to Article 11.5), Article 11.9(b), Article
11.9(c), Article 12 (in relation to the other Party’s Confidential Information only), Article 13, this Article 14.9, Article 14.10, Article 18, Article 19, and all ancillary provisions necessary for the implementation of this Article 14.9.
(iii)All other rights and obligations under this Agreement shall terminate. 


  

	 	(iv)	 By the [*] of the Termination Date, each Party (unless there is a Continuing Party, in which case only the non-Continuing Party) shall destroy, or
at the other Party’s request return, all of the other Party’s Confidential Information (other than with respect to maintaining one (1) archival copy of Confidential Information related thereto for its legal files, for the sole purpose
of determining its obligations under this Agreement) and Materials. In each instance where a Party is required to destroy or return the other Party’s Confidential Information under this Article 14.9(a)(iv), such Party shall provide the other
Party with certification by an officer of such Party that all such Confidential Information and Materials have been destroyed or returned to the other Party, as appropriate. 



  
 106










	 	(b)	 Upon 


  

	 	(i)	 Receipt of a notice of termination of this Agreement pursuant to Article 14.2.2, where the Continuing Party has served notice under Article 14.2.2
indicating that it wishes to assume the Research, Development and/or Commercialisation of Antibody Product, or 


  

	 	(ii)	 Mutual consent of the Parties to terminate this Agreement, under Article 14.3, where the Parties have agreed for one Party to assume, the Research,
Development and/or Commercialisation of Antibody Product, or 


  

	 	(iii)	 Termination of this Agreement pursuant to Article 14.2, Article 14.4, Article 14.5, Article 14.6 or Article 14.7; the Collaboration Committee shall
promptly meet to devise a transition plan which provides for an orderly and cost-effective transition or winding down of, and which sets forth the responsibilities and a timetable for transferring or winding down (in each case as appropriate),
Research, Development and Commercialisation responsibilities (“Transition Plan”). Where the Collaboration Committee cannot agree the timetable the [*] shall have [*]. Such transition shall be completed as soon as practicable and, in
any event, shall be no later than the [*] of the Termination Date. Such Transition Plan shall provide for transferring or winding down (as appropriate) Research, Development and Commercialisation responsibilities as expeditiously as possible in
accordance with this Article 14 while (in the case of transition) maintaining a supply of Antibody Product to meet the Development and/or Commercialisation requirements (as appropriate), and minimizing interruption of Research, Development and/or
Commercialisation of the Antibody Product, including the following: 


  

	 	(1)	 Until the [*] of the Termination Date each Party shall make its personnel and other resources reasonably available to the other Party, as necessary,
and shall by the [*] of the Termination Date transfer copies of all relevant information, files or data containing Information and transfer all Materials to the other Party. 



  
 107










	 	(2)	 By the [*] of the Termination Date, the other Party shall transfer to the Continuing Party all Regulatory Filings and Regulatory Approvals then in
its name for all Antibody Products and shall notify the appropriate Regulatory Authorities and take any other action reasonably necessary to effect such transfer. 



 

	 	(3)	 By the [*] of the Termination Date, the other Party shall assign its rights or grant sufficient sublicence rights to the Continuing Party under the
other Party’s right, title and interest in the Product Trademarks (but otherwise not any of the other Party’s Trademarks). The Continuing Party shall also have the right, for a reasonable period not to exceed [*] from the Termination Date,
to use the other Party’s Trademarks solely in the selling of any existing inventory of Antibody Products (and to use Promotional Materials it then has on hand), with no obligation of accounting to the other Party. 



 

	 	(4)	 By the [*] of the Termination Date, the other Party shall, at the request of the Continuing Party, assign its rights or grant sufficient sublicence
rights to the Continuing Party, under all of the other Party’s rights (but only to the extent permitted by its terms and subject to the obligations) under any [*] to the extent the same relates to Researching, Developing, Commercialising,
making, having made, using, selling, having sold, offering to sell or resell, importing, exporting, distributing or otherwise transferring physical possession of or otherwise transferring title in or to Antibody Products and shall not (until
receiving notice of whether or not the Continuing Party desires such an assignment or sublicence) terminate or amend any such [*]. 


  

	 	(5)	 To the extent the other Party is the Manufacturing Lead it shall remain responsible for supplying Antibody Raw Material (and if




  
 108










	 	 
the Manufacturing Lead is a Third Party then Celltech shall remain responsible for fulfilling its obligations under Article 6.1(a)(iii)), and Amgen shall also remain responsible for supplying
Antibody Product in Finished Form, in each case in the amount that it was supplying at the time of such termination (and in accordance with the terms of Articles 6.5, 6.6 and 6.8), for a reasonable period of time not to exceed [*] from the
Termination Date, to allow the Continuing Party (or with respect to Antibody Product in Finished Form, Celltech) to obtain an alternate source of supply, if necessary. The other Party shall also assign its rights or grant sufficient sublicence
rights (but only to the extent permitted by its terms and only to the extent the same relates to Antibody Raw Material and/or Antibody Product in Finished Form) under all Third Party manufacturing agreements relating to Antibody Product to the
Continuing Party, if requested to do so by the Continuing Party. The other Party shall no longer be responsible for supplying Antibody Raw Material and/or Antibody Product in Finished Form, or for fulfilling its obligations under Article
6.1(a)(iii), (as appropriate) from the date of such assignment or sublicence or the rejection of a written offer of such assignment or sublicence (such rejection to be deemed to be given if the offer is not accepted in writing within [*] of receipt
by the Continuing Party of such written offer from the other Party). In the event the other Party is obligated to continue to supply Antibody Products under this Article, the Continuing Party shall use Commercially Reasonable Efforts to identify one
or more viable Third Party manufacturers in order to transfer manufacturing operations as soon as commercially reasonable. 


  

	 	(6)	 By the [*] of the Termination Date, to the extent the other Party is the Manufacturing Lead it shall itself transfer any Information




  
 109










	 	 
Controlled by it and, to the extent it is using a Third Party manufacturer(s), shall either use Commercially Reasonable Efforts to enforce or assign to the Continuing Party the right to enforce
the terms and conditions of each Third Party Supply Agreement entered into by it including (but only to the extent permitted by each such Supply Agreement with the Third Party) the provision to the Continuing Party of any Information and assistance
reasonably required by the Continuing Party from such Third Party pertaining to the manufacture and analysis of Antibody Raw Material with the objective of the Continuing Party being enabled to implement the [*] of [*], including Information
contained in the [*] of any applicable Regulatory Filings and the results of any stability studies performed by or on behalf of the other Party. 


  

	 	(7)	 By the [*] of the Termination Date, to the extent Celltech is the Continuing Party, Amgen shall transfer any Information Controlled by it pertaining
to the manufacture and analysis of Antibody Product in Finished Form, and to the extent it is using a Third Party manufacturer(s), shall either use Commercially Reasonable Efforts to enforce or assign to Celltech the right to enforce the terms and
conditions of any Third Party supply agreement entered into relating to Antibody Product in Finished Form by it, including (but only to the extent permitted by any such supply agreement) the provision to Celltech of any Information and assistance
reasonably required by Celltech from such Third Party pertaining to the manufacture and analysis of Antibody Product in Finished Form with the objective of Celltech being enabled to implement the [*] of [*], including Information contained in the
[*] of any applicable Regulatory Filings and the results of any stability studies performed by or on behalf of Amgen. 



  
 110










	 	(8)	 The other Party shall continue to use Commercially Reasonably Efforts to Promote, Detail and otherwise Commercialise the Antibody Product in those
countries where it is the Territorial Commercial Lead, and shall if required to do so complete those [*] to which it has committed for the relevant time period in those countries where it is [*], as modified by the Transition Plan, to enable the
Continuing Party to assume the Commercialisation responsibilities previously carried out by the other Party with a minimum of disruption. 


  

	 	(9)	 By the [*] of the Termination Date, the other Party shall (a) assign its rights or grant sufficient sublicence rights under all other Third
Party agreements (but only to the extent permitted by their terms and subject to the obligations) to the extent the same relate to the Antibody Products and as requested to do so by the Continuing Party; and (b) shall provide reasonable
assistance to the Continuing Party in assuming management of such agreements. 


  

	 	(c)	 Each Party shall assist (and, other than Wind Down Costs, be responsible for its own costs and expenses) in the transition or wind down of affairs
as set forth in the Transition Plan in a timely, reasonable and businesslike manner. After completion of the responsibilities set forth in the Transition Plan the Parties shall have no further obligation to assist in such transition or winding down
(as appropriate). 


  

	 	(d)	 If, under Article 14.2.2 the Continuing Party elects to cease Research, Development and Commercialisation of Antibody Products under this Agreement,
the Collaboration Committee shall establish, by unanimous decision, a wind down plan which sets forth the responsibilities and timing for ceasing the Research, Development and/or Commercialisation of Antibody Product as expeditiously and cost
effectively as possible. Both Parties shall co-operate to achieve this end, including complying with its obligations under the wind down plan. 



  
 111










	 	(e)	 During any period after receipt or delivery of a notice of termination to the Termination Date the Parties’ respective rights and obligations
under this Agreement shall (to the extent applicable) remain in full force and effect, including the sharing of the Product Contribution. 


  

	 	(f)	 In the event this Agreement is terminated by Celltech pursuant to Article 14.2.2 or by the Parties pursuant to Article 14.3 and Amgen shall have
elected or agreed (as appropriate) to assume Research, Development and/or Commercialisation of Antibody Product, or if this Agreement terminates pursuant to Article 14.7, or if this Agreement is terminated by Amgen pursuant to Article 14.4 or 14.5,
the Antibody Licence Agreement attached as Schedule G shall come into full force and effect immediately on termination of this Agreement. In the event this Agreement is terminated by Amgen pursuant to Article 14.2.2 or by the Parties pursuant to
Article 14.3 and Celltech shall have elected or agreed (as appropriate) to assume Research, Development and/or Commercialisation of Antibody Product, or if this Agreement is terminated by Celltech pursuant to Article 14.4, 14.5 or 14.6, or if this
Agreement is terminated pursuant to Article 14.2.1, [*] shall grant to [*] a [*] licence under any [*] Technology (including the Information and [*] Patent Rights pertaining to the [*] of the [*] of Antibody Products) to Research, Develop,
Commercialise, make, have made, use, sell, have sold, offer to sell or resell, import, export, distribute or otherwise transfer physical possession of or otherwise transfer title in or to Antibody Products. 



Such [*] licence shall be on substantially the same terms as the Antibody Licence Agreement attached as Schedule G (but
with Amgen as licensor and Celltech as licensee) provided that no [*] shall be payable and the [*] payable by Celltech to Amgen shall: 
  

	 	(i)	 be agreed by the Parties, or failing such agreement within [*] of the Termination Date; 



  
 112










	 	(ii)	 be determined by an expert appointed by an independent accountant of internationally recognised standing reasonably acceptable to both Parties,
taking into account: 


  

	 	(1)	 the value, if any, of any [*] Technology used or to be used by Celltech in connection with the Antibody Product(s) (then being [*] or then being [*]
or [*]); and 


  

	 	(2)	 the value, if any, of the investment made by Amgen in the Antibody Product(s) (then being [*] or then being [*] or [*]), relative to the value of
the investment made by Celltech in such Antibody Product(s); and 


  

	 	(3)	 the [*] on the Antibody Product(s) (then being [*] or then being [*] or [*]). 



In any event, the [*] shall not be a [*] which would make Commercialisation of such Antibody Product(s) by Celltech [*].

  

	 	(g)	 If a Party serves a notice pursuant to Article 2.7 after expiry of Celltech’s opt-out right as set out in Article 3.4, but before completion of
the Pivotal Studies of an Antibody Product as set out in the Late Stage Development Plan in effect at the date of such notice, the Party serving such notice shall, notwithstanding such termination, bear its share of all Research and Development
Costs of such Pivotal Studies in accordance with Article 3.6 as though the Agreement had not been terminated. This is without prejudice to the other provisions of this Article 14. 



 

	 	(h)	 Termination of this Agreement by Celltech due to a notice served by it pursuant to Article 2.7 shall not relieve either Party of its obligations to
share Research and Development Costs as set forth in Articles 3.6.1 and 3.6.2. Termination of this Agreement by Amgen due to a notice served by it pursuant to Article 2.7 shall not




  
 113










	 	 
relieve either Party of its obligations to share Research and Development Costs as set forth in Articles 3.6.1 and 3.6.2 for a period of [*] from the date of Amgen’s notice.



  

	14.10	 Accrued Rights.  Termination, relinquishment or expiration of any licences under this Agreement or of this Agreement for any reason
in accordance with this Article 14 shall be without prejudice to any rights which shall have accrued to the benefit of either Party or any liability incurred by either Party prior to such termination, relinquishment or expiration.



 ARTICLE 15 
 DISPUTE RESOLUTION 
  

	15.1	 Referral of Unresolved Matters to [*].  The Parties recognise that disputes as to certain matters may from time to time
arise during the term of this Agreement which relate to either Party’s rights and/or obligations hereunder and which are not resolved by the Collaboration Committee. It is the objective of the Parties to establish procedures to facilitate the
resolution of disputes arising from, concerning or in any way relating to this Agreement in an expedient manner by mutual co-operation and without resort to litigation. If the Collaboration Committee is unable to resolve any matter falling within
its authority, the matter shall be referred to the respective [*] of Research or Development of each Party (in the case of a dispute involving Research or Development respectively) or the respective [*] of Marketing of each Party (in the case of a
dispute involving Commercialisation), or to such other senior officer of similar authority and standing as each Party may from time to time designate (collectively, the “[*]”), to be resolved by negotiation in good faith as soon as is
practicable but in no event later than [*] after written request from either Party to the other Party for such a referral. If such [*] are unable to resolve the matter within the said [*] it shall be referred to the [*] (together, the [*] and [*],
the “[*]”) as soon as practicable but in any event no later than [*] after a written request from either Party to the other Party for such a referral. Each [*]shall have the right to engage the services of any number of independent experts
in the 



  
 114










	 	 
field in question (such independent expert(s) to be engaged under obligations of confidentiality and the expense of the Party so engaging such expert(s)) to assist the [*] in making a
determination on the unresolved matter, and each [*] shall consider in good faith the analyses and opinions of any such independent experts engaged by either of them in making a determination. In the event that following discussions between the [*],
the [*] are unable to resolve such dispute within such [*] of the matter being referred to them, then either Party may at any time thereafter pursue any legal or equitable remedy available to it. Notwithstanding the above, either Party shall be
entitled at all times and without delay to seek equitable relief. 


 ARTICLE 16 

REPRESENTATIONS AND WARRANTIES 
  

	16.1	 Authority and Consents.  Celltech and Amgen each represent and warrant to the other Party that as of the Effective Date (a) it
has full right, power and authority to enter into this Agreement and perform its obligations hereunder and has taken all necessary corporate action on its part required to authorise the execution and delivery of the Agreement and the performance of
its obligations hereunder; (b) this Agreement has been duly executed by such Party and so far as it is aware (not having made enquiry) constitutes a legal, valid and binding obligation of such Party that is enforceable against it in accordance
with its terms subject to all limitations of bankruptcy, liquidation, principles of equity (including moratorium and enforcement of creditors’ rights generally), general principles of equity (including, those relating to specific performance,
injunctions and other remedies) and public policy constraints (including those pertaining to limitations and/or exclusions of liability, competition law, penalties and jurisdictional issues including conflicts of law); and (c) the execution and
delivery of this Agreement and the performance of such Party’s obligations hereunder (i) do not conflict with or violate such Party’s corporate charter and bylaws or so far as it is aware (not having made enquiry) any requirement of
applicable laws or regulations of any court, governmental body or administrative or other agency having jurisdiction over it and (ii) do not and shall not conflict with, violate or breach or constitute a default or require any consent under any
contractual obligation of such Party. 



  
 115










	16.2	 Mutual Representations and Warranties.  Each Party hereby represents and warrants to the other Party that as of the Effective Date:
(a) it is aware of no action, suit, inquiry or investigation instituted by any Third Party which questions or threatens the validity of this Agreement and (b) it is not aware of any facts or circumstances, individually or in the aggregate,
which it knows are reasonably likely to have a material adverse effect on its ability to perform its obligations under this Agreement; and (c) it has acted in good faith in providing Information to the other Party and has not wilfully misled
the other Party with respect to any such Information. 


  

	16.3	 Additional Representation and Warranty of Celltech. 



Celltech further represents and warrants to Amgen that as of the Effective Date (a) it is the exclusive owner of the
Patent Rights listed in Parts A, B and C of Schedule F and the owner, licensee or holder of option rights under the Patent Rights listed in Part D of Schedule F; (b) it has disclosed to Amgen in good faith all Information which Celltech has and
which it reasonably believes to be material to the validity of the [*] Patent Rights, provided however, that nothing herein shall be construed as a warranty or representation by Celltech of the validity of such Patent Rights;
(c) it has disclosed to Amgen in good faith all Information Celltech has and which it reasonably believes to be material to the safety of [*] Antibodies for therapeutic use and (d) it has not received a written notice that Celltech is in
material breach or material default of the agreements listed in Part E of Schedule F and disclosed to Amgen prior to the Effective Date. 
  

	16.4	 Mutual Covenants.  Each Party hereby covenants to the other Party as follows: 



 

	 	(a)	 No Misappropriation.  It shall not knowingly misappropriate the trade secret of a Third Party in its activities to Research, Develop or
Commercialise Antibody Products. 


  

	 	(b)	 No Debarment.   In the course of the Development of Antibody Products and




  
 116










	 	 
during the Term, such Party shall not knowingly use and shall not have knowingly used any employee or consultant who is or has been debarred by a Regulatory Authority or, to the best of such
Party’s knowledge (not having made enquiry), who is or has been the subject of debarment proceedings by a Regulatory Authority. 


  

	 	(c)	 No Conflict.  It will not enter into any agreement with a Third Party that is in conflict with this Agreement, and will not take any
action that would in any way prevent it from assuming its obligations or granting the rights granted to the other Party under this Agreement or that would otherwise materially conflict with or adversely affect its obligations or its assumption of
the rights granted to the other Party under this Agreement. 


  

	 	(d)	 [*].  It shall work [*] with the other Party with respect to [*], and it shall not during the term of this Agreement grant any right,
licence, consent or privilege to any Third Party(ies) in the Territory which would conflict with the rights granted to the other Party under this Agreement. 



 

	 	(e)	 Compliance.  Notwithstanding anything to the contrary in this Agreement, each Party shall comply with all applicable statutes and
regulations of Regulatory Authorities in carrying out its respective activities regarding the Research, Development and Commercialisation of Antibody Products in the Field in the Territory. 



 

	 	(f)	 Workmanship.   Each Party shall commit the personnel, facilities and other resources reasonably necessary to conduct its obligations
under this Agreement, and shall conduct its Research and/or Development obligations using the same standard of skill and care which it applies to its other products, but in no event less than commonly accepted good professional standards of
workmanship. 



  
 117










	16.5	 Disclaimer of Representation and Warranty. 



 

	 	(a)	 Nothing in this Agreement shall be construed as a warranty or representation by either Party (i) that the Research, Development,
Commercialisation, making, having made, using, selling, having sold, offering to sell or resell, importing, exporting, distributing or otherwise transferring physical possession of or otherwise transferring title in any Antibody Products under, or
in connection with, this Agreement are or will be free from infringement of, or that the activities conducted pursuant to this Agreement will not infringe, Patents Rights, copyrights, Trademarks, industrial design or other intellectual property
rights of any Third Party or (ii) that any Antibody Product Researched, Developed, Commercialised, made, have made, used, sold, have sold, offered to sell or resell, imported, exported, distributed or in which physical possession or title is
transferred under this Agreement is or will be effective, valuable, safe, non-toxic or patentable. Each Party explicitly accepts all of the same, and accepts that the activities conducted and the Antibody Products are experimental as at the
Effective Date. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, EACH PARTY EXPRESSLY DISCLAIMS, WAIVES, RELEASES, AND RENOUNCES ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, ANY WARRANTY OF EFFICACY, SAFETY, SATISFACTORY QUALITY
OR FITNESS FOR A PARTICULAR PURPOSE. 


  

	 	(b)	 Notwithstanding Articles 16.5(a) and 19.14, nothing in this Agreement limits or excludes any Party’s liability for fraud or for death or
personal injury caused by that Party’s own negligence. 


 ARTICLE 17 

CHANGE OF CONTROL 
  

	17.1	 Change of Control.  In the event that, during the term of this Agreement, a Third Party (the “Acquiring Party”)
shall acquire, directly or indirectly: (i) fifty percent (50%) or 



  
 118










	 	 
more of the shares of a Party’s stock entitled to vote for the election of directors of a Party, or (ii) a substantial equity interest in, together with the power to direct the
management and policies of, a Party; the other Party (the “non-Acquired Party”) shall have the right, within [*] of such acquisition, to terminate the Acquired Party’s right to [*] with its [*] right to [*] in accordance with
Article 5.2. If such a termination notice is served, the Parties shall co-operate to ensure an orderly wind down of all [*] throughout the Territory as soon as practicable. 



ARTICLE 18 

INDEMNIFICATION; INSURANCE 
  

	18.1	 Indemnification by Amgen.  Amgen hereby agrees to defend, hold harmless and indemnify (collectively “Indemnify”)
Celltech and its Affiliates, agents, directors, officers and employees (the “Celltech Indemnitees”) from and against any and all Third Party claims, suits, actions or demands and all out-of-pocket liabilities, damages, costs,
settlements, expenses and/or losses paid to any Third Party bringing any such Third Party claim, as well as reasonable legal expenses and attorney and expert fees incurred in defending and/or compromising the same, (“Celltech
Loss(es)”) arising out of any of (a) Amgen’s representations or warranties set forth in this Agreement being untrue in any material respect when made; (b) any material breach or material default by Amgen of its material
covenants and material obligations under this Agreement; (c) Amgen’s negligence or intentional misconduct in carrying out its activities set forth in this Agreement; and (d) any Trademark infringement claim, lawsuit or other action,
resulting solely from Celltech’s proper use of Amgen Trademarks in connection with an Antibody Product in accordance with the terms of this Agreement. Celltech shall provide Amgen with prompt written notice of any claim (with a description of
the claim and the nature and amount (if determinable) of any such Celltech Loss) giving rise to the indemnification obligation pursuant to this Article 18.1 and the exclusive ability to defend such Third Party claim; provided however,
that Amgen shall be relieved of its obligations only to the extent the failure to be provided prompt written notice shall have been prejudicial to its ability to defend such action. Celltech shall co-operate as




  
 119










	 	 
reasonably requested in the defence of the claim; provided however, that Celltech shall have the right to retain its own counsel, at its own expense, if representation of the counsel of
Amgen would be inappropriate due to actual or potential differing interests between the Parties. Celltech shall not settle any claim for Celltech Losses for which any Celltech Indemnitee is seeking to be Indemnified by Amgen, without Amgen’s
prior written consent. Amgen’s obligation to Indemnify the Celltech Indemnitees pursuant to this Article 18.1 shall not apply to the extent any Celltech Losses (i) arise from the negligence or intentional misconduct of any Celltech
Indemnitee; (ii) arise from any material breach by Celltech of this Agreement; or (iii) for which Celltech is obligated to Indemnify the Amgen Indemnitees pursuant to Article 18.2 of this Agreement. 



 

	18.2	 Indemnification by Celltech.  Celltech hereby agrees to Indemnify Amgen and its Affiliates, agents, directors, officers and
employees (the “Amgen Indemnitees”) from and against any and all Third Party claims, suits, actions or demands and all out-of-pocket liabilities, costs, settlements, damages, expenses and/or losses paid to any Third Party bringing
any such Third Party claim, as well as reasonable legal expenses and attorney and expert fees incurred in defending and/or compromising the same, (“Amgen Loss(es)”) arising out of any of (a) Celltech’s representations or
warranties set forth in this Agreement being untrue in any material respect when made; (b) any material breach or material default by Celltech of its material covenants and material obligations under this Agreement; (c) Celltech’s
negligence or intentional misconduct in carrying out its activities set forth in this Agreement; and (d) any Trademark infringement claim, lawsuit or other action, resulting solely from Amgen’s proper use of Celltech Trademarks in
connection with an Antibody Product in accordance with the terms of this Agreement. Amgen shall provide Celltech with prompt written notice of any claim (with a description of the claim and the nature and amount (if determinable) of any such Amgen
Loss) giving rise to the indemnification obligation pursuant to this Article 18.2 and the exclusive ability to defend such Third Party claim; provided however, that Celltech shall be relieved of its obligations only to the extent the
failure to be provided prompt written notice shall have been prejudicial to its ability to defend such action. Amgen shall co-operate as reasonably requested in the defence of the claim; provided however, that




  
 120










	 	 
Amgen shall have the right to retain its own counsel, at its own expense, if representation of the counsel of Celltech would be inappropriate due to actual or potential differing interests
between the Parties. Amgen shall not settle any claim for Amgen Losses for which any Amgen Indemnitee is seeking to be Indemnified by Celltech, without Celltech’s prior written consent. Celltech’s obligation to Indemnify the Amgen
Indemnitees pursuant to this Article 18.2 shall not apply to the extent any Amgen Losses (i) arise from the negligence or intentional misconduct of any Amgen Indemnitee; (ii) arise from any material breach by Amgen of this Agreement;
or (iii) for which Amgen is obligated to Indemnify the Celltech Indemnitees pursuant to Article 18.1 of this Agreement. 


  

	18.3	 Joint Liability.  Any and all liabilities, damages, costs, settlements expenses and/or losses (“Joint Loss(es)”)
arising from Third Party claims, suits, actions or demands (other than those subject to indemnification pursuant to Article 18.1 or 18.2) resulting directly or indirectly out of Researching, Developing, Commercialising, making, having made, using,
selling, having sold, offering to sell or resell, importing, exporting, distributing or otherwise transferring physical possession of or otherwise transferring title in or to Antibody Products (including a claim that an Antibody Product caused death
or personal injury of any kind) shall be charged to the Product Contribution account as a Commercialisation Expense at the time such claim is finally determined. In the event a Party becomes aware of a claim which, if resulting in a Joint Loss, it
intends to charge to the Product Contribution account, such Party shall inform the other Party of such claim as soon as reasonably practicable after it receives notice thereof. Amgen shall have the right to assume direction and control of the
defence of any claim alleging a date of injury (or in the event of a continuing injury alleging the then-most recent date of injury) to be prior to the completion of the first [*] for an Antibody Product; and, with respect to Third Party claims in a
country, each Territorial Commercial Lead in such country shall have the right to assume direction and control of the defence of any claim alleging a date of injury (or in the event of a continuing injury alleging the then-most recent date of
injury) to be upon or after completion of the first [*] for such Antibody Product. The Party not in control of such defence shall co-operate as reasonably requested in the defence of the




  
 121










	 	 
claim; provided however, that such Party shall have the right to retain its own counsel (at its own expense) if representation of the counsel of the Party in control would be inappropriate
due to actual or potential differing interests between the Parties. The Party in control shall not settle any such claim without the other Party’s prior written consent, such consent not to be unreasonably withheld or delayed.



  

	18.4	 Insurance.  Each Party shall maintain (through a captive insurer or Third Party insurer) appropriate product liability insurance
with respect to Antibody Products and appropriate comprehensive general liability insurance to cover its obligations hereunder and which is/are consistent with normal business practices of prudent companies similarly situated. Each Party shall use
reasonable endeavours to ensure that any insurance policy required by, and procured under, this Article 18.4 by a Party shall name the other Party as an additional insured. Such insurance shall not be construed to create a limit of the insuring
Party’s liability with respect to its indemnification obligations under this Article 18. Each Party shall furnish the other Party with a certificate(s) or other evidence from an insurance carrier showing all such insurance. Each Party shall
diligently pursue recovery of insurance proceeds when a claim arises. The Parties acknowledge that it is the normal business practice of prudent companies similarly situated to have a reasonable level of uninsured loss. 



 

	18.5	 No Liability.  Without prejudice to each Party’s obligations as specified in this Agreement, a Party shall have no liability
to the other Party with respect to (a) the results obtained in the Research, Development and Commercialisation of Antibody Product; or (b) [*], or any agreement relating thereto; or (c) the results obtained in the filing, prosecution,
enforcement, maintenance or defence of any intellectual property; in each case when conducted in accordance with this Agreement. The Parties agree that the risks, liabilities and benefits relating to the Research, Development and Commercialisation
of Antibody Product, including [*], and including the filing, prosecution, enforcement, maintenance or defence of any intellectual property, in each case when conducted, in accordance with this Agreement, is [*]. 



  
 122










	18.6	 Pre-Effective Date Losses.  In connection with this Agreement, neither Party shall assume or be liable for any liabilities,
damages, expenses and/or losses resulting from or arising in connection with activities of the other Party which occurred on or prior to the Effective Date. 


 ARTICLE 19 
 MISCELLANEOUS 

 

	19.1	 Amendments.  This Agreement may not be modified or supplemented by any purchase order, change order, acknowledgement, order
acceptance, standard terms of sale, invoice or the like. Any amendment or modification to this Agreement shall be made in a writing expressly stated for such purpose and signed by an authorised officer of each Party; except that the Research Plan
and the Commercialisation Plan may be amended or updated by the Joint Research Committee and the Joint Commercialisation Committee, respectively, as expressly permitted hereby. 



 

	19.2	 Notices.  Any consent or notice required or permitted to be given or made under this Agreement by one of the Parties to the other
shall be in writing, delivered personally or by facsimile (and promptly confirmed by personal delivery or courier), by a next business day delivery service of a nationally recognised overnight courier service or by courier, postage prepaid (where
applicable), addressed to such other Party at its address indicated below, or to such other address as the addressee shall have last furnished in writing to the addressor in accordance with this Article 19.2 and shall be effective upon receipt by
the addressee. 


  
  

 

			
	 If to Celltech:
	  	 Celltech R&D Limited
  

208 Bath Road
  

Slough SL1 3WE
  

Berkshire, England



  
 123










			
		  	 Attention: Company Secretary

		  	  
 Facsimile: (XXX) (XX) XXXX
XXXXXX

	  
 If to Amgen:
	  	  
 Amgen Inc.

		  	  
 One Amgen Center Drive

 
 Thousand Oaks, CA 91320-1799 U.S.A.

 
 Attention: Vice President, Licensing

Marked to be copied to: Corporate Secretary
  

Facsimile: (XXX) (XXX) XXX-XXXX


  

	19.3	 Force Majeure.  Neither Party shall be held liable or responsible to the other Party nor be deemed to have defaulted under or
breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement to the extent such failure or delay is caused by or results from Force Majeure, provided however, that the Party so affected shall use
Commercially Reasonable Efforts to avoid, remove or mitigate such causes of non-performance and shall continue performance with reasonable dispatch wherever such causes are removed. Each Party shall provide the other Party with prompt written notice
of any delay or failure to perform that occurs by reason of Force Majeure. Such excuse shall be continued so long as the condition constituting Force Majeure continues. The Parties shall mutually seek in good faith a resolution of the delay
or failure to perform. 


  

	19.4	 Use of Names, Logos or Symbols.  Subject to Articles 5.11(h), 10.2 and 12.5, no Party hereto shall use and no rights are granted to
the Trademarks (including the names “[*]” and “[*]”), physical likeness, employee names or owner symbol of the other Party for any purpose (including private or public securities placements) without the prior written consent of
the other Party, such consent not to be unreasonably withheld or delayed so long as use of such name is limited to objective statement of fact rather than for endorsement purposes. Neither Party shall use any Trademark or domain name in connection
with the subject matter of this Agreement which either substantially 



  
 124










	 	 
resembles or is confusingly similar to, misleading or deceptive with respect to, or which dilutes any of the other Party’s Trademarks or domain names, other than its own Product Trademark or
domain names actually used in connection with an Antibody Product. 


  

	19.5	 Governing Law; Jurisdiction.  


  

	 	(a)	 This Agreement shall be governed and interpreted in all respects under the substantive laws of the State of New York, United States, as applied to
agreements executed and performed entirely in the State of New York by residents of the State of New York, without regard to conflicts of law rules and without regard to the United Nations Convention on International Contracts for the Sales of
Goods. 


  

	 	(b)	 Each Party consents to the exclusive jurisdiction of the federal or state courts in the State of New York for any suit, action or other proceeding
arising out of or relating to this Agreement whether denominated or arising in contract, tort or otherwise, and further agrees that any process, notice of motion or other application to either such court or judge thereof may be served outside of New
York City, New York by personal service, provided that a reasonable time for appearance is allowed. Each Party hereby irrevocably and unconditionally waives any objection to the laying of venue of any action, suit or proceeding arising out of
or relating to this Agreement whether denominated or arising in contract, tort or otherwise, in the federal or state courts in the State of New York. Each Party hereby irrevocably and unconditionally waives and agrees not to plead or claim in any
such court that any action, suit or proceeding brought in any such court has been brought in inconvenient forum. As between the Parties, any dispute, controversy or claim relating to the scope, validity, enforceability or infringement of any Patent
Rights claiming the use or sale of any Antibody Product or of any Trademark rights relating to an Antibody Product shall be submitted to a court of competent jurisdiction in the Territory in which such Patent Rights or Trademark rights were granted
or arose which in the case of any United States Patent Rights and Trademark rights shall be a court of competent jurisdiction in the State of New York. 



  
 125










	 	(c)	 Each Party hereby waives, to the fullest extent permitted by applicable law, any right it may have to a trial by jury in respect to any litigation
directly or indirectly arising out of or relating to this Agreement. 


  

	19.6	 Performance by Affiliates.  


  

	 	(a)	 Each of Amgen and Celltech acknowledge that obligations under this Agreement may be performed on a subcontracting basis by Affiliates of Amgen and
Celltech. Each of Amgen and Celltech remain responsible for the acts and omissions in the performance of this Agreement, by its Affiliates, notwithstanding any assignment to Affiliates in accordance with Article 19.7 of this Agreement. Wherever
in this Agreement the Parties delegate responsibility to Affiliates, the Parties agree that such entities may not make decisions inconsistent with this Agreement, nor amend the terms of this Agreement or act contrary to its terms in any way.



  

	 	(b)	 Each Party agrees that any information or material provided by the other Party’s Affiliates or subcontractors shall be deemed to be the
Information or Material of the other Party. 


  

	19.7	 Assignment. 


  

	 	(a)	 This Agreement may not be assigned or otherwise transferred by any Party without the consent of the other Party not to be unnecessarily withheld or
delayed; provided however, that either Celltech or Amgen may, without such consent, assign its rights and obligations under this Agreement (i) to any Affiliate, provided such interest shall be retransferred to the relevant Party
if such entity ceases to be an Affiliate of such Party, and provided further that the assigning Party shall remain responsible for the acts and omissions in the performance of this Agreement, by its Affiliate, (ii) in connection with a merger,
consolidation or sale of substantially all of the business to which this Agreement relates to an 



  
 126










	 	 
unrelated Third Party of [*], provided that the other Party shall have the right, within [*] of such acquisition, to terminate the assigning Party’s right to [*] with its [*]right to [*] in
accordance with Article 5.2. If such termination notice is served, the Parties shall co-operate to ensure an orderly wind down of all [*] throughout the Territory as soon as practicable. 



 

	 	(b)	 Except as aforesaid, any permitted assignee shall assume all rights and obligations of its assignor under this Agreement; accordingly, all
references to the assigning Party shall be deemed references to the assignee to whom the Agreement is so assigned. The assigning Party shall forward to the other Party a copy of those portions of each such fully executed assignment agreement which
relate to the assumption of the rights and responsibilities of the assigning Party, within [*] of the execution of such assignment agreements. 


  

	 	(c)	 Any assignment or attempted assignment by either Party in violation of the terms of this Article 19.7 shall be null and void and of no legal
effect. 


  

	19.8	 [*].  [*]. 


  

	19.9	 Joint Committees.    Members of the Collaboration Committee, Joint Research Committee, Joint Development Committee, the
Joint Commercialisation Committee and any subcommittees thereof shall be, and shall remain, employees of Celltech or Amgen, as the case may be. No Party shall incur any liability to the other Party for any act or failure to act by members of the
Collaboration Committee, Joint Research Committee, Joint Development Committee, the Joint Commercialisation Committee and any subcommittees thereof who are employees of the other Party. 



 

	19.10	 Subcontracting.  The Parties acknowledge and agree that, notwithstanding anything to the contrary in this Agreement, elements of
the work involved in Research, Development and Commercialisation of Antibody Products may be subcontracted to a Third Party by the responsible Party and that the Party entering into such subcontract may, as part of such subcontract, grant to such
Third Party a licence or sublicence to [*] Technology or 



  
 127










	 	 
to [*] Technology, as applicable, only to the extent and only for so long as such licence or sublicence is necessary for such Third Party to perform such tasks; provided however, that the
responsible Party shall remain responsible for the acts and omissions in the performance of such work by its subcontractors pursuant to the terms and conditions of this Agreement, and that each subcontractor shall enter into a written agreement
binding such subcontractor to the obligations the responsible Party has to the other Party (and containing any other provisions normal and customary for similar types of agreements) including: (a) Amgen may, [*], subcontract to a Third Party
various preclinical activities referred to in Article 3.2.1(c); (b) each Party may, [*], contract with / establish clinical sites, investigators and CROs pursuant to Article 3.2.2; (c) each Party may subcontract to a Third Party
manufacturer pursuant to Article 6.4; and (d) each Territorial Commercialisation Lead may enter into agreements with distributors or agents for commercial distribution of Antibody Products pursuant to Article 5.3. The subcontracting Party shall
use Commercially Reasonable Efforts to enter into an Agreement with the bidder that is best able to meet the Parties’ mutual requirements, taking into consideration such factors as price, quality, capacity, quantity, reliability and reputation.



  

	19.11	 No Strict Construction.  This Agreement has been prepared jointly and shall not be strictly construed against either Party.



  

	19.12	 Interpretation and Schedules.  (a) The captions or headings of the Articles or other subdivisions hereof are inserted only as
a matter of convenience or for reference and shall have no effect on the meaning of the provisions hereof. (b) Unless otherwise specified, (i) references in this Agreement to any Article, or Schedule shall mean references to such Article,
or Schedule of this Agreement; and (ii) references to any agreement, instrument or other document in this Agreement refer to such agreement, instrument or other document as originally executed or, if subsequently varied, replaced or
supplemented from time to time, as so varied, replaced or supplemented and in effect at the relevant time of reference thereto. (c) Any statute defined or referred to herein or in any agreement or instrument that is referred to herein means
such statute as from time to time 



  
 128










	 	 
amended, modified or supplemented, including by succession of comparable successor statutes and references to all attachments thereto and instruments incorporated therein. References to a person
are also to its permitted successors and assigns. (d) All Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth in full herein. Any capitalised terms used in any Schedule but
not otherwise defined therein, shall have the meaning as defined in this Agreement. (e) Whenever the words “include”, “includes” or “including” are used in this Agreement, they shall be deemed
to be followed by the words “without limitation”. 


  

	19.13	 Severability.  If any provision hereof should be held invalid, illegal or unenforceable from which no appeal can be or is taken, in
any respect in any jurisdiction, the invalidity, illegality or unenforceability of one or several provisions of this Agreement shall not affect the validity of this Agreement as a whole. The Parties shall make a good faith effort to replace the
invalid or unenforceable provision with a valid one which in its economic effect is most consistent with the objectives contemplated by the Parties as evidenced by the terms and conditions of this Agreement when entering into such invalid or
unenforceable one. 


  

	19.14	 No Consequential Damages.   NEITHER PARTY HERETO WILL BE LIABLE (WHETHER UNDER AN INDEMNITY OR OTHERWISE) FOR SPECIAL,
INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING WITHOUT LIMITATION LOST PROFITS, ANTICIPATED PROFITS, LOST GOODWILL, LOST REVENUE, LOST PRODUCTION, LOST CONTRACTS
AND LOST OPPORTUNITY, ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, WHETHER DENOMINATED IN OR ARISING IN CONTRACT, TORT OR OTHERWISE REGARDLESS OF ANY NOTICE OF SUCH DAMAGES. NOTHING IN THIS ARTICLE 19.14 IS INTENDED TO LIMIT OR RESTRICT
ANY PAYMENT OBLIGATION EXPLICITLY SET FORTH UNDER THIS AGREEMENT. 



  
 129










	19.15	 General Provisions. 


  

	 	(a)	 The representations, warranties, covenants and agreements set forth in this Agreement are for the sole benefit of the Parties hereto and their
successors and permitted assigns, and a person who is not a Party to this Agreement may not enforce any of its terms. 


  

	 	(b)	 A waiver (whether express or implied) by one of the Parties of any of the provisions of this Agreement or of any breach of or default by the other
Party in performing any of those provisions must be in writing executed by a responsible officer of the Party providing the waiver and expressly waiving such provisions or breach or default by reference to this Agreement, and any waiver shall not
constitute a continuing waiver, and that waiver shall not prevent the waiving Party from subsequently enforcing any of the provisions of this Agreement not waived or from acting on any subsequent breach of or default by the other Party under any of
the provisions of this Agreement. 


  

	 	(c)	 Each Party undertakes to execute all documents which may be reasonably necessary to give full effect to this Agreement.



  

	 	(d)	 Each Party shall pay its costs and expenses incurred by it in connection with negotiation and execution of this Agreement.



  

	 	(e)	 It is expressly agreed that for tax, legal or all other purposes (i) this Agreement or any portion of this Agreement shall not be considered to
be a partnership agreement, and (ii) the relationship between the two Parties shall not constitute an employee-employer, partnership, joint venture, agency or similar business relationship between the Parties. Neither Celltech nor Amgen shall
have the authority to make any statements, representations, warranty, guarantee or commitments (express or implied) of any kind or to take any action which shall bind the other Party to a Third Party, without the prior consent of the other Party to
do so. Each Party shall use its own discretion, shall have complete and authoritative control over its employees and the methods and means by which it performs its activities under this Agreement (including the management of permitted
subcontractors). 



  
 130










	 	(f)	 This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. 


  

	19.16	 Whole Agreement.  This Agreement and the Schedules referred to in this Agreement constitute the entire agreement between the
Parties with respect to the subject matter hereof, and supersede all previous understandings, arrangements and agreements with respect to the subject matter hereof, whether written or oral. Each Party acknowledges that in entering into this
Agreement it has not relied on any representation, warranty, collateral contract or other assurance (except those expressly set out in this Agreement together with the Schedules) made by or on behalf of any other Party before the signature of this
Agreement. Each Party waives all rights and remedies which, but for this Article 19.16, might otherwise be available to it in respect of any such representation, warranty, collateral contract or other assurance. As of the Effective Date, the
Confidential Disclosure Agreement dated [*] (Amgen Reference No. XXXXXXXX) and amended on [*] (Amgen Reference No. XXXXXXXX-XXX) is hereby superseded, provided that all Proprietary Information as defined in and disclosed pursuant to or covered by
such Confidential Disclosure Agreement and its Amendment shall be treated as Confidential Information as if disclosed under, and shall be subject to the terms of, this Agreement. 



IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth above. 

 
  

									
	 AMGEN INC.
	 		 	 CELLTECH R & D LIMITED

					
	 By:
	 	 /s/ R.M. Perlmutter
	 		 	 By:
	 	 /s/ P.V. Allen



									
					
	 Name:
	 	 R.M. Perlmutter
	 		 	 Name:
	 	 P.V. Allen



									
					
	 Title:
	 	 EVP, R&D
	 		 	 Title:
	 	 CFO



  
 131










	
	 SCHEDULE A
  

Research Plan
  

The primary objective of the Research Plan is the [*] that has suitable [*] attributes to designate it as a clinical development
candidate. To accomplish this, there will be [*] major [*] work streams. The objective of the [*] workstream is to identify [*] that will be used to validate the [*], the [*] representing the most likely initial [*] for the corresponding [*]. The
work includes, but may not be limited to, characterizing [*] in a number of [*] and [*] and then [*] of [*] to identify [*]. A reasonable number of [*] will then be profiled in both [*] and [*]. It is recognised that aspects of this program are
iterative by their very nature and that revisions to plan may need to occur based on experimental results. This phase would be considered successful if a [*] proved to be [*].

 
 In parallel with this [*], a [*] workstream will be
engaged around generating [*] suitable for clinical testing. Similar to the activities above, [*] will be characterized in a number of [*] and then by [*] of [*] to identify [*]. The [*] will serve as the basis for the generation of [*] which at the
present time are envisioned to represent the [*]. The choice of [*], as opposed to a [*], as a clinical candidate will be decided based on the properties of the [*] and also on background data provided by [*] on clinical experience with these [*],
especially their [*]. As the [*] are converted to [*], the [*] of the newly generated [*] will be tested against appropriate [*] and [*]. The selection of the [*] candidate will be based on a number of criteria. At the end of this workstream,
sufficient material to initiate [*] and perform [*] will be produced. It is recognised that [*] of the [*] workstream would interrupt this plan. In that case, an alternative research plan would be identified through discussions at the Joint Research
Committee.
  
 In the event that the [*]
workstreams are successful and a clinical candidate is put forward, a [*] program will be engaged to identify additional clinical candidates should the first [*] for any reason. Additionally, it is recognised that additional work directed against
understanding the [*] will take place. Such activities could include [*] studies, [*] identification and so forth.



  
 A1 










	
	 On selection of a clinical candidate, [*] will start work on development of a suitable [*] for both [*] studies and
ultimately for clinical evaluation. [*] will expect advice from [*] on the [*] of such a [*] based on [*]’s previous experience with such products. [*] will need sufficient quantities of [*] to enable it to start such studies. A preliminary
estimate is [*] for these [*] studies. [*] will expect this material to be supplied by [*] according to a timeline that will be agreed at the Joint Research Committee. Similarly, [*] will require suitable quantities of [*] to enable it to conduct
[*] studies. The time line for this will also be agreed by the Joint Research Committee.
  
 The initial work plan, which shall be agreed by the Joint Research Committee at their first meeting, is as follows:

 
 BEER Draft Timeline

 
 [*] [2 pages of redactions]



  
 A2 









 Milestone definitions 
 Milestone 1. 
 [*]: 

 

	 	a)	 [*] and 


  

	 	b)	 [*]. 



In addition, these [*] shall [*]. “[*]” and “[*]” shall mean [*]. 

Milestone 1 shall also be considered to have been met if [*]. 
 Milestone 2. 
 [*]: 

 

	 	1.	 [*]. [*]. And, 


  

	 	2.	 [*], and 


  

	 	3.	 [*], and 


  

	 	4.	 [*]. 



Milestone 2 will also be considered to have been met upon [*]. 
 Milestone 3. 
 [*]. 

Milestone 3 will also be considered to have been met if the [*]. 

  
 A5 









 SCHEDULE B 
 Costs and Calculation of Product Contribution 
 “Product
Contribution” shall be calculated for each Calendar Quarter by subtracting the sum of (a) Other Expense, (b) Cost of Goods of Antibody Product sold, (c) Commercialisation Expense, and (d) Licence Fees, (in each case,
incurred in that quarter) from Net Sales of Antibody Products and recoveries from legal actions pursuant to Articles 6 and 11 and from insurance claims referenced in Article 18 (in each case as recognised in that quarter). Definitions of capitalised
terms used for the purposes of calculating Product Contribution are set forth below in this Schedule B:  
  

			
	 Commercialisation Expense
	  	 means the sum of (a) Promotion Expense, (b) Marketing Expense, (c) Marketing Personnel Costs, (d) Drug Regulatory Expense, (e) Medical Affairs Expense, (f)
Direct Sales Force Expense, (g) any out-of-pocket costs incurred in filing, prosecuting and maintaining applications and registrations for Antibody Product Trademarks in any country and (h) the costs of filing suit against or defending against
infringers of Patent Rights pursuant to Article 11; (i) Distribution Costs; and (j) any other cost or expense expressly stated to be a Commercialisation Expense in this Agreement. Commercialisation Expense may occur prior to and subsequent to
Regulatory Approval and First Commercial Sale.

		
	 Cost of Goods
	  	 means the FAMC for an Antibody Product as determined by reference to Schedule E.

		
	 Detail
	  	 Shall have the meaning set forth in Article 1.



  
 B1 










					
	 Detail Cost
	 	 means the cost of a sales force Detailing Antibody Product calculated in accordance with the principles outlined in Schedule C.

		
	 Direct Sales Force Expense
	 	 means, for each country, the sum of :

			
		 	 (a)
	  	 the Detail Cost of each sales force; and

			
		 	 (b)
	  	 out-of-pocket costs and expenses paid to Third Parties for Details provided by such Third Parties.

		
	 Distribution Costs
	 	 means all out-of-pocket costs, expenses, and Personnel Costs incurred in the distribution of Antibody Products, including, without limitation,
freight, insurance, warehousing, order entry, billing, credit and collection of debt to the extent that such costs are not included in the calculation of Net Sales or Cost of Goods.

		
	 Drug Regulatory Expense
	 	 means Personnel Costs, out-of-pocket costs and expenses (e.g., filing fees, user fees, annual product registration fees and the like) incurred for
obtaining or maintaining Regulatory Approvals for an Antibody Product in a country and all out-of-pocket costs incurred in satisfying all registration and other requirements of Regulatory Authorities (including for example adverse event reporting)
including costs associated with a change of site manufacture or change of container.

		
	 Licence Fees
	 	 means all upfront payments, milestone payments, licence fees, royalties or other payments, payable to any Third Party under any Third Party Licence
Agreement following the first Regulatory Approval of an Antibody Product to the extent such payments are attributable to such Antibody Product. If the rights under any Third Party
Licence



  
 B2 










			
		  	 Agreement are also attributable to products other than Antibody Products then only an equitable portion of any amounts payable under it shall be allocated to
Antibody Products as Licence Fees.

		
	 Marketing Expense
	  	 means all out-of-pocket costs and expenses incurred (i.e., paid to Third Parties or accrued therefor) by Amgen or Celltech for the following functions to the
extent directly attributable to the Antibody Product (a) market research on Antibody Product, (b) marketing communications, (c) corporate accounts, (d) managed care, (e) sales force training, (f) product hotlines, (g) reimbursement support, (h)
contracting, (i) pricing, (j) conducting compassionate use programs for Antibody Products (including without limitation FAMC for any Antibody Product utilized in such compassionate use programs) and (k) telemarketing services.

		
	 Marketing Personnel Costs
	  	 means the Personnel Costs of marketing personnel and support staff working directly (either full time or part of the time) on the Commercialisation of Antibody
Products. Examples of functions that would be included in the marketing headcount cost are: Marketing, marketing communications, clinical research and educational managers (CREMS), clinical support managers (CSS), corporate accounts, managed care,
product hotlines, reimbursement support (Government economic managers), marketing research, contracting, pricing, regulatory, adverse event reporting, sales force training, and sales force operations, including dedicated IT
support.



  
 B3 










			
	 Medical Affairs Expense
	  	 means, for all Marketing Clinical Studies (a) all out-of-pocket costs and expenses incurred (i.e., paid to Third Parties or accrued therefor) by Amgen or
Celltech for such studies, (b) Personnel Cost of personnel working directly on Marketing Clinical Studies Antibody Products and the Medical Affairs Supply Cost of such studies and (c) other out-of-pocket expenses directly attributable to Marketing
Clinical Studies on Antibody Product but not included in (a) or (b).

		
	 Medical Affairs Supply Cost
	  	 means the sum of (a) the Cost of Goods of Antibody Product (as determined in accordance with Schedule D) utilized in performing Marketing Clinical Studies, and
(b) out-of-pocket costs and expenses incurred in purchasing comparator and in packaging comparator and/or Antibody Product, shipping clinical supplies to centers or disposal of clinical supplies.

		
	 Other Expense
	  	 means the sum of all out-of-pocket costs and expenses incurred in processing and destroying of returns of Antibody Product.

		
	 Personnel Costs
	  	 means the costs of employment of personnel employed by or under contract to a Party, including, but not limited to, salaries, benefits (including the costs of
cars or allowances therefor), travel, lodging, meals and entertainment, office and computing supplies, space costs, recruiting, relocation and subscriptions.

		
	 Promotion Expense
	  	 means all out-of-pocket costs and expenses incurred (i.e., paid to Third Parties or accrued therefor) by Amgen or Celltech for the Promotion of an Antibody
Product



  
 B4 










			
		
		  	 including, but not limited to (i) marketing, advertising and promoting of Antibody Products (including, without limitation, educational expenses, advocate
development programs and symposia, sales meetings, direct to consumer/patient advertising, samples, agency fees for the development of promotional materials and printing of promotional materials), (ii) FAMC for samples of Antibody Product
distributed free of charge and (iii) training and communication materials for the Antibody Products.

		
	 Representative
	  	 means an individual (i) employed and trained by Amgen or Celltech or (ii) employed by a Third Party or self-employed and trained by or on behalf of Amgen or
Celltech, in either case, to Detail an Antibody Product.

		
	 Sales Force Cost
	  	 means the Personnel Costs of Representatives and their support staff in a sales force engaged in the Detailing of Antibody Products, including training
costs.


 In calculating the Product Contribution the following shall apply: 

 

	1.	 There shall be no double counting of any costs or expenses or of any revenues, and to the extent a cost or expense has been included in one category
or sub-category, it shall not be included in another; similarly, to the extent any revenue has been taken into account in one category or sub-category it shall not be taken into account in another. 



 

	2.	 When allocating costs and expenses under this Agreement, each Party shall utilise the same policies and principles as it utilises consistently
within its group and business units when making internal cost allocations. 


  

	3.	 Each Party shall bear its own out-of pocket costs (without limitation, travel costs, meals and accommodation) associated with attendance at meetings
of the Joint Research Committee, Joint Development Committee, Joint Commercialisation Committee, 



  
 B5 










	 	 
Collaboration Committee or such other joint meetings that the Parties agree shall be held in the furtherance of the Research, Development or Commercialisation of Antibody Products.



  

	4.	 To the extent an item of income or revenue is received by a Party or a cost or expense is incurred by a Party, and is necessary and specifically and
directly identifiable, attributable and allocable to the Commercialisation of Antibody Product and is not otherwise accounted for in the calculation of Product Contribution, such Party shall credit such income or revenue and shall be permitted to
charge such cost or expense to the Product Contribution. 



  
 B6 









 SCHEDULE C 
 Principles for Detail Cost 
 Each Party shall determine the Sales Force
Costs for each Calendar Quarter for each sales force Detailing Antibody Products. 
 Each Party shall undertake to promote
Antibody Product as a Primary Detail, Secondary Detail or Tertiary Detail throughout a Calendar Quarter. 
 The Detail Cost for
each sales force in each country for each Party for each Calendar Quarter shall be calculated by multiplying the Sales Force Costs for that sales force in that country by [*]% when Antibody Product has been promoted as Primary Detail in that
Calendar Quarter, and by [*]% when Antibody Product has been promoted as Secondary Detail in that Calendar Quarter and [*]% where Antibody Product has been promoted as Tertiary Detail in that Calendar Quarter, provided that a Party may not charge
for a Tertiary Detail for Antibody Product in a country during the [*] following the date of First Commercial Sale of such Antibody Product in a country. For a period not to exceed [*] from the date of First Commercial Sale of an Antibody Product in
any country and when a sales force has promoted only an Antibody Product and no other product in a Calendar Quarter in that country, the Detail Cost shall be [*]% of the Sales Force Cost, excluding extraordinary bonuses and the like. 

  
 C1 









 SCHEDULE D 
 Net Sales Definition 
 Net Sales means with respect to any Antibody
Product, all revenues recognised in accordance with GAAP, consistently applied as between the Parties, from sales of an Antibody Product by a Party, its Affiliate, sublicensees, and agents, to Third Parties (but not including sales relating to
transactions between a Party, its Affiliates, and their respective sublicensees and agents), less the total of the following (if not already deducted in the amount invoiced or not otherwise accounted for in Commercialisation Expenses or Cost of
Goods): 
  

	 	1.	 Normal or customary trade, cash, prompt payment and/or quantity discounts actually allowed and taken; 



 

	 	2.	 Returns, allowances, free goods, rebates, chargebacks, other allowances or payments to government agencies actually allowed and taken;



  

	 	3.	 Retroactive price reductions applicable to sales of such product actually allowed and taken; 



 

	 	4.	 Fees paid to distributors, selling agents (excluding any sales representatives of a Party or any of its Affiliates), group purchasing organisations
and managed care entities; 


  

	 	5.	 Credits or allowances (actively paid or allowed) for wastage replacement, whether cash or trade; 



 

	 	6.	 Non-recoverable sales taxes, excise taxes, tariffs and duties (excluding taxes when assessed on income derived from sales); and



  

	 	7.	 [*] percent of the amount invoiced to cover bad debt, freight or other transportation charges, insurance charges, additional special packaging, and
other governmental charges. 



  
 D1 









 In the case of any sale of an Antibody Product between or among a Party and its Affiliates
or sublicensees for resale, Net Sales shall be calculated as above only on the first arm’s length sale by any such Party, Affiliate or sublicensee to a Third Party. 
 Upon any sale or other disposal of any Antibody Product for any consideration other than an exclusively monetary consideration on bona fide arm’s length terms then for the purposes of calculating the
Net Sales under this Agreement, such Antibody Product shall be deemed to be sold exclusively for money at the average sales price during the applicable reporting period generally achieved for such Antibody Product in the country in which such sale
or other disposal occurred when such Antibody Product is sold alone and not with other products. 
 Where an Antibody Product is
sold together with other pharmaceutical products for a single price (whether sold together in the same package, or merely price bundled), then for the purposes of calculating the Product Contribution payable under this Agreement such Antibody
Product shall be deemed sold for an amount equal to the following: 
 (X divided by Y) multiplied by Z

 where X is the average sales price during the applicable reporting period generally achieved for such Antibody Product in the
country in which such sale or other disposal occurred when such Antibody Product is sold alone and not with other pharmaceutical products; Y is the sum of the average sales price during the applicable reporting period generally achieved in that
country when sold alone by each product (including the Antibody Product) included in the bundle of pharmaceutical products that is sold for the single price; and Z equals the single price at which the bundle of pharmaceutical products represented in
Y was actually sold. In the event one or more of the products in the bundled product are not sold separately, the parties shall confer in good faith to determine a fair market price that shall equitably compensate the Product Contribution for the
value of the Antibody Product(s) within the bundled product. 

  
 D2 









 SCHEDULE E 
 Calculation of Fully Absorbed Manufacturing Cost 
 DEFINITION OF FULLY
ABSORBED MANUFACTURING COSTS (“FAMC”) 
  

	I.	FAMC includes the costs of all [*] consumed, provided or procured by manufacturing facilities in the manufacture of Antibody Product in Finished Form, together with
(i) [*], (ii) [*] and (iii) [*]. 

  

	 	A.	 [*] costs are: 


  

	 	1.	The cost of [*] materials used in production. 

  

	 	2.	[*] materials, [*] ([*] of [*]in excess of a [*] limits). 

  

	 	3.	Other costs of materials used in the manufacture of Antibody Products not included in the preceding two paragraphs. 


 

	 	B.	 [*] costs are: 


 The [*] involved in the manufacture of Antibody Products, but excluding such costs to the extent that they are included within [*]. 

 

	 	C.	 [*] costs are: 


 The amounts paid or payable to [*] for the manufacture of Antibody Product in Finished Form or any component thereof ([*] of Antibody Products). 

  
 E1 










	 	D.	 [*] are all [*] and [*] manufacturing costs that [*] with [*] and, therefore, cannot be included in [*] FAMC as [*]. Such [*] costs are:



  

	 	1.	[*], including, but not limited to, [*]. 

  

	 	2.	[*], which reflects on a [*] basis, the [*] used for manufacturing the Antibody Product. 


 

	 	3.	The [*] allocations from [*], including [*] and other services required to be performed in connection with the manufacturing of the Antibody Product.


  

	 	4.	The [*] allocations for [*] services used at the [*] including [*]. 

  

	 	5.	[*] and other [*] costs on Antibody Raw Materials and Antibody Product, [*], [*] Antibody Raw Material or Antibody Product in Finished Form. 


 

	 	6.	[*] and other costs allocable to the [*] used to manufacture the Antibody Product. 


 

	 	7.	[*] cost incurred for [*] or otherwise in connection with compliance with [*] as a [*] of the manufacture of the Antibody Product. 


 

	 	E.	 Allowances for [*] include [*] variances within [*] and [*]. 



 

	 	F.	 Allowances for [*] to [*] include [*] charges for [*] charges. 



 

	II.	FAMC does not include: 

  

	 	A.	 [*], except the [*] allowance included under item IA.2. 



  
 E2 










	 	B.	 The value of [*] in the manufacturing operation (other than [*] as stated above). 



 

	 	C.	 [*] on [*] shipment. 


  

	 	D.	 [*]. 


  

	 	E.	 Costs associated with the [*] and the [*], including without limitation the costs of [*], to the extent that such costs are included under
other elements of [*]. 


  

	 	F.	 Any [*] on [*] manufacturing plants or [*]. 



 

	 	G.	 [*] related to [*]. 


  

	 	H.	 [*] categorized separately in Schedule A. 


  


	 	I.	 [*] expenses. 


  

	III.	Calculation of FAMC 

 FAMC
will be calculated in accordance with GAAP, applied on a consistent basis as between the Parties. Such calculations shall allocate to Antibody Products a fair and reasonable portion of manufacturing overhead consistent with the allocation of such
manufacturing overheads to all products manufactured at the relevant facility. Actual FAMC incurred will be charged against Product Contribution as Antibody Product is sold on a first in-first out basis. FAMC incurred for launch inventory build up
shall be [*] as Antibody Product is [*]. Such FAMC shall include, without limitation, costs incurred in [*] of Antibody Products in Finished Form. 

  
 E3 









 SCHEDULE F 
 PART A 
 [*] PATENT RIGHTS 

a)  Product 
  

					
	[*] Ref. No.            [*]	 	
			
	Subject Matter:	 		 	[*]
			
	Title:	 		 	[*]
			
	Inventors:	 		 	[*]
		 		 	[*]
		 		 	[*]
		 		 	[*]
		 		 	[*]
		 		 	[*]
		 		 	[*]
		
	Priority Application Date:	 	[*]
	Earliest Publication Date/No.	 	[*]

  

									
	Territory	 	Application Date	 	Application No.	    	Patent No.	  	Expiry Date
					
	[*]	 	[*]	 	[*]	    		  	
	[*]	 	[*]	 	[*]	    		  	
	[*]	 	[*]	 	[*]	    		  	
	[*]	 	[*]	 	[*]	    		  	
	[*]	 	[*]	 	[*]	    		  	
	[*]	 	[*]	 	[*]	    		  	
	[*]	 	[*]	 	[*]	    		  	
	[*]	 	[*]	 	[*]	    		  	
	[*]	 	[*]	 	[*]	    		  	
	[*]	 	[*]	 	[*]	    		  	
	[*]	 	[*]	 	[*]	    		  	
	[*]	 	[*]	 	[*]	    		  	
	[*]	 	[*]	 	[*]	    		  	
	[*]	 	[*]	 	[*]	    		  	
	[*]	 	[*]	 	[*]	    		  	
	[*]	 	[*]	 	[*]	    		  	

 *[*] 

  
 F1 









 SCHEDULE F 
 PART B 
 [*] PATENT RIGHTS 

b)  [*] 
  

					
	[*] Ref. No:	 	[*]
			
	Subject Matter:	 		 	[*]
			
	Title:	 		 	[*]
			
	Inventors:	 		 	[*]
		 		 	[*]
		
	Priority Application Date:	 	[*]
	Earliest Publication Date/No:	 	[*]

  

									
	Territory	 	Application Date	  	Application No.	  	Patent No.	    	Expiry Date
					
	[*]	 	[*]	  	[*]	  	[*]	    	[*]
	[*]	 	[*]	  	[*]	  	[*]	    	[*]
	[*]	 	[*]	  	[*]	  	[*]	    	[*]

 *[*] 

  
 F2 









 SCHEDULE F 
 PART B 
 [*] PATENT RIGHTS 

b)  [*] 
  

					
	[*] Ref. No:	 	[*]
			
	Subject Matter:	 		 	[*]
			
	Title:	 		 	[*]
			
	Inventors:	 		 	[*]
		 		 	[*]
		
	Priority Application Date:	 	[*]
	Earliest Publication Date/No:	 	[*]

  

									
	Territory	 	Application Date	  	Application No.	  	Patent No.	    	Expiry Date
					
	[*]	 	[*]	  	[*]	  	[*]	    	[*]
	[*]	 	[*]	  	[*]	  	[*]	    	[*]

 *[*] 

  
 F3 









 SCHEDULE F 
 PART B 
 [*] PATENT RIGHTS 

 

					
	 c)  [*]
  
	 		 	
	  
 [*] Ref. No.

 
	 	  
 [*]
	 	
	 Subject Matter:
  
	 	[*]	 	
	 Title:
  
	 	[*]	 	
	 Inventors:
	 	[*]	 	
		 	 [*]
  
	 	
	 Priority Application Date:
	 	[*]	 	
	 Earliest Publication Date/No.    
	 	[*]	 	

  

									
	Territory	 	Application Date	 	Application No.	 	Patent No.	 	Expiry Date
					
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 		 	
	[*]	 	[*]	 	[*]	 		 	
	[*]	 	[*]	 	[*]	 		 	
	[*]	 	[*]	 	[*]	 		 	
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 		 	
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 		 	
	[*]	 	[*]	 	[*]	 		 	
	[*]	 	[*]	 	[*]	 		 	

 *[*] 

  
 F4 









 SCHEDULE F 
 PART B 
 [*] PATENT RIGHTS 

 

					
	 c)  [*]
  
	 		 	
	  
 [*] Ref. No.

 
	 	  
 [*]
	 	
	 Subject Matter:
  
	 	[*]	 	
	 Title:
  
	 	[*]	 	
	 Inventors:
	 	[*]	 	
		 	 [*]
  
	 	
	 Priority Application Date:
	 	[*]	 	
	 Earliest Publication Date/No.    
	 	[*]	 	

  

									
	Territory	 	Application Date	 	Application No.	 	Patent No.	 	Expiry Date
					
	[*]	 	[*]	 	[*]	 		 	
	[*]	 	[*]	 	[*]	 		 	
	[*]	 	[*]	 	[*]	 		 	
	[*]	 	[*]	 	[*]	 		 	
	[*]	 	[*]	 	[*]	 		 	
	[*]	 	[*]	 	[*]	 		 	
	[*]	 	[*]	 	[*]	 		 	

 *[*] 

  
 F5 









 SCHEDULE F 
 PART C 
 [*] PATENT RIGHTS ([*]) 

 

					
	 d)  [*]
  
	 		 	
	  
 [*] Ref. No:

 
	 	  
 [*]
	 	
	 Subject Matter:
  
	 	[*]	 	
	 Title:
  
	 	[*]	 	
	 Inventors:
	 	[*]	 	
		 	[*]	 	
		 	[*]	 	
		 	 [*]
  
	 	
	 Priority Application Date:
	 	[*]	 	
	 Earliest Publication Date/No:    
	 	[*]	 	

  

									
	Territory	 	Application Date	 	Application No.	 	Patent No.	 	Expiry Date
					
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 		 	
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 		 	
	[*]	 	[*]	 	[*]	 		 	
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 		 	
	[*]	 	[*]	 	[*]	 		 	
	[*]	 	[*]	 	[*]	 		 	
	[*]	 	[*]	 	[*]	 		 	

 *[*] 

  
 F6 









 SCHEDULE F 
 PART C 
 [*] PATENT RIGHTS ([*]) 

 

					
	 d)  [*]
  
	 		 	
	  
 [*] Ref. No:

 
	 	  
 [*]
	 	
	 Subject Matter:
  
	 	[*]	 	
	 Title:
  
	 	[*]	 	
	 Inventors:
	 	[*]	 	
		 	[*]	 	
		 	 [*]
  
	 	
	 Priority Application Date:
	 	[*]	 	
	 Earliest Publication Date/No:    
	 	[*]	 	

  

									
	Territory	 	Application Date	 	Application No.	 	Patent No.	 	Expiry Date
					
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]

 *[*] 

  
 F7 









 SCHEDULE F 
 PART C 
 [*] PATENT RIGHTS ([*]) 

 

					
	 d)  [*]
  
	 		 	
	  
 [*] Ref. No:

 
	 	  
 [*]
	 	
	 Subject Matter:
  
	 	[*]	 	
	 Title:
  
	 	[*]	 	
	 Inventors:
	 	[*]	 	
		 	[*]	 	
		 	 [*]
  
	 	
	 Priority Application Date:
	 	[*]	 	
	 Earliest Publication Date/No:    
	 	[*]	 	

  

									
	
Territory
	 	Application Date	 	Application No.	 	Patent No.	 	Expiry Date
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	 	 	 
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	 	 	 
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	 	 	 
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	 	 	 
	[*]	 	[*]	 	[*]	 	 	 	 
	[*]	 	[*]	 	[*]	 	 	 	 
	[*]	 	[*]	 	[*]	 	 	 	 
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	 	 	 
	[*]	 	[*]	 	[*]	 	 	 	 
	[*]	 	[*]	 	[*]	 	 	 	 

 *[*] 

  
 F8 









 SCHEDULE F 
 PART D 
 [*] PATENT RIGHTS ([*]) 

 

					
	 [*]
  
	 		 	
	 Applicants:
  
	 	[*]	 	
	 Inventor:
  
	 	[*]	 	
	 Priority Application Date:
	 	[*]	 	
	 Earliest Publication Date/No:    
	 	[*]	 	
			
	 Title:
	 	[*]	 	

  

									
	Territory	 	Application Date	 	Application No.	 	Patent No.	 	Expiry Date
					
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]

 *[*] 
  

Whether or not the above Patent Rights fall within the [*] Patent Rights is determined by the [*] relating to these Patent Rights as such [*] have been
disclosed to [*] prior to [*]. 

  
 F9 









 SCHEDULE F 
 PART D 
 [*] PATENT RIGHTS ([*]) 

 

					
	 [*]
  
	 		 	
	 Applicants:
  
	 	[*]	 	
	 Inventors:
	 	 [*],[*],[*]

[*],[*]
	 	
			
	 Priority Application Dates:
	 	[*]	 	
	 Earliest Publication Date/No:    
	 	[*]	 	
			
	 Title:
	 	[*]	 	

  

									
	
Territory
	 	Application Date	 	Application No.	 	Patent No.	 	Expiry Date
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 		 	 	 	 
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	 	 	 
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	 	 	 
	[*]	 	[*]	 	[*]	 	 	 	 
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	 	 	 
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]

 *[*] 
 Whether or not the above Patent Rights fall within the [*] Patent Rights is determined by the [*] relating to these Patent Rights as such [*] have been disclosed to [*] prior to [*]. 

  
 F10









 SCHEDULE F 
 PART D 
 [*] PATENT RIGHTS ([*]) 

 

					
	 [*]
  
	 		 	
	 Applicants:
  
	 	[*]	 	
	 Inventors:
	 	 [*],[*],[*],[*],

[*]
	 	
			
	 Priority Application Date:
	 	[*]	 	
	 Earliest Publication Date/No:    
	 	[*]	 	
			
	 Title:
	 	[*]	 	

  

									
	
Territory
	 	Application Date	 	Application No.	 	Patent No.	 	Expiry Date
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	 	 	 
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	 	 	 
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]	 	[*]

 *[*] 
 Whether
or not the above Patent Rights fall within the [*] Patent Rights is determined by the [*] relating to these Patent Rights as such [*] have been disclosed to [*] prior to [*]. 

  
 F11









 SCHEDULE G 
 ANTIBODY LICENCE AGREEMENT 







 ANTIBODY LICENCE AGREEMENT 

BY AND BETWEEN 
 AMGEN INC. 
 AND 

CELLTECH R&D LIMITED 







 ANTIBODY LICENCE AGREEMENT 

INDEX 
  

									
	Article        	 	  Description

 
	  	Page      
	 	 	   
	Recitals  
	  	1
	
1
	 	   
	Definitions  
	  	2
	
2
	 	   
	Grant of Licences and Other Rights
 
	  	2
	 	 	   

 
  
  
  
	2.1  

2.2
  
 2.3
  
	    
   
  

  
  
	    	 Patent Licences
  

Trademark; Copyright Licences
  

Sublicensing
  
	  	 2

 
 3
  

4
  

	
3
	 	   
	Research, Development, Commercialisation
 
	  	4
	 	 	   

 
  
  
  
  

 
	3.1  
 3.2
  
 3.3
  
 3.4
  
	    
   
  

  
  
   
  
	    	 Diligence
  

Research, Development and Commercialisation
  

Regulatory Filings and Regulatory Approvals
  

Notification due to Regulatory Obligation
  
	  	 4

 
 5
  

6
  
 6
  

	
4
	 	   
	Consideration  
	  	7
	 	 	   
  
  
  

 
  

 
  

 
  

 
  

 
  

 
  
	4.1  

4.2
  

4.3
  

4.4
  

4.5
  

4.6
  

4.7
  

4.8
  

4.9
	    

  
  
   
  

  
  
   
  

  
  
   
  

  
  
   
	    	 Milestones
  

Royalties
  
 FAMC Cost
  
 Third Party
Licences
  
 Royalty Reduction

 
 Competition Reduction

 
 No Competition Reduction

 
 Term of Royalties

 
 Revival of Royalty Where Patent Becomes a Valid Claim

 
	  	 7

 
 8
  

10
  
 10
  
 11

 
 11
  

12
  
 13
  

13



  
 i 









									
	Article        	 	 Description

 
	  	Page      
	5	 	 Intellectual Property

 
	  	14
	 	 	   

 
  
  
  
  

 
  

 
  
  
	5.1  
 5.2
  
 5.3
  
 5.4
  
 5.5
  
 5.6
  
	    
   
  

  
  
   
  

  
  
   
  
	    	 Technology Ownership
  

Prosecution
  
 Enforcement
  
 Infringement
Defence
  
 Patent Marking

 
 Co-operation
  
	  	 14

 
 14
  

18
  
 19
  
 20

 
 20

	6	 	 Payments; Records; Audits

 
	  	21
	 	 	   

 
  
	6.1  
 6.2
  
	    
   
  
	    	 Payments
  
 Records; Audit
	  	 21

 
 23

	7	 	 Publications

 
	  	25
	 	 	   

 
  
	7.1  
 7.2
  
	    
   
  
	    	 Procedure
  
 Credit
	  	 25

 
 26

	8	 	 Confidentiality

 
	  	26
	 	 	   
  
  
  

 
  

 
  

 
  

 
  
  
	8.1  

8.2
  

8.3
  

8.4
  

8.5
  

8.6
  

8.7
  
	    

  
  
   
  

  
  
   
  

  
  
   
  
	    	 Confidential Information

 
 Authorised Disclosure

 
 Exceptions

 
 Materials

 
 Terms of Agreement

 
 Public Announcements

 
 Third Party Obligations

 
	  	 26

 
 29
  

30
  
 30
  
 30

 
 30
  

31



  
 ii 










							
	Article        	 	 Description

 
	  	Page      
	
9
	 	Covenants  
	  	31
	 	 	9.1  

9.2
  
 9.3
	    	 Mutual Covenants
  

Covenants of Amgen
  
 Disclaimers
  
	  	 31

 
 32
  

32

	
10
	 	Indemnification  
	  	33
	 	 	10.1  

10.2
  
 10.3
  
 10.4

 
 10.5
	    	 Indemnification by Celltech
  

Indemnification by Amgen
  
 Insurance
  
 Pre-Effective Date
Losses
  
 Limitation of Liability

 
	  	 33

 
 34
  

35
  
 35
  
 36

	
11
	 	Term and Termination
 
	  	36
	 	 	11.1  

11.2
  
 11.3
  
 11.4

 
 11.5

 
 11.6

 
 11.7

 
 11.8

 
 11.9
	    	 Term
  
 Termination for Convenience
  

Termination for Default
  
 Bankruptcy
  
 Additional
Termination Rights of Celltech
  
 Termination Date

 
 Effects of Termination

 
 No Transition

 
 Accrued Rights

 
	  	 36

 
 36
  

37
  
 38
  
 39

 
 40
  

40
  
 46
  
 46

	
12
	 	Dispute Resolution  
	  	46
	 	 	12.1	    	 Disputes

 
	  	46


  
 iii










											
	Article        	 	 Description

 
	 	  	 	Page      
	
13
	 	General  
	 	 	 	47
	 	 	13.1  

13.2
  
 13.3
  
 13.4

 
 13.5

 
 13.6

 
 13.7

 
 13.8

 
 13.9

 
 13.10

 
 13.11

 
 13.12  
	 	Amendments  
 Notices
  
 Force
Majeure
  
 Use of Names, Logos or Symbols

 
 No Strict Constriction

 
 Assignment

 
 Severability

 
 Interpretation and Schedules

 
 No Consequential Damages

 
 Governing Law; Jurisdiction

 
 General Provisions

 
 Whole Agreement

 
	 		 	 47

 
 47
  

48
  
 48
  
 49

 
 49
  

49
  
 50
  
 50

 
 51
  

52
  
 53

	 	 	 	 	 	 
	 	 	     	 		    		 		 	 
	
Schedule One
	 	Defined Terms	 	 S1-1 thru S1-13       

 

	 Schedule Two
	 	Patent Rights  
	 	S2-1 
thru S2-5       


  
 iv 









 ANTIBODY LICENCE AGREEMENT 

THIS ANTIBODY LICENCE AGREEMENT (the “Licence
Agreement”) is made effective as of the Effective Date of Termination of the Collaboration Agreement (as defined in Schedule One) (the “Licence Agreement Effective Date”) by and between Amgen Inc., a corporation
organised and existing under the laws of the State of Delaware and having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799 (“Amgen”) and Celltech R & D Limited, a company organised
and existing under the laws of England and having its principal office at 208 Bath Road, Slough, Berkshire SL1 3WE, United Kingdom (“Celltech”). 
 RECITALS 
 WHEREAS,
Celltech and Amgen, under the terms and conditions of the Collaboration Agreement, as defined in Schedule One attached hereto, have been collaborating in the Joint development and commercialisation of certain Antibody Products (as defined
therein;) 
 WHEREAS, pursuant to Article 14 of the Collaboration Agreement, the
Collaboration Agreement is now terminated, in whole or part, and Amgen is the Continuing Party as defined in the Collaboration Agreement. 
 WHEREAS, in accordance with Article 14 of the Collaboration Agreement, Celltech now wishes to grant to Amgen and Amgen wishes to obtain from Celltech a license under certain Celltech
rights to Research, Develop, and Commercialise such certain Antibody Products (for purposes of this Licence Agreement termed “Licensed Antibody Products”, all terms as hereinafter defined in the attached Schedule One), on the
terms and conditions herein; 

  
 1 








 NOW THEREFORE, based on the foregoing
premises and the mutual covenants and obligations set forth below, the Parties agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 Capitalised terms used but not otherwise defined herein have the meanings provided in Schedule One hereto. 
 ARTICLE 2 
 GRANT OF LICENCES AND OTHER RIGHTS 

 

	2.1	 Patent Licences. 


  

	 	(a)	 Celltech hereby grants to Amgen: 


  

	 	(i)	 an exclusive licence even as to Celltech under the [*] Patent Rights, [*] Patent Rights, [*] Patent Rights, [*] Know-How [*],[*] Know-How and [*]
Know-How, with the right to sublicense in accordance with Article 2.3; and 


  

	 	(ii)	 a non-exclusive licence to all other [*] Technology, with the right to sublicense in accordance with Article 2.3; 



to Research, Develop, Commercialise, make, have made, use, sell, have sold, offer to sell or resell, import, export,
distribute or otherwise transfer physical possession of or otherwise transfer title in or to Licensed Antibody Products in the Field in the Territory, solely in compliance with the terms and conditions of this Licence Agreement. 

 

	 	(b)	 Certain licence rights granted to Amgen under this Article 2 may include a sublicence of Patent Rights and/or know-how of Third Parties under Third
Party licences. Notwithstanding anything to the contrary in this Licence Agreement, Amgen shall, in exercising such sublicence rights be subject to and so far as the terms are applicable to its activities, comply with the provisions of such Third
Party licences relating to Licensed Antibody Products to the extent Celltech has notified in writing the terms of such Third Party licence to Amgen. Celltech shall promptly provide to Amgen a copy of any notice of breach received by it under such
Third Party licence. 



  
 2 









	2.2	 Trademark; Copyright Licences.  


  

	 	(a)	 Celltech hereby grants to Amgen an exclusive royalty-free licence, with the right to grant sublicences (subject to Amgen’s compliance with
Article 2.3 of this Licence Agreement), under Celltech’s entire right, title and interest in and to the Product Trademarks, to use and display the Product Trademarks in connection with relevant Licensed Antibody Products in the Territory;
provided however, that Amgen shall not have any licence to use and display Celltech Trademarks other than as set forth in Article 14.9(b)(iii)(3) of the Collaboration Agreement (sale of then-existing inventory). For the avoidance of doubt,
Amgen shall have the right to select for and use and display with Licensed Antibody Products such Trademarks as it desires. 


  

	 	(b)	 Celltech hereby grants to Amgen a royalty-free licence under Celltech’s entire right, title and interest in any copyrights in and to
Promotional Materials, with the right to grant sublicences (subject to Amgen’s compliance with Article 2.3 of this Licence Agreement), to reproduce, distribute copies of, prepare derivative works of and publicly perform and display such
Promotional Materials in connection with Licensed Antibody Products in the Territory solely in compliance with the terms and conditions of this Licence Agreement; provided however, that Amgen shall not have any licence to use and display
Celltech Trademarks other than as set forth in Article 14.9(b)(iii)(3) of the Collaboration Agreement (sale of then-existing inventory). Such licence shall be exclusive to the extent the Promotional Materials are exclusive to Licensed Antibody
Products and otherwise shall be non-exclusive. 


  

	2.3	 Sublicensing.  


  

	 	(a)	 Amgen shall have the sole right to determine whether to sublicense any or all of its rights under Article 2.1 or Article 2.2. Any such sublicence
shall require the 



  
 3 









	 	 
Sublicensee to comply with the obligations of Amgen as contained herein. Any such sublicence shall provide for the termination of such sublicence, or the conversion to (with respect to [*]
Technology) a licence directly between such Sublicensee and Celltech, [*], upon termination of this Licence Agreement. 


  

	 	(b)	 Notwithstanding the sublicensing of all or part of Amgen’s rights and obligations hereunder, Amgen shall remain responsible for the actions and
omissions of its Sublicensees and for the full and complete performance of all of Amgen’s obligations and duties under this Licence Agreement. 


 ARTICLE 3 
 RESEARCH, DEVELOPMENT AND COMMERCIALISATION 

 

	3.1	 Diligence. 


  

	3.1.1	 From and after the Licence Agreement Effective Date Amgen shall: 



 

	 	(a)	 use diligent and timely efforts to satisfactorily complete Research of Licensed Antibody Products and obtain in [*] for a Licensed Antibody Product
an IND. For the avoidance of doubt, nothing in this Licence Agreement shall preclude Amgen from filing INDs in [*]; 


  

	 	(b)	 use Commercially Reasonable Efforts to satisfactorily complete all Development activities with respect to a Licensed Antibody Product; and



  

	 	(c)	 use Commercially Reasonable Efforts to obtain Regulatory Approval to Commercialise a Licensed Antibody Product; 



in each case for the [*] or if the [*] is dropped, [*]; and 

 

	 	(d)	 use Commercially Reasonable Efforts to maximise Net Sales of each Licensed Antibody Product in the Territory. 



  
 4 








 For the avoidance of doubt, the Parties acknowledge that the diligence
obligations may have been met, in whole or in part, by activity conducted under the Collaboration Agreement. 
  

	3.1.2	 Amgen acknowledges that using Commercially Reasonable Efforts requires it to take ongoing actions that are consistent with a good faith intention to
achieve the objective of Developing a Licensed Antibody Product and obtaining Regulatory Approvals to Commercialise such Licensed Antibody Product for the [*] (or if the [*] is dropped, [*]) in the Field, and to Commercialise such Licensed Antibody
Product [*]. For the avoidance of doubt, Development and Commercialisation in each instance includes the manufacture and supply of Licensed Antibody Product. If Amgen decides that deployment of Commercially Reasonable Efforts does not justify it
making continued, ongoing efforts towards this objective it shall promptly notify Celltech in writing. 


  

	3.1.3	 Amgen shall not be in breach of any obligation under this Licence Agreement to the extent its inability to perform such obligation is caused by
Celltech’s failure to perform any of its obligations under this Licence Agreement or under Article 14.9 of the Collaboration Agreement. Celltech acknowledges that in applying the Commercially Reasonable Efforts standard to Amgen’s
obligation pursuant to Article 3.1.1, a relevant factor to be taken into account shall be [*]. 


  

	3.1.4	 Amgen acknowledges that the obligations it undertakes pursuant to this Article 3.1 are [*]. 



 

	3.2	 Research, Development and Commercialisation.  Subject to and consistent with its obligations set out in this Licence Agreement, as
between the Parties, Amgen shall have sole and full control, discretion, authority and right for conducting, funding and pursuing all aspects of Research, Development and Commercialisation (including the manufacture and supply for Research,
Development and Commercialisation) of Licensed Antibody Products in the Territory. Amgen shall conduct its Research activities and Development activities in compliance with all laws, regulations and guidelines that are applicable to the particular
stage of Research or Development for the Licensed Antibody Product, including, GLP, GCP and GMP, of the relevant jurisdiction as the same may be amended from time to time. 



  
 5 









	3.3	 Regulatory Filings and Regulatory Approvals.    With respect to each Licensed Antibody Product, in a manner consistent
with its obligations set out in this Licence Agreement, Amgen shall have the sole and full control, discretion authority and right to prepare, file and pursue and shall own all right, title and interest in Regulatory Filings and Regulatory Approvals
relating to each said Licensed Antibody Product in the Territory. 


  

	3.4	 Notification Due to Regulatory Obligation.  Notwithstanding any other term of this Agreement, if any other Antibody being developed
by Celltech is [*] by a Regulatory Authority for reasons which Celltech believes are attributable to [*] rather than to [*], Celltech shall notify Amgen of this as soon as reasonably practicable after receipt of written notice of [*] from the
Regulatory Authority. 



  
 6 








 ARTICLE 4 
 CONSIDERATION 
  
  

	4.1	 Milestones. 


  

	 	(a)	 Within [*] following the first achievement or occurrence with the first Licensed Antibody Product(s) of each of the following milestone events by
performance of Amgen or an Affiliate or Sublicensee of Amgen (“Milestone Event(s)”), Amgen shall pay to Celltech the corresponding non-creditable, non-refundable milestone payments set forth herein (“Milestone
Payment(s)”): 


  

			
	 Milestone Event
  
	    	
        Milestone Payment        

 

	  
	    	  

		
	   (i)  [*]
	    	$[*]
		
	  (ii)  [*]
	    	  $[*]
		
	 (iii)  [*]
	    	   $[*]
  

 

	  
	    	  

		
	 Total
	    	  $[*]


  
  

	 	(b)	 Subject to Article 4.1(c) below, if any Milestone Event set forth above is achieved prior to or in the absence of the achievement of any preceding
Milestone Event then, effective upon achievement of any such Milestone Event, all previously unpaid Milestone Payments set forth in Article 4.1(a) shall also become due and payable. Each Milestone Payment shall be payable only once, no matter how
many times achieved by one or more Licensed Antibody Product(s). Each Milestone Payment shall be non-refundable and non-creditable whether against Royalties payable pursuant to Article 4.2, any other fees, other Milestone Payments, or any other
payments due to Celltech with respect to Licensed Antibody Product(s) under this Licence Agreement, or any other amounts accrued and owed prior to termination of the Collaboration Agreement or otherwise. 



  
 7 









	 	(c)	 If the Licence Agreement Effective Date is after the date of achievement of any Milestone Event(s) set forth in Articles 4.1(a)(i)-(iii), then the
Milestone Payment(s) payable in respect of such Milestone Event(s) shall be deemed waived and not payable to Celltech (but without prejudice to any amounts accrued and owed prior to termination of the Collaboration Agreement, and without prejudice
to any Milestone Payment payable in respect of a Milestone Event occurring after the Licence Agreement Effective Date). 


  

	4.2	 Royalties. 


  

	 	(a)	 Subject to Articles 4.4 and 4.5 below, if the FAMC of the Antibody Raw Material is more than [*] ($[*]) [*], Amgen shall pay to Celltech a Royalty,
based on the following Royalty rates, for annual Net Sales of each Licensed Antibody Product (on a Licensed Antibody Product-by-Licensed Antibody Product basis of cumulative Net Sales in those countries for which a Royalty is due in accordance with
Article 4.8) by Amgen, its Affiliates, and its Sublicensees in the Territory: 


  

	 	(i)	 a Royalty rate of [*] ([*]%) of that portion of annual Net Sales in the Territory of each such Licensed Antibody Product that is less than [*]
($[*]); 


  

	 	(ii)	 a Royalty rate of [*] ([*]%) of that portion of annual Net Sales in the Territory of each such Licensed Antibody Product that is equal to or greater
than [*] ($[*]) and less than or equal to [*] ($[*]); and 


  

	 	(iii)	 a Royalty rate of [*] ([*]%) of that portion of annual Net Sales in the Territory of each such Licensed Antibody Product that is greater than
[*] ($[*]). 


  

	 	(b)	 Subject to Articles 4.4 and 4.5, below, if the FAMC of the Antibody Raw Material is less than or equal to [*] Dollars ($[*]) [*] and greater than
[*] Dollars 



  
 8 









	 	 
($[*]) [*], Amgen shall pay to Celltech a Royalty based on the following Royalty rates for annual Net Sales of each Licensed Antibody Product (on a Licensed Antibody Product-by-Licensed Antibody
Product basis of cumulative Net Sales in those countries for which a Royalty is due in accordance with Article 4.8) by Amgen, its Affiliates, and its Sublicensees in the Territory: 



 

	 	(i)	 a Royalty rate of [*] ([*]%) of that portion of annual Net Sales in the Territory of each such Licensed Antibody Product that is less than [*]
Dollars ($[*]); 


  

	 	(ii)	 a Royalty rate of [*] ([*]%) of that portion of annual Net Sales in the Territory of each such Licensed Antibody Product that is equal to or greater
than [*] Dollars ($[*]) and less than or equal to [*] Dollars ($[*]); and 


  

	 	(iii)	 a Royalty rate of [*] ([*]%) of that portion of annual Net Sales in the Territory of each such Licensed Antibody Product that is greater than
[*] Dollars ($[*]). 


  

	 	(c)	 Subject to Articles 4.4 and 4.5 below, if the FAMC of the Antibody Raw Material is less than or equal to [*] Dollars ($[*])[*], Amgen shall pay to
Celltech a Royalty based on the following Royalty rates for annual Net Sales of each Licensed Antibody Product (on a Licensed Antibody Product-by-Licensed Antibody Product basis of cumulative Net Sales in those countries for which a Royalty is due
in accordance with Article 4.8) by Amgen, its Affiliates, and its Sublicensees in the Territory: 


  

	 	(i)	 a Royalty rate of [*] ([*]%) of that portion of annual Net Sales in the Territory of each such Licensed Antibody Product that is less than [*]
Dollars ($[*]); 



  
 9 









	 	(ii)	 a Royalty rate of [*] ([*]%) of that portion of annual Net Sales in the Territory of each such Licensed Antibody Product that is equal to or greater
than [*] Dollars ($[*]) and less than or equal to [*] Dollars ($[*]); and 


  

	 	(iii)	 a Royalty rate of [*] ([*]%) of that portion of annual Net Sales in the Territory of each such Licensed Antibody Product that is greater than
[*] Dollars ($[*]). 


  

	 	(d)	 In the event that the Antibody Raw Material is not a [*] Antibody, the Royalty rates set forth in Article 4.2 (a) (i), (ii) and
(iii) shall apply regardless of the FAMC of the Antibody Raw Material. 


  

	4.3	 FAMC.  Amgen shall use Commercially Reasonable Efforts to ensure that the FAMC of the Antibody Raw Material is an FAMC that [*].



  

	4.4	 Third Party Licences.  To the extent not sublicensed by Celltech hereunder, Amgen shall be responsible for obtaining any licences
for rights to any Third Party intellectual property required to Research, Develop, Commercialise, make, have made, use, sell, have sold, offer to sell or resell, import, export, distribute or otherwise transfer physical possession of or otherwise
transfer title in or to, a Licensed Antibody Product in one or more countries in the Territory. Amgen shall be responsible for making all Third Party Payments for rights to any Third Party intellectual property (when licensed directly by Amgen)
required to Research, Develop, Commercialise, make, have made, use, sell, have sold, offer to sell or resell, import, export, distribute or otherwise transfer physical possession of or otherwise transfer title in or to, a Licensed Antibody Product
in one or more countries in the Territory. Where Celltech has sublicensed Third Party intellectual property rights to Amgen pursuant to this Licence Agreement, in addition to the Royalties payable by Amgen under Article 4.2, but subject to Article
4.5, Amgen shall pay Celltech against invoice for, and Celltech shall be responsible for making, all Third Party Payments in connection with the rights sublicensed to Amgen pursuant to this Licence Agreement, unless the Parties agree that such Third
Party Payments shall be made by Amgen directly to such Third Party. 



  
 10 










	4.5	 Royalty Reduction.  If, and for so long as Amgen is required to pay Third Party Payments, as set forth in Article 4.4, as royalties
for such licence in respect of sale or other disposal of a Licensed Antibody Product in a country in the Territory, such royalties shall be creditable by Amgen against any Royalties due to Celltech under Article 4.2 above for the Net Sales of such
Licensed Antibody Product in such country as follows: 


  

	 	(a)	 [*] ([*]%) of Third Party royalties payable by Amgen equal to or less than [*] ([*]%) in aggregate of Net Sales of such Licensed Antibody Product in
such country shall be creditable against Royalties payable to Celltech 


  

	 	(b)	 [*] ([*]%) of Third Party royalties payable by Amgen greater than [*] ([*]%) in aggregate of Net Sales of such Licensed Antibody Product in such
country shall be creditable against Royalties payable to Celltech 


 provided however,
that on a Licensed Antibody Product-by-Licensed Antibody Product basis, the Royalty rate payable by Amgen pursuant to this Licence Agreement in any given Calendar Year shall not be less than [*] ([*]%) of Net Sales of such Licensed Antibody Product
in such country. Subject to the foregoing, Amgen shall have sole discretion, authority and right with respect to determining whether to enter into an agreement for a licence (or to accept, pursuant to Article 3, a sublicence) or other rights and to
incur an obligation for any Third Party Payments. 
  

	4.6	 Competition Reduction.  Upon [*], Amgen shall have the immediate and continuing right to reduce the Royalty rates set forth in
Article 4.2 on Net Sales of each such Licensed Antibody Product(s) in such country to: 


  

	 	(a)	 [*] ([*]%) during the first [*] period following such sale of commercial quantities and thereafter; and 



  
 11 










	 	(b)	 [*] ([*]%) for each [*] period thereafter until expiration of the obligation to pay a Royalty for such Licensed Antibody Product under Article 4.8;



  

	4.7	 No Competition Reduction.  With respect to a Competitive Product, in any country in the Territory where such Competitive Product
either is being or has been sold: 


  

	 	(a)	 If 


  

	 	(i)	 Celltech provides a written request pursuant to Article 5.3.2 and Amgen does not bring suit or action within the time frame for bringing suit in
accordance with Article 5.3.2 or, 


  

	 	(ii)	 Amgen having brought a suit or action described in Article 5.3.1, ceases to progress it and Celltech then requests Amgen in writing to progress such
suit or action; 


 and Amgen elects, at its option, (or is deemed to have so elected by
failing to respond to Celltech’s written notice pursuant to Article 5.3.2 or within [*] of Celltech’s written request pursuant to Article 4.7(a)(ii)) that Celltech shall not have the right to bring any such suit or action, then the Royalty
reduction to which Amgen is entitled under Article 4.6 (the “Royalty Reduction”) shall not apply with respect to that Competitive Product in that country for the period from the date of expiry of the relevant time frame under
(i) above or the date Amgen ceases to progress such suit or action under (ii) above, as appropriate. 
  

	 	(b)	 If Celltech provides a written request pursuant to Article 5.3.2 or Article 4.7(a)(ii) and Amgen, within the time frame for bringing suit in
accordance with Article 5.3.2 (or within [*] of Celltech’s written request pursuant to Article 4.7(a)(ii)), provides Celltech with written notice of Amgen’s election, at its option, that Celltech shall have the right to bring any suit or
action described in Article 5.3.2, then the Royalty Reduction shall not apply for the period commencing on the date of Celltech’s written notice and ending [*] after the date Amgen notifies Celltech in writing of Amgen’s election that
Celltech shall have such right to bring such suit or action with respect to such Competitive Product in such country. 



  
 12 










	 	(c)	 If Celltech provides a written request pursuant to Article 5.3.2 or Article 4.7(a)(ii) and Amgen, within the time frame for bringing suit in
accordance with Article 5.3.2, or within [*] of Celltech’s written request pursuant to Article 4.7(a)(ii), elects, at its option (as notified to Celltech in writing), that Celltech shall have the right to bring any suit or action described in
Article 5.3.2 and 


  

	 	(i)	 Celltech exercises such right; and 


  

	 	(ii)	 the court concludes that Celltech has been prejudiced in obtaining a preliminary injunction by the delay from Celltech’s written request to the
date of Amgen’s election to allow Celltech to exercise such right, or by Amgen failing to progress such action, then 


 the Royalty Reduction shall not apply and Amgen shall pay Celltech all Royalties Celltech would otherwise have been entitled to receive plus interest (at the rate provided in Article 6.1(d)) on such sum
for the period from the later of Celltech’s written request or the date of first commercial sale of such Competitive Product in such country up to the date of the final court decision, such sum plus interest to be paid within [*] of such final
court decision. 
  

	 	(d)	 From such time as a Competitive Product is ordered to be withdrawn from sale or otherwise ceases to be sold as a result of any suit or action
brought by Celltech or by Amgen, the Royalty Reduction set forth in Article 4.6 shall not apply. 


  

	4.8	 Term of Royalties.  Amgen’s obligations to pay Royalties under Article 4.2 shall expire, on a Licensed Antibody
Product-by-Licensed Antibody Product and country-by-country basis, upon the later of: (a) the expiration of the last-to-expire of the [*] Patent Rights, the [*] Patent Rights, [*] Patent Rights and/or [*] Patent Rights containing a Valid Claim
that, but for the licence granted by Celltech to Amgen, would be [*] in such country; or (b) [*] after the [*] of the first Licensed Antibody Product in such country. 



 

	4.9	 Revival of Royalty Where Patent Application Becomes a Valid Claim.  If, in respect of any Licensed Antibody Product in any country,
(a) Amgen’s obligation to pay Royalties under Article 4.2 has expired, in accordance with Article 4.7 and (b) after such 



  
 13 










	 	 
expiry the use, manufacture, sale or other disposal of such Licensed Antibody Product in such country would, but for this licence, [*] of any [*] Patent Right, [*] Patent Right, [*] Patent Right
and/or [*] Patent Right, Amgen shall pay to Celltech: (i) within [*] of receipt of invoice a sum equal to the Royalties set out in Article 4.2 calculated from the date such claim published to the date such claim issued (and became a Valid
Claim) together with interest at the rate set out in Article 6.1(d) on such sum from the date such claim published until the date of payment and (ii) the Royalties set out in Article 4.2 until expiry of such Valid Claim as set out in Article
4.8. 


 ARTICLE 5 
 INTELLECTUAL PROPERTY 
  
  

	5.1	 Technology Ownership.  


  

	5.1.1	 As between the Parties, [*] shall own all right, title and interest in and to all [*] Technologies, subject to the rights and licenses granted to
Amgen hereunder. 


  

	5.1.2	 Other than as expressly set forth in this Licence Agreement, neither Party shall have any right in and to any intellectual property owned or
controlled by the other Party and neither Party shall have an obligation to grant the other Party any rights therein. 


  

	5.1.3	 Other than as expressly set forth in Articles 5.2, 5.3 and 5.4, neither Party shall have the right to prepare, file, prosecute, maintain, defend,
settle and/or enforce Patent Rights or Trademarks Controlled by the other Party, such activity being the exclusive right (but not the obligation) of the Party Controlling the same. 



 

	5.2	 Prosecution. 


  

	5.2.1	 Promptly after the Licence Agreement Effective Date, and to the extent not already provided under the Collaboration Agreement, Celltech shall
provide Amgen with copies of all material documents in Celltech’s possession pertaining to [*] Patent Rights existing as of the Licence Agreement Effective Date. During the term of this Agreement, each Party shall as soon as practicable provide
the other Party (as appropriate) with all material 



  
 14 










	 	 
documents and any other document Controlled by a Party reasonably requested by the other Party (such request to identify the specific documents required), pertaining to [*] Patent Rights and [*]
Patent Rights. 


  

	5.2.2    (a)	 Amgen shall have the first right (but not the obligation) at its expense to have mutually acceptable outside counsel (i) at any time prepare,
file, prosecute, maintain and defend the Product Trademarks and [*] Patent Rights throughout the Territory; (ii) prior to, on and following the Transition Date (as defined in Article 5.2.7 below) prepare, file, prosecute and maintain any [*]
Patent Rights and the [*] Patent Rights that are [*] to any Antibody Products (“[*] Patent Rights”); and (iii) on and following the Transition Date, defend any [*] Patent Rights and [*] Patent Rights throughout the Territory.



  

	 	(b)	 Celltech shall have the right to review and comment on any papers pertaining to proposed applications, responses, interferences and oppositions
before the filing thereof by such counsel with any patent or trademark office (e.g., national, regional or international) (“Consultation Rights”), regarding [*] Patent Rights, [*] Patent Rights and [*] Patent Rights. If such outside
counsel concludes that taking, or failing to take, any specific action(s) would be inconsistent with its instructions under Article 5.2.4, then Amgen shall not take, or shall take (as the case may be), such specific action(s) unless the prior
express written consent of Celltech shall have been obtained. Amgen shall have the right to propose an alternative strategy for Celltech’s consideration. To that end, Amgen shall instruct such outside counsel to furnish Celltech with a
reasonably complete draft of each submission to a patent or trademark authority regarding any such [*] Patent Rights, [*] Patent Rights, [*] Patent Rights and Product Trademarks no later than [*] prior to the date such submission is proposed to be
made, or if given less than [*] to respond as soon as practicable, and will consider any of Celltech’s reasonably timely comments thereon. Additionally, Amgen shall instruct such outside counsel to provide Celltech with a copy of each
submission made to and document received from a patent or trademark authority regarding any such [*] Patent Rights, [*] Patent Rights, [*] Patent Rights and Product Trademarks reasonably promptly after making such filing.




  
 15 










	 	(c)	 Amgen shall have the right, at any time and at its sole option, to elect not to proceed with and/or to abandon the preparation, filing, prosecution,
maintenance and/or defence of any Patent Right or any Product Trademark it is permitted to pursue under Article 5.2.2(a), provided that it shall give Celltech notice of such intention at least [*] before a final due date which would result in
the abandonment, cancellation or lapse of an issued patent or pending patent application or abandonment, cancellation or lapse of such granted trademark or pending trademark application. In such case, Celltech, at its option, may assume the right to
prepare, file, prosecute, maintain and/or defend any such Patent Right or Product Trademark. Amgen shall have Consultation Rights in respect of any such Patent Right and Product Trademark and if such outside counsel concludes that taking, or failing
to take (as the case may be), any specific action(s) would be inconsistent with its instructions under Article 5.2.4, then Celltech shall not take, or shall take (as the case may be), such specific action(s) unless the prior express written consent
of Amgen has been obtained. Celltech shall have the right to propose an alternative strategy for Amgen’s consideration. To that end, Celltech shall instruct such outside counsel to furnish Amgen with a reasonably complete draft of each
submission to a patent or trademark authority regarding any such Patent Rights and Product Trademark no later than [*] prior to the date such submission is proposed to be made, or if given less than [*] to respond as soon as practicable, and will
consider any of Amgen’s reasonably timely comments thereon. Additionally, Celltech shall instruct such outside counsel to provide Amgen with a copy of each submission made to and document received from a patent or trademark authority regarding
any such Patent Rights and Product Trademark reasonably promptly after making such filing. 


  

	 	(d)	 A decision by Amgen not to exercise its right pursuant to Article 5.2.2(a) to prepare, file, prosecute, maintain and/or defend any Patent Right
or any Product Trademark as permitted by the terms of that Article shall not affect any of Amgen’s licence or other rights under this Licence Agreement. 



  
 16 










	5.2.3    (a)	 Celltech shall have the first right (but not the obligation), at its expense, to have mutually acceptable outside counsel prior to the Transition
Date defend any [*] Patent Rights and [*] Patent Rights. 


  

	 	(b)	 Celltech shall have the right, at any time and at its sole option, to elect not to proceed with and/or to abandon the defence of any Patent Right it
is permitted to pursue under Article 5.2.3(a). In such case Amgen, at its option, may assume the right to have mutually acceptable outside counsel defend any such Patent Right. 



 

	 	(c)	 A decision by Celltech or Amgen not to exercise its right pursuant to Article 5.2 to defend any Patent Right as permitted by the terms of that
Article shall not affect any of its licence or other rights under this Licence Agreement. 


  

	5.2.4	 Outside counsel retained under this Article 5 shall be instructed to act in the best interests of both Parties under this Licence Agreement and such
counsel shall also be instructed to secure claims of the broadest possible scope without jeopardising validity. 


  

	5.2.5	 The Parties shall closely co-ordinate the defence of any attack on the validity and/or any enforcement (against a Third Party developing or
commercialising an Antibody that [*]) of the [*] Patent Rights, [*] Patent Rights, and/or the [*] Patent Rights (including the right of the Party not responsible for such defence or enforcement to review and comment on any papers relating thereto
which are material to the conduct of such defence or enforcement). Notwithstanding anything to the contrary in this Article 5, prior to the Transition Date, Amgen shall not have any right to enforce or defend the validity of Patent Rights Controlled
by Celltech, which right shall be exclusively that of Celltech. The Party responsible for such defence or enforcement shall not take (nor fail to take) any action with respect to any such defence and/or enforcement which would, in the opinion of the
retained outside counsel, be inconsistent with the instructions given to outside counsel under Article 5.2.4. 


  

	5.2.6	 Notwithstanding any other provision of this Article 5, neither Party shall have an obligation, which is in violation of, or not permitted by, the
terms of a Third Party agreement, to prosecute or maintain, or take or defend any action in respect of, nor shall 



  
 17 










	 	 
either Party have any right, in violation of the terms of a Third Party agreement, to take or defend any action in respect of, any Patent Right which is owned by a Third Party and licensed to
such Party under such Third Party agreement. 


  

	  5.2.7	 For purposes of this Article 5, “Transition Date” means the date of [*]. 



 

	5.3	 Enforcement. 


  

	5.3.1	 Amgen, at its expense, shall have the first right but not the obligation to bring any suit or action (or to otherwise seek payment and/or claim)
against a Third Party developing or commercialising an Antibody product which [*], and Celltech agrees to be joined as a plaintiff to any such suit or action if Amgen so requests, at Amgen’s expense: 



 

	 	(a)	 after the Transition Date, for infringement of a claim within the [*] Patent Rights, [*] Patent Rights and/or [*] Patent Rights, in each case in the
Territory; and/or 


  

	 	(b)	 regarding any Product Trademark in the Territory. 



Amgen shall, subject to prior consultation with Celltech, have the right to determine the strategy and to exclusively
control the conduct and all aspects of any such proceedings including the right to settle or compromise such proceedings (by, for example, granting any such Third Party a sublicence, covenant not to sue, or other rights to the Patent Rights or
Trademarks being enforced); provided however, that in any such settlement or compromise Amgen will not admit the invalidity of any claim within [*] Patent Rights, [*] Patent Rights, and/or [*] Patent Rights without the prior written approval
of Celltech. Any amount recovered by Amgen by way of costs and damages pursuant to any such claim or action shall be: 
  

	 	(i)	 [*]; and 


  

	 	(ii)	 [*]. 


  

	5.3.2	 If Celltech provides Amgen with a written request for Amgen to bring a suit or action described in Article 5.3.1, and Amgen does not, within [*]
after receipt of such written request from Celltech to do so (provided however, Celltech may only make a written 



  
 18 










	 	 
request to bring a suit or action in any country after a Third Party has filed for Regulatory Approval for an Antibody that [*] in that country and [*] that such Antibody falls within the scope
of one or more claims of any of the Patent Rights referred to in Article 5.3.1(a)), bring a suit or action described in Article 5.3.1, then, at Amgen’s option (to be notified in writing to Celltech prior to the expiry of the [*] period),
Celltech shall have the right but not the obligation within [*] after Amgen’s written notification to Celltech to bring any such suit or action (or to otherwise seek payment and/or claim) against any such Third Party, and Amgen agrees to be
joined as a plaintiff to any such suit or action if Celltech so requests, at Celltech’s expense. Celltech shall, subject to prior consultation with Amgen, have the right to determine the strategy and to exclusively control the conduct and all
aspects of any such proceedings, including the right to settle or compromise such proceedings (by, for example, granting any such Third Party a licence, a covenant not to sue, or other rights to the Patent Rights being enforced); provided
however that in any such settlement or compromise Celltech will not admit the invalidity of any claim within the [*] Patent Rights, [*] Patent Rights and/or [*] Patent Rights without the prior written approval of Amgen. Any amount recovered by
Celltech by way of costs and damages pursuant to any such claim or action shall be: 


  

	 	(a)	 [*]; and 


  

	 	(b)	 [*]. 


  

	5.3.3	 Amgen may, but shall not be obligated to, elect to defend the Product Trademarks against any challenges in the Territory and/or to enforce the
Product Trademarks against any actual, alleged or threatened infringement by Third Parties or against any unfair trade practices, trade dress imitation, passing off of counterfeit goods or like offences in the Territory. In the event it elects such
defence or enforcement action, Amgen shall determine the strategy. 


  

	5.4	 Infringement Defence.  Amgen, at its own expense, shall subject to prior consultation with Celltech where Celltech is a named
party, have the first right to defend any actual, alleged or threatened claim or action in the Territory which names Amgen and/or Amgen 



  
 19 










	 	 
and Celltech and which claims (a) the infringement of Third Party Patent Rights or know-how through Researching, Developing, Commercialising, making, having made, using, selling, having
sold, offering to sell or resell, importing, exporting, distributing or otherwise transferring physical possession of or otherwise transferring title in or to a Licensed Antibody Product or (b) that any Product Trademark infringes any Third
Party Trademark or its use constitutes any unfair trade practice, trade dress imitation, passing off of counterfeit goods or like offence. If Amgen shall decide not to defend such an action, Celltech (to the extent it is named) may, at its own
expense, defend any such claim or action. The Party defending such claim or action shall have the right, subject to prior consultation with the other Party where both Parties are named, to determine the strategy and to exclusively control the
conduct and all aspects of any such proceedings; provided however that the Party defending such claim or action shall not settle or compromise such proceedings that affect the other Party’s rights or interests, without the prior written
consent of the other Party (which consent shall not be unreasonably withheld or delayed). When named, the Party not defending such claim or action shall be entitled, at its own expense, to participate in and to have counsel selected by it
participate in any action in which the other Party is a named party. 


  

	5.5	 Patent Marking.  To the extent practical, Amgen will mark the Licensed Antibody Product(s) sold in its Territory with all
applicable patent numbers of Patent Rights of Celltech to the extent permitted by law in the Territory in which such markings have notice value as against infringers of patents. 



 

	5.6	 Co-operation. 


  

	 	(a)	 Each Party agrees to co-operate with the other Party in the preparation, filing, prosecution, maintenance and defence of intellectual property
rights as set forth in this Article 5.6, including the signing of any necessary legal papers, and to provide the other Party with data or other information in support thereof, and to use best efforts to ensure the co-operation of any of their
respective personnel as might reasonably be requested in any such matters. 



  
 20 










	 	(b)	 Each Party shall promptly notify the other Party upon becoming aware of (i) any actual, alleged or threatened Third Party claim or action
against Celltech and/or Amgen for infringement of any Third Party Trademark through the Development or Commercialisation of a Licensed Antibody Product; or of any Third Party Patent Rights through Researching, Developing, Commercialising, making,
having made, using, selling, having sold, offering to sell or resell, importing, exporting, distributing or otherwise transferring physical possession of or otherwise transferring title in or to Licensed Antibody Products in the Field in the
Territory; or (ii) any Third Party infringement of the Product Trademarks or any Patent Rights of either Party relating to an Antibody that [*]; or (iii) in respect of any Licensed Antibody Product, any unfair trade practices, trade dress
imitation, passing off of counterfeit goods or like offences. 


  

	 	(c)	 The other Party shall assist and cooperate with the Party bringing or defending such suit, and if the Party bringing or defending such suit finds it
necessary or desirable to join the other Party in such suit, the other Party shall execute all papers or perform such other acts as may reasonably be required by the Party bringing or defending such suit. The Party bringing or defending such suit
shall notify the other Party of all substantive developments with respect to such enforcement or defensive actions including all material filings, court papers and other related documents, substantive settlement negotiations and offer of settlement.



 ARTICLE 6 
 PAYMENTS; RECORDS; AUDIT 
  

	6.1	 Payments. 


  

	 	(a)	 No later than [*] after the conclusion of each Calendar Quarter after First Commercial Sale of a Licensed Antibody Product in each country and
extending until the Calendar Quarter during which Amgen’s obligation to pay Royalties for all Licensed Antibody Product(s) expires under Article 4.8, Amgen shall submit 




  
 21 










	 	 
to Celltech a report setting forth (i) the Net Sales of each Licensed Antibody Product sold by Amgen, and its Affiliates and/or Sublicensees during the previous Calendar Quarter [*];
(ii) any Third Party royalties payable in respect of such Net Sales ([*]) and (iii) the amount of Royalty due hereunder. The report shall be accompanied by a remittance of the corresponding Royalty payment. 



 

	 	(b)	 All payments to be made under this Licence Agreement shall be made in U.S. Dollars by bank wire transfer in immediately available funds to a bank
account designated from time to time in writing by Celltech. 


  

	 	(c)	 Net Sales or other revenues received or payments due in currencies other than Dollars shall first be calculated in the relevant foreign currency and
then converted to Dollars against the currency in question on the rate of exchange applicable on the last Business Day of the Calendar Quarter in respect of which the funds are payable using the currency exchange rates quoted by Bloomberg
Professional, a service of Bloomberg L.P., during the period of such Net Sales, or in the event Bloomberg Professional is not available then The Wall Street Journal. 



 

	 	(d)	 Any payment of any amount under this Licence Agreement not received by the due date specified herein shall accrue interest thereafter on the sum due
and owing from the date payment is due until the date payment is received at the rate equal to [*] ([*]%) [*]. 


  

	 	(e)	 All amounts due under this Licence Agreement shall be paid in full without deduction for any applicable taxes, levies, imposts, duties and fees of
whatever nature imposed by or under the authority of any government or public authority, except for tax legally required to be deducted or withheld. Where any sum due to be paid to Celltech is subject to any withholding or similar or other tax, the
Parties shall take all reasonable steps to do all such acts and things and to sign all such deeds and documents as will enable them to take advantage of any applicable double taxation agreements to reduce the rate of withholding or similar taxes
with the object of paying the sums due under deduction of a reduced rate of 



  
 22 










	 	 
withholding tax or on a gross basis. In the event there is no double taxation agreement or the reduced rate of withholding tax under the relevant double taxation agreement is greater than [*]
([*]%), the Party making payment shall pay such withholding or similar tax, deduct the relevant amount from the payment due to the other Party, and secure and send to the other Party proof of such withholding or similar tax in a form in accordance
with the relevant taxation authority as evidence of such payments. Each Party agrees to inform the other Party forthwith if it concludes that there is any law or practice or any change in such law or practice which requires it to deduct or withhold
tax in respect of any payments due pursuant to this Licence Agreement at any time after the Licence Agreement Effective Date with a view to the Parties using their best endeavours to agree on the manner in which subsequent payments shall be made to
reduce or eliminate the liability of both Parties to deduct or withhold any amount on account of tax. 


  

	 	(f)	 All amounts due under this Licence Agreement shall be paid exclusive of any Value Added Tax (which, if applicable shall be payable by a Party in
addition upon receipt of a valid Value Added Tax invoice). Each Party agrees to inform the other Party forthwith if it concludes that there is a Value Added Tax law or practice, or a change in such law or practice, which requires it to account for
Value Added Tax on any payments due pursuant to this Licence Agreement at any time after the Licence Agreement Effective Date, with a view to the Parties using their best endeavours to agree on the manner in which subsequent payments shall be made
to reduce or eliminate the liability of the Parties to pay Value Added Tax. 


  

	6.2	 Records; Audit.    Amgen and its Affiliates shall keep and maintain complete and accurate records and books of
account documenting in a detail sufficient to track and determine, in a manner consistent with GAAP, all revenues, expenses and Royalties due or other sums payable pursuant to this Licence Agreement and in compliance with the terms of this Licence
Agreement. Such records shall be retained for a period of the later of (a) a [*] following the year in which any payments were made hereunder; (b) the 



  
 23 










	 	 
expiration of the applicable tax statute of limitations (or any extensions thereof); or (c) such longer period as may be required by law. Amgen and its respective Affiliates shall permit
independent accountants of internationally recognised standing retained by Celltech and reasonably acceptable to Amgen, upon reasonable prior written notice, to have access to its and its Affiliates’ records and books and premises for the sole
purpose of determining the correctness of any payment of Royalties and other amounts due and payable under this Licence Agreement for any year ending no more than [*] prior to the date of such request; provided however, that the books and
records for any particular Calendar Year shall only be subject to one audit. Such examination shall be conducted during regular business hours and no more than once in each Calendar Year. The report of such accountant shall be limited to a
certificate verifying (or not verifying, as the case may be) any report made or payment submitted by Amgen during such period. In the event the accountant shall be unable to verify the correctness of any such payment, the accountant’s report
shall specify why such payment is unverifiable and the amount of any discrepancy. Amgen shall receive a copy of each such report concurrently with receipt by Celltech, and the Parties shall use good faith efforts to resolve any discrepancies. All
information contained in any such report shall be deemed Confidential Information hereunder. If such examination reveals that such costs or payments have been misstated, any adjustment shall be promptly refunded or paid, as appropriate. Celltech
shall pay the fees and expenses of the accountant engaged to perform the audit, unless such audit reveals a net discrepancy of [*] ([*]%) or more for the period examined which is to the disadvantage of Celltech, in which case Amgen shall pay all
reasonable costs and expenses incurred by Celltech in the course of making such determination. Upon the expiration of [*] following the end of any Calendar Year, the calculation of any such amounts payable with respect to such year shall be
binding and conclusive upon Celltech and Amgen shall be released from any liability or accountability with respect to such amounts for such year. 



  
 24 









 ARTICLE 7 
 PUBLICATIONS 
  

	7.1	 Procedure.  Each Party (or its appropriate designees) shall determine the strategy for and co-ordinate the publication and
presentation of results of studies of Licensed Antibody Products carried out under the Collaboration Agreement or which incorporate data generated under the Collaboration Agreement. Each Party to this Licence Agreement recognises that the
publication of papers regarding results of and other information regarding activities under the Collaboration Agreement, including oral presentations and abstracts, may be beneficial to both Parties provided such publications are subject to
reasonable controls to protect Confidential Information. In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any patent application until such patent application has been
published. Accordingly, each Party will have the right to review and approve any paper proposed for publication by the other Party, including oral presentations and abstracts, which incorporates data generated under the Collaboration Agreement
and/or includes Confidential Information of the other Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party will deliver a complete copy of the paper or materials for oral
presentation to the other Party at least [*] prior to submitting the paper to a publisher or making the presentation. The other Party will review any such paper and give its comments to the publishing Party within [*] of the delivery of such paper
to the other Party. With respect to oral presentation materials and abstracts, the other Party will make reasonable efforts to expedite review of such materials and abstracts, and will return such items as soon as practicable to the publishing or
presenting Party with appropriate comments, if any, but in no event later than [*] from the date of delivery to the other Party. Failure to respond within such [*] shall be deemed approval to publish or present. Celltech may withhold approval of any
proposed Amgen publication or presentation to the extent such publication or presentation contains the Confidential Information of Celltech. Amgen may withhold approval of any proposed Celltech publication or presentation to the extent such
publication or presentation is contrary to Amgen’s publication strategy. The publishing or presenting Party will comply with the 



  
 25 










	 	 
other Party’s request to delete references to the other Party’s Confidential Information in any such paper and agrees to withhold publication of same for an additional [*] in order to
permit the Parties to obtain patent protection, if either of the Parties deems it necessary, in accordance with the terms of this Licence Agreement. [*]. 



 

	7.2	 Credit.  Any such publication will include recognition of the contributions of the other Party according to standard practice for
assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. 


 ARTICLE
8 
 CONFIDENTIALITY 
  

	8.1	 Confidential Information.  Except as otherwise provided in this Article 8, (a) the Parties shall maintain in confidence and
use only for purposes specifically authorised under this Licence Agreement any Confidential Information of the other Party; (b) Celltech shall keep confidential all [*] Know-How which is [*] to [*] and/or which is [*] to [*] to [*], and all [*]
Know-How and [*] Know-How which is [*] to Licensed Antibody Products and/or [*] (whether generated prior to or during the term of this Licence Agreement), provided however, where such [*]Know-How may have [*] outside [*], or where such [*]
Know-How or [*] Know-How may have [*] outside Licensed Antibody Products and/or [*], Celltech shall be free to use and exploit the same and to disclose the same to Third Parties subject always to obligations of confidentiality; and (c) Amgen
shall keep confidential all [*] Know-How which is [*] to Licensed Antibody Products and/or [*] (whether generated prior to or during the term of this Licence Agreement) and, provided however, where such [*] Know-How may have [*] outside
Licensed Antibody Products and/or [*], Amgen shall be free to use and exploit the same and to disclose the same to Third Parties subject always to obligations of confidentiality. 



 

	8.2	 Authorised Disclosure. 


  

	8.2.1	 To the extent it is reasonably necessary or appropriate to fulfil its obligations or exercise its rights under this Licence Agreement, a Party may
disclose such Confidential Information of the other Party as it is obliged under Article 8.1 not to disclose as follows: 


  

	 	(a)	 Each Party may disclose such Confidential Information of the other Party, to its Affiliates, consultants and outside contractors and Amgen may
disclose such Confidential Information to its (whether actual or potential) Sublicensees and clinical investigators, in each case on a need-to-know basis and on the condition that such entities or persons agree to keep the Confidential Information
confidential for the same time periods and to the same extent as each Party is required to keep such Confidential Information confidential; 



  
 26 










	 	(b)	 Amgen may disclose such Confidential Information of Celltech, as it is otherwise obliged not to disclose under Article 8.1, to Regulatory
Authorities to the extent that such disclosure is reasonably necessary to obtain authorisations to conduct clinical studies or to file, obtain and maintain Regulatory Approvals and to Commercialise the Licensed Antibody Products;



  

	 	(c)	 Each Party may disclose such Confidential Information of the other Party, as it is otherwise obliged not to disclose under Article 8.1, to the
extent that such disclosure is reasonably necessary in connection with preparing, filing, prosecuting, defending or maintaining and/or enforcing Patent Rights in accordance with Article 5; and 



 

	 	(d)	 Either Party may disclose such Confidential Information of the other Party, as it is otherwise obliged not to disclose under Article 8.1, in
prosecuting or defending litigation as explicitly authorised under this Licence Agreement; and in establishing rights or enforcing obligations under this Licence Agreement or in complying with applicable laws, regulations and/or court orders, other
than as set forth in Article 8.2.1(b); provided that it shall (i) give reasonable advance notice to the other Party of such disclosure requirement; (ii) provide a copy of the proposed disclosure to the other Party; and (iii) at
the request of the other Party, use Commercially Reasonable Efforts in assisting the other Party to secure confidential treatment of such Confidential Information required to be disclosed, including cooperating with the other Party to obtain a
protective order of the other Party’s Confidential Information. 



  
 27 










	8.2.2	 Notwithstanding Article 8.1, Celltech may disclose [*] Know-How, [*] Know-How and [*] Know-How and Amgen may disclose [*] Know-How which is subject
to an obligation of confidentiality under Article 8.1 in any of the following circumstances: 


  

	 	(a)	 where such disclosure would [*]; 


  

	 	(b)	 to its Affiliates and with respect to products other than Licensed Antibody Products, to its (whether actual or potential) sublicensees,
consultants, outside contractors and clinical investigators, on a need-to-know basis and on the condition that such entities or persons agree to keep the Know-How confidential for the same time periods and to the same extent as such Party is
required to keep such Know-How confidential; 


  

	 	(c)	 to Regulatory Authorities to the extent that such disclosure is reasonably necessary to obtain authorisations to conduct clinical studies or to
file, obtain and maintain regulatory approvals and to commercialise products other than Licensed Antibody Products; 


  

	 	(d)	 without prejudice to Article 5 to the extent that such disclosure is reasonably necessary in connection with preparing, filing, prosecuting,
maintaining and/or defending and/or enforcing Patent Rights; or 


  

	 	(e)	 in prosecuting or defending litigation and in establishing rights or enforcing obligations under this Licence Agreement or in complying with
applicable laws, regulations, court or administrative orders, the rules of any relevant stock exchange or the U.S. Securities and Exchange Commission; provided however, in the case of [*] Know-How which is [*] and/or which is [*] to
Antibodies to [*],[*] Know-How and [*] Know-How only, to the extent practicable it shall (i) give reasonable advance notice to the other Party of such disclosure requirement; (ii) provide a copy of the proposed disclosure to the other
Party; and (iii) at the request of the other Party, use Commercially Reasonable Efforts to secure confidential treatment of such [*] Know-How which is [*] to [*] and/or which is exclusive to Antibodies to [*],[*] Know-How and [*] Know-How




  
 28 










	 	 
required to be disclosed, including seeking a protective order of such [*] Know-How which is [*] to [*]and/or which is [*] to Antibodies to [*],[*] Know-How and [*] Know How.



  

	8.3	 Exceptions.  The obligation not to disclose Confidential Information under this Article 8 shall not apply to any part of such
Confidential Information that: 


  

	 	(a)	 is or becomes published or otherwise becomes publicly known other than by acts of the Party obligated not to disclose such Confidential Information
or its Affiliates or permitted Third Parties pursuant to Article 8.2.1(a) or 8.2.2(b) in breach of this Licence Agreement; 


  

	 	(b)	 was disclosed to the receiving Party or its Affiliates or sublicensees by a Third Party, provided that such Confidential Information was not
obtained by such Third Party from the disclosing Party under an obligation of confidentiality; 


  

	 	(c)	 prior to disclosure under the Collaboration Agreement or this Licence Agreement, was already in the possession of the receiving Party or its
Affiliates or sublicensees, provided that such Confidential Information was not obtained from the disclosing Party under an obligation of confidentiality; 



 

	 	(d)	 can be shown by written documents to have been independently developed by the receiving Party or its Affiliates without breach of any of the
provisions of this Licence Agreement or the Collaboration Agreement or access to any Confidential Information provided by the disclosing Party; or 


  

	 	(e)	 is required to be disclosed by the receiving Party to comply with applicable laws, or with a court or administrative order or the rules of any
relevant stock exchange, or the U.S. Securities and Exchange Commission; provided however, that this Article 8.3(e) shall not permit a Party to disclose the other Party’s Confidential Information for the purpose of obtaining Patent
Rights and, further provided however, the receiving Party shall, if practicable, notify the disclosing Party in writing (and if practicable provide a copy of the proposed disclosure) prior to any such disclosure and shall use reasonable
efforts to secure confidential treatment thereof prior to its disclosure (whether by protective order or otherwise). 



  
 29 










	8.4	 Materials.  The Parties anticipate that Celltech may transfer certain of its Materials to Amgen. Amgen agrees that it will use such
Materials of Celltech only in accordance with the terms and conditions of, and solely for the purposes of the activities conducted pursuant to, this Licence Agreement, and will not transfer such Materials of Celltech to any Third Party without the
consent of Celltech, except as expressly permitted under and subject to the terms of this Licence Agreement. 


  

	8.5	 Terms of Agreement.  Except as permitted by the foregoing provisions or as otherwise required by law or the rules of any relevant
stock exchange or the U.S. Securities and Exchange Commission, the Parties shall not disclose any terms or conditions of this Licence Agreement to any Third Party without the prior consent of the other Party; provided however, that each Party
shall be entitled to disclose the terms of this Licence Agreement without such consent on a need-to-know basis to its financial and legal advisors and potential investors or other financing sources on the condition that such entities or persons
agree to keep such terms confidential for the same time periods and to the same extent as such Party is required to keep such terms confidential. Each Party shall give the other Party a reasonable opportunity to review all filings with the United
States Securities and Exchange Commission or any stock exchange describing the terms of this Licence Agreement prior to submission of such filings, and shall give due consideration to any reasonable comments by the non-filing Party relating to such
filing, including the provisions of this Licence Agreement for which confidential treatment should be sought. 


  

	8.6	 Public Announcements.  Except to the extent required by law or the rules of a relevant stock exchange or as otherwise permitted in
accordance with this Article 8, neither Party shall make any further public announcements concerning this Licence Agreement or the subject matter hereof without the prior written consent of the other, which shall not be unreasonably withheld or
delayed. The Parties agree to consult with each other reasonably and in good faith with respect to the text and timing of any press releases prior to the issuance thereof. 



  
 30 










	8.7	 Third Party Obligations.   Other than with respect to Article 9.2(b), neither Party is obliged to disclose to the other any
Information if to do so would put the disclosing Party in breach of an existing or future obligation owed to a Third Party. Without limitation to the foregoing, Amgen acknowledges that Celltech is not obliged to disclose to Amgen, and will not
disclose to Amgen, any Information, data or know-how concerning Celltech’s products [*] whether arising out of Celltech’s [*] or otherwise. 


 ARTICLE 9 
 COVENANTS 

 

	9.1	 Mutual Covenants.  Each Party hereby covenants to the other Party as follows: 



 

	 	(a)	 No Misappropriation. It shall not knowingly misappropriate the trade secret of a Third Party in its activities to Research, Develop or Commercialise
Licensed Antibody Product. 


  

	 	(b)	 No Conflict.   It will not enter into any agreement with a Third Party that is in conflict with this Licence Agreement, and will not
take any action that would in any way prevent it from assuming its obligations or granting the rights granted to the other Party under this Licence Agreement or that would otherwise materially conflict with or adversely affect its obligations or its
assumption of the rights granted to the other Party under this Licence Agreement. 


  

	 	(c)	 [*].   It shall work [*] with the other Party with respect to [*], and it shall not during the term of this Licence Agreement grant
any right, licence, consent or privilege to any Third Party(ies) in the Territory which would conflict with the rights granted to the other Party under this Licence Agreement. 



  
 31 










	9.2	 Covenants of Amgen.  


  

	 	(a)	 No Debarment. In the course of the Development of Licensed Antibody Products and during the Term, Amgen shall not knowingly use and shall not have
knowingly used any employee or consultant who is or has been debarred by a Regulatory Authority or, to the best of Amgen’s knowledge (not having made enquiry), who is or has been the subject of debarment proceedings by a Regulatory Authority.



  

	 	(b)	 Compliance. Amgen shall comply with all applicable statutes and regulations of Regulatory Authorities in carrying out its activities regarding the
Research, Development, and Commercialisation of Licensed Antibody Products in the Field in the Territory. 


  

	 	(c)	 Workmanship. Amgen shall commit the personnel, facilities and other resources reasonably necessary to conduct its obligations under this Licence
Agreement, and shall conduct its Research and/or Development obligations using the same standard of skill and care which it applies to its other products, but in no event less than commonly accepted good professional standards of workmanship.



  

	9.3	 Disclaimers. 


  

	 	(a)	 Nothing in this Licence Agreement shall be construed as a warranty or representation by either Party (i) that the Research, Development,
Commercialisation, making, having made, using, selling, having sold, offering to sell or resell, importing, exporting, distributing or otherwise transferring physical possession of or otherwise transferring title in any Licensed Antibody Products
under or in connection with this Licence Agreement are or will be free from infringement of, or that the activities conducted pursuant to this Licence Agreement will not infringe, Patents Rights, copyrights, Trademarks, industrial design or other
intellectual property rights of any Third Party or (ii) that any Licensed Antibody Product Researched, Developed, Commercialised, made, have made, used, sold, have sold, offered to sell or resell, imported, exported, distributed or in which
physical possession or title is transferred under this Licence Agreement is or will be effective, valuable, safe, non-toxic or patentable. 



  
 32 










	 	 
EXCEPT AS EXPRESSLY SET FORTH IN THIS LICENCE AGREEMENT, EACH PARTY EXPRESSLY DISCLAIMS, WAIVES, RELEASES, AND RENOUNCES ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, ANY
WARRANTY OF EFFICACY, SAFETY, SATISFACTORY QUALITY OR FITNESS FOR A PARTICULAR PURPOSE. 


  

	 	(b)	 Notwithstanding Articles 9.3(a) and 13.9, nothing in this Licence Agreement limits or excludes any Party’s liability for fraud or for death or
personal injury caused by that Party’s own negligence. 


 ARTICLE 10 

INDEMNIFICATION 
  

	10.1	 Indemnification by Celltech.   Celltech hereby agrees to defend, hold harmless and indemnify (collectively,
“Indemnify”) Amgen and its Affiliates, agents, directors, officers and employees (the “Amgen Indemnitees”) from and against any and all Third Party claims, suits, actions or demands and all out-of-pocket
liabilities, costs, settlements, damages, expenses and/or losses paid to any Third Party bringing any such Third Party claim, as well as reasonable legal expenses and attorney and expert fees incurred in defending and/or compromising the same
(“Amgen Loss(es)”) arising out of any of (a) any material breach or material default by Celltech of its material covenants and material obligations under this Licence Agreement; and (b) Celltech’s negligence or
intentional misconduct in carrying out its activities set forth in this Licence Agreement. Amgen shall provide Celltech with prompt written notice of any claim (with a description of the claim and the nature and amount, if determinable, of any such
Amgen Loss) giving rise to the indemnification obligation pursuant to this Article 10.1 and the exclusive ability to defend such Third Party claim; provided however, that Celltech shall be relieved of its obligations only to the extent
the failure to be provided prompt written notice shall have been prejudicial to its ability to defend such action. Amgen shall co-operate as reasonably requested in the defence of the claim; provided however, that Amgen shall have the right
to retain its own counsel, at its own expense, if representation of the counsel of Celltech would be inappropriate due to actual or potential differing interests 



  
 33 










	 	 
between the Parties. Amgen shall not settle any claim for Amgen Losses for which any Amgen Indemnitee is seeking to be Indemnified by Celltech, without Celltech’s prior written consent.
Celltech’s obligation to Indemnify the Amgen Indemnitees pursuant to this Article 10.1 shall not apply to the extent any Amgen Losses (i) arise from the negligence or intentional misconduct of any Amgen Indemnitee; (ii) arise
from any material breach by Amgen of this Licence Agreement; or (iii) for which Amgen is obligated to Indemnify the Celltech Indemnitees pursuant to Article 10.2 of this Licence Agreement. 



 

	10.2	 Indemnification by Amgen.   Amgen hereby agrees to Indemnify Celltech and its Affiliates, agents, directors, officers and
employees (the “Celltech Indemnitees”) from and against any and all Third Party claims, suits, actions or demands and all out-of-pocket liabilities, damages, costs, settlements, expenses and/or losses paid to any Third Party
bringing any such Third Party claim, as well as reasonable legal expenses and attorney and expert fees incurred in defending and/or compromising the same (“Celltech Loss(es)”) arising out of any of (a) any material breach or
material default by Amgen of its material covenants and material obligations under this Licence Agreement; (b) Amgen’s negligence or intentional misconduct in carrying out its activities set forth in this Licence Agreement; and
(c) the exercise of any rights by Amgen, its Affiliates, Sublicensees or any of their agents or distributors pursuant to this Licence Agreement (including any product liability claim). Celltech shall provide Amgen with prompt written notice of
any claim (with a description of the claim and the nature and amount, if determinable, of any such Celltech Loss) giving rise to the indemnification obligation pursuant to this Article 10.2 and the exclusive ability to defend such Third Party
claim; provided however, that Amgen shall be relieved of its obligations only to the extent the failure to be provided prompt written notice shall have been prejudicial to its ability to defend such action. Celltech shall co-operate as
reasonably requested in the defence of the claim; provided however, that Celltech shall have the right to retain its own counsel, at its own expense, if representation of the counsel of Amgen would be inappropriate due to actual or potential
differing interests between the Parties. Celltech shall not settle any claim for Celltech Losses for which any Celltech Indemnitee is seeking to be Indemnified by Amgen, without Amgen’s prior written consent. Amgen’s obligation to
Indemnify the 



  
 34 










	 	 
Celltech Indemnitees pursuant to this Article 10.2 shall not apply to the extent any Celltech Losses (i) arise from the negligence or intentional misconduct of any Celltech Indemnitee;
(ii) arise from any material breach by Celltech of this Licence Agreement; or (iii) for which Celltech is obligated to Indemnify the Amgen Indemnitees pursuant to Article 10.1 of this Licence Agreement. 



 

	10.3	 Insurance.  Amgen shall maintain (through a captive insurer or Third Party insurer) appropriate product liability insurance with
respect to Licensed Antibody Products and appropriate comprehensive general liability insurance to cover its obligations hereunder and which is/are consistent with normal business practices of prudent companies similarly situated. Amgen shall use
reasonable endeavours to ensure that any insurance policy required by, and procured under, this Article 10.3 shall name Celltech as an additional insured. Such insurance shall not be construed to create a limit of the insuring Party’s
liability with respect to its indemnification obligations under this Article 10. Amgen shall furnish Celltech with a certificate(s) or other evidence from an insurance carrier showing all such insurance. Amgen shall diligently pursue recovery of
insurance 


 proceeds when a claim arises. The Parties acknowledge that it is the normal
business practice of prudent companies similarly situated to have a reasonable level of uninsured loss. 
  

	10.4	 Pre-Effective Date Losses.  In accordance with Article 14.10 of the Collaboration Agreement, each Party shall retain its
obligations for any liabilities, damages, expenses and/or losses accrued under the Collaboration Agreement prior to the Effective Date of Termination of the Collaboration Agreement (“Pre-Effective Date Losses”), and this Licence
Agreement shall not release, waive, alter or otherwise modify the Parties’ respective obligations thereunder. Other than with respect to its obligation for any Pre-Effective Date Losses under and prior to the termination of the Collaboration
Agreement, neither Party shall assume or be liable for (pursuant to this Licence Agreement) any liabilities, damages, expenses and/or losses resulting from or arising in connection with activities of the other Party which occurred on or prior to the
Licence Agreement Effective Date. 



  
 35 










	10.5	 Limitation of Liability.  Without prejudice to either Party’s obligations, as specified in this Licence Agreement, a Party
shall have no liability with respect to (a) the results obtained in the Research, Development and Commercialisation of Licensed Antibody Product or (b) the results obtained in the prosecution, enforcement or defence of any intellectual
property in accordance with Article 5. 


 ARTICLE 11 

TERM AND TERMINATION 
  

	11.1	 Term.   This Licence Agreement shall become effective on the Licence Agreement Effective Date and shall remain in full force
and effect, unless earlier terminated pursuant to this Article 11, on a country-by-country basis until there is no remaining payment obligation in any country. Upon the fulfilment of Amgen’s obligation to pay Royalties under this Licence
Agreement for a given Licensed Antibody Product in a country, Amgen’s licence under the [*]Know-How, [*]Know-How and [*] Know-How to make, have made, use, sell, have sold, offer to sell or resell, import, export, distribute or otherwise
transfer physical possession of or otherwise transfer title in or to such given Licensed Antibody Product in such country shall become fully paid and compensation free, provided that Amgen shall continue to be responsible for any Third Party
Payments in accordance with Article 4.4 of this Licence Agreement. 


  

	11.2	 Termination for Convenience.  


  

	 	(a)	 Amgen may terminate this Licence Agreement in its entirety at any time by providing [*] prior written notice of termination to Celltech. Termination
shall be effective upon expiry of the [*] notice period. 


  

	 	(b)	 Celltech may terminate this Licence Agreement by providing [*] prior written notice of termination to Amgen if Amgen indicates in a document it
provides in accordance with Article 3.4(d) of the Collaboration Agreement that any of the written representations and warranties of Amgen set out in Articles 16.1 and 16.2 of the Collaboration Agreement are not true and correct as of the date of
such document (as if referring to this Licence Agreement and not the Collaboration 



  
 36 










	 	 
Agreement) and that this has a material and adverse effect on Celltech in relation to this Licence Agreement. Termination shall be effective upon expiry of the [*] notice period.



  

	 	(c)	 If Amgen fails to provide a document in accordance with Article 3.4(d) of the Collaboration Agreement in a timely manner as required by that Article
3.4(d), Celltech may (within [*] of the date on which Amgen was due to provide such document) request in writing that Amgen provide such document. If Amgen fails to provide such document within [*] of receipt of such request, Celltech may terminate
this Licence Agreement by providing Amgen with written notice thereof within [*] after expiry of such [*] period. Termination shall be effective upon receipt of such notice by Amgen. 



 

	 	(d)	 Should Amgen provide a notice pursuant to Article 3.1.2 of this Licence Agreement Amgen shall be deemed to have served a termination notice pursuant
to this Article 11.2(d). Termination shall be effective on Celltech’s receipt of such notice. 


  

	11.3	 Termination for Default. 


  

	 	(a)	 In the event any material representation or warranty made under the Collaboration Agreement by either Party shall have been untrue in any material
respect and this has had a material and adverse effect on the other Party in relation to this Licence Agreement (“Representation Default”) or upon any material breach or material default of a material obligation of this Licence
Agreement by a Party (“Performance Default”), the Party not in default (“Non-Defaulting Party”) must first give the other Party (“Defaulting Party”) written notice thereof (“Notice of
Default”), which notice must state the nature of the Representation Default or Performance Default in reasonable detail and must request the Defaulting Party cure such Representation Default or Performance Default within [*], or if such
Default cannot be cured, take such action as will substantially mitigate the material adverse effect of such Default on the other Party. During any such [*] period after receipt or delivery of a Notice of Default under this Article 11.3(a)




  
 37 










	 	 
for which termination of this Licence Agreement is a remedy, all of each Party’s respective rights and obligations under this Licence Agreement (to the extent applicable) shall remain in
force and effect. If the Defaulting Party shall dispute the existence, extent or nature of any default set forth in a Notice of Default, the Parties shall use good faith efforts to resolve the dispute. 



 

	 	(b)	 In the event of a Representation Default or a Performance Default by Celltech that shall not have been cured or mitigated within the [*] period, as
set forth in Article 11.3(a) above, Amgen, at its option, may immediately terminate this License Agreement upon prior written notice to Celltech. Termination shall be effective upon the receipt of such notice by Celltech.



  

	 	(c)	 In the event of a Representation Default or a Performance Default by Amgen that shall not have been cured or mitigated within the [*] period, all as
set forth in Article 11.3(a) above, Celltech, at its option, may immediately terminate this Licence Agreement upon prior written notice to Amgen. Termination shall be effective upon the receipt of such notice by Amgen. 



 

	11.4	 Bankruptcy.  


  

	 	(a)	 All rights and licences granted under or pursuant to this Licence Agreement by Celltech are, and shall otherwise be deemed to be licences of rights
to “intellectual property”. The Parties agree that Amgen shall retain and may fully exercise all of its rights and elections under bankruptcy legislation in the Territory. The Parties further agree that, in the event of the
commencement of a bankruptcy proceeding by or against Celltech, Amgen shall be entitled to a complete duplicate of (or complete access to, as appropriate) any intellectual property which at that date is known to be necessary or useful to a Licensed
Antibody Product (then the subject of Research, Development or Commercialisation) and all embodiments of such intellectual property; and same, if not already in Amgen’s possession, shall be promptly delivered to Amgen (i) upon any such
commencement of a bankruptcy proceeding, upon Amgen’s written request therefor (which request must identify the specific intellectual 



  
 38 










	 	 
property), unless Celltech (or a trustee on behalf of Celltech) elects within [*] to continue to perform all of its obligations under this Licence Agreement or (ii) if not delivered under
(i) above, upon the rejection of this Licence Agreement by or on behalf of Celltech, upon written request therefor by Amgen. 


  

	 	(b)	 Without prejudice to Article 11.4(a), this Licence Agreement may be terminated by Celltech upon written notice to Amgen in the event that
(i) Amgen shall make an assignment for the benefit of its creditors, file a petition in bankruptcy, petition or apply to any tribunal for the appointment of a custodian, receiver or any trustee for it or a substantial part of its assets, or
shall commence any proceeding under any bankruptcy, reorganisation, arrangement, readjustment of debt, dissolution or liquidation law or statute of any jurisdiction (other than for the purposes of a solvent amalgamation or reconstruction) whether
now or hereafter in effect; or (ii) if there shall have been filed against Amgen any such bona fide petition or application, or any such proceeding shall have been commenced against it in which an order for relief is entered or which remains
undismissed for a period of ninety (90) days or more; or (iii) if Amgen by any act or omission shall indicate its consent to, approval of or acquiescence in any such petition, application or proceeding or order for relief or the
appointment of a custodian, receiver or trustee for it or any substantial part of its assets, and shall suffer any such custodianship, receivership or trusteeship to continue undischarged for a period of ninety (90) days or more. Termination
shall be effective upon the date specified in such notice. Notwithstanding the foregoing, this Licence Agreement shall not be terminated pursuant to this Article 11.4(b) if, prior to the effective date of termination stated in the written notice
from Celltech, Amgen demonstrates to Celltech that it is not insolvent. 


  

	11.5	 Additional Termination Right of Celltech. 



If in any suit or proceeding where Celltech or any of its Affiliates is a named party Amgen or any of its Affiliates
asserts, or Amgen or any of its Affiliates provides Confidential Information, financial assistance or technical assistance in collusion with a 

  
 39 










	 	 
Third Party to assist such Third Party in asserting that any claim within the [*] Patent Rights or any [*] Patent Rights is invalid, Celltech, at its option, may, within [*] of such assertion,
terminate this Agreement in its entirety upon [*] prior written notice to Amgen (with termination being effective upon expiry of the [*] notice period); provided however, that nothing contained herein shall prohibit Amgen or any of its
Affiliates from asserting the invalidity of any claim within the [*] Patent Rights or any [*] Patent Rights, where such assertion is raised as a defence against an assertion of such [*] Patent Rights or [*] Patent Rights in such suit or proceeding
brought against Amgen or any of its Affiliates or any of its licensees (provided such suit or proceeding relates to the licensed subject matter) or its intellectual property rights. If the inclusion of this Article 11.5 would make invalid or
unenforceable any other provision of this Agreement, or any of the Patent Rights licensed pursuant to this Agreement, this Article 11.5 shall be automatically and without notice severed from this Agreement and the remaining provisions of this
Agreement shall remain in force. 


  

	11.6	 Termination Date.    The effective date of termination of this Agreement, as set forth in each instance in Articles 11.2
through 11.5, is hereby referred to as the “Termination Date”. 


  

	11.7	 Effects of Termination.    In addition to any other remedies which may be available at law or equity upon termination of
this Licence Agreement, the rights and obligations of the Parties shall be as set forth in this Article 11.7. 


  

	 	(a)	 Upon termination of this License Agreement, howsoever caused, the following rights and obligations shall apply: 



 

	 	(i)	 The following provisions shall remain in full force and effect after the expiration or termination of this Licence Agreement if Amgen is obliged to
transfer to Celltech the Research, Development and Commercialisation responsibilities in accordance with Article 11.7(b) below: Article 1, Articles 4 and 6 (in case of any payments relating to the period prior to the Termination Date), Article 5.1,
Article 8 (in relation to the other Party’s Confidential Information only), Article 9.3, Article 10, this Article 11.7, Article 11.9 and Article 13, and all ancillary provisions necessary for the implementation of this Article 11.7.




  
 40 










	 	(ii)	 The following provisions shall remain in full force and effect after the expiration or termination of this Licence Agreement if Amgen is not obliged
to transfer to Celltech the Research, Development and Commercialisation responsibilities in accordance with Article 11.7(b) below: Article 1, Articles 4 and 6 (in the case of any payments relating to the period prior to the Termination Date),
Article 5.1, Article 8 (in relation to the other Party’s Confidential Information only), Article 9.3, Article 10, this Article 11.7, Article 11.9, and Article 13, and all ancillary provisions necessary for the implementation of this Article
11.7. 


  

	 	(iii)	 All other rights and obligations under this Licence Agreement shall terminate. 



 

	 	(iv)	 By the [*] of the Termination Date, each Party (unless Amgen is obliged to transfer to Celltech the Research, Development and Commercialisation
responsibilities in accordance with Article 11.7(b) below, in which case only Amgen) shall destroy, or at the other Party’s request return, all of the other Party’s Confidential Information (other than with respect to maintaining one
(1) archival copy of Confidential Information related thereto for its legal files, for the sole purpose of determining its obligations under this Licence Agreement) and Materials. In each instance where a Party is required to destroy or return
the other Party’s Confidential Information under this Article 11.7(a)(iv), such Party shall provide the other Party with certification by an officer of such Party that all such Confidential Information and Materials have been destroyed or
returned to the other Party, as appropriate. 


  

	 	(b)	 Subject to Article 11.8 below, where Amgen has terminated this Agreement pursuant to Article 11.2(a) or Article 11.2(d), or where Celltech has
terminated this Agreement pursuant to Article 11.2 (b) or Article 11.2(c), Article 11.3, Article 



  
 41 










	 	 
11.4 or Article 11.5, the Parties shall promptly meet to devise a transition plan which provides for an orderly and cost-effective transition of, and which sets forth the responsibilities and a
timetable for transferring to Celltech the Research, Development and Commercialisation responsibilities (“Transition Plan”). Where the Parties cannot agree the timetable Celltech shall determine the same. Such transition shall be
completed as soon as practicable and, in any event, shall be no later than the [*] of the Termination Date. Such Transition Plan shall provide for transferring to Celltech the Research, Development and Commercialisation responsibilities as
expeditiously as possible in accordance with this Article 11 while maintaining a supply of Licensed Antibody Products to meet the Development and/or Commercialisation requirements (as appropriate), and minimizing interruption of Research,
Development and/or Commercialisation of the Licensed Antibody Products, including the following: 


  

	 	(i)	 Until the [*] of the Termination Date Amgen shall make its personnel and other resources reasonably available to Celltech, as necessary, and shall
by the [*] of the Termination Date transfer copies of all relevant information, files or data containing Information and transfer all Materials to Celltech. 



 

	 	(ii)	 By the [*] of the Termination Date, Amgen shall transfer to Celltech all Regulatory Filings and Regulatory Approvals then in its name for all
Licensed Antibody Products and shall notify the appropriate Regulatory Authorities and take any other action reasonably necessary to effect such transfer. 



 

	 	(iii)	 By the [*] of the Termination Date, Amgen shall assign its rights or grant sufficient sublicence rights to Celltech under Amgen’s right, title
and interest in the Product Trademarks (but otherwise not any of Amgen’s Trademarks). Celltech shall also have the right, for a reasonable period not to exceed [*] from the Termination Date, to use Amgen’s Trademarks solely in the selling
of any existing inventory of Licensed Antibody Products (and to use Promotional Materials it then has on hand), with no obligation of accounting to Amgen. 



  
 42 










	 	(iv)	 By the [*] of the Termination Date, Amgen shall, at the request of Celltech, assign its rights or grant sufficient sublicence rights to Celltech,
under all of Amgen’s rights (but only to the extent permitted by its terms and subject to the obligations) under any [*] to the extent the same relates to Researching, Developing, Commercialising, making, having made, using, selling, having
sold, offering to sell or resell, importing, exporting, distributing or otherwise transferring physical possession of or otherwise transferring title in or to Licensed Antibody Products and shall not (until receiving notice of whether or not
Celltech desires such an assignment or sublicence) terminate or amend any such [*]. 


  

	 	(v)	 Amgen shall be responsible for supplying to Celltech the amounts of Licensed Antibody Product that it was supplying at the time of such termination
for a reasonable period of time not to exceed [*] from the Termination Date, to allow Celltech to obtain an alternate source of supply, if necessary. Amgen shall also assign its rights or grant sufficient sublicence rights (but only to the extent
permitted by its terms and only to the extent the same relates to Licensed Antibody Product) under all Third Party manufacturing agreements relating to Licensed Antibody Product to Celltech, if requested to do so by Celltech. Amgen shall no longer
be responsible for supplying Licensed Antibody Product from the date of such assignment or sublicence or the rejection of a written offer of such assignment (such rejection to be deemed to be given if not accepted within [*] of receipt by Celltech
of such written offer from Amgen) in writing by Celltech. In the event Amgen is obligated to continue to supply Licensed Antibody Products to the extent covered by such agreements, Celltech shall use Commercially Reasonable Efforts to identify one
or more viable Third Party manufacturers in order to transfer manufacturing operations as soon as commercially reasonable. 



  
 43 










	 	(vi)	 By the [*] of the Termination Date, Amgen shall itself transfer any Information Controlled by it and, to the extent it is using a Third Party
manufacturer(s), shall either use Commercially Reasonable Efforts to enforce or assign to Celltech the right to enforce the terms and conditions of each Third Party supply agreement entered into by it including (but only to the extent permitted by
each such supply agreement with the Third Party) the provision to Celltech of any Information and assistance reasonably required by Celltech from such Third Party pertaining to the manufacture and analysis of Licensed Antibody Product, with the
objective of Celltech being enabled to implement the [*] of [*], including Information contained in the [*] of any applicable Regulatory Filings and the results of any stability studies performed by or on behalf of Celltech.



  

	 	(vii)	 Amgen shall continue to use Commercially Reasonably Efforts to promote, detail and otherwise Commercialise the Licensed Antibody Product and shall,
if required to do so, complete [*], as modified by the Transition Plan, to enable Celltech to assume the Commercialisation responsibilities previously carried out by Amgen with a minimum of disruption. 



 

	 	(viii)	 By the [*] of the Termination Date, Amgen shall (1) assign its rights or grant sufficient sublicense rights under all other Third Party
agreements (but only to the extent permitted by their terms and subject to the obligations) to the extent the same relate to the Licensed Antibody Products and as requested to do so by Celltech; and (2) shall provide reasonable assistance to
Celltech in assuming management of such agreements. 


  

	 	(ix)	 Amgen shall grant to Celltech a [*] licence under any [*] Technology ([*]) to Research, Develop, Commercialise, make, have made, use, sell, have
sold, offer to sell or resell, import, export, distribute or otherwise transfer physical possession of or otherwise transfer title in or to Licensed Antibody Products. 



  
 44 









 Such [*] licence shall be [*] (but with Amgen as licensor and Celltech as
licensee) provided that such licence shall not [*]: 
  

	 	(1)	 [*]; 


  

	 	(2)	 [*]: 


  

	 	A.	 [*]; and 


  

	 	B.	 [*]; and 


  

	 	C.	 [*]. 


  

	 	[*].	      


  

	 	(c)	 Each Party shall assist in the transition as set forth in the Transition Plan in a timely, reasonable and businesslike manner. After completion of
the responsibilities set forth in the Transition Plan, the Parties shall have no further obligation to assist in such transition. 


  

	 	(d)	 During any period after receipt or delivery of a notice of termination to the Termination Date, the Parties’ respective rights and obligations
under this Agreement shall (to the extent applicable) remain in full force and effect. 


  

	 	(e)	 If this Licence Agreement is terminated by [*] pursuant to Article 11.4, [*]. If this Licence Agreement is terminated by [*] pursuant to Articles
11.2(b), 11.2(c), 11.3 or 11.5, [*]. Where this Licence Agreement is terminated pursuant to Article 11.2(a) or 11.2(d), the Parties’ reasonable out-of-pocket costs in implementing the transition provisions Article 11.7(b) shall be [*] (subject
to each Party providing the other Party with reasonable supporting evidence of such costs). 



  
 45 










	11.8	 No Transition.            Articles 11.7(b), (c) and (e) shall not apply
where this Licence Agreement has come into force as a result of termination of the Collaboration Agreement by Amgen pursuant to Article 14.4(b) (Default of Celltech) or Article 14.5(b) (Bankruptcy of Celltech) or by Celltech pursuant to Article
14.2.2(b) (No Parking) of the Collaboration Agreement. 


  

	11.9	 Accrued Rights.    Termination, relinquishment or expiration of any licences under this Licence Agreement or of this
Licence Agreement for any reason in accordance with this Article 11 shall be without prejudice to any rights which shall have accrued to the benefit of either Party or any liability incurred by either Party prior to such termination,
relinquishment or expiration. 


 ARTICLE 12 

DISPUTE RESOLUTION 
  

	12.1	 Disputes.    The Parties recognise that disputes as to certain matters may from time to time arise during the term of
this Licence Agreement which relate to either Party’s rights and/or obligations hereunder. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising from, concerning or in any way relating to
this Licence Agreement in an expedient manner by mutual co-operation and without resort to litigation. In the event of a dispute, it shall be referred to the [*] of Celltech and the [*] of Amgen, or their respective officer designees (all such
individuals being referred to herein as the “[*]”), as soon as practicable but in any event no later than [*] after a written request from either Party to the other Party for such a referral. If delegated by the [*] to other [*] and such
other [*] are unable to resolve the matter within said [*], it shall be referred back to the [*] as soon as practicable but in any event no later than [*] after a written request from either Party to the other Party for such referral. Each [*] shall
have the right to engage the services of any number of independent experts in the field in question (such independent expert(s) to be engaged under obligations of confidentiality and the expense of the Party so engaging such expert(s)) to assist the
[*] in making a determination on the unresolved matter, and each [*] shall consider in good faith the analyses and opinions of any such independent experts engaged by either of them in




  
 46 










	 	 
making a determination. In the event that following discussions between the [*], the [*] are unable to resolve such dispute within such [*] of the matter being referred to them, then either Party
may at any time thereafter pursue any legal or equitable remedy available to it. Notwithstanding the above, either Party shall be entitled at all times and without delay to seek equitable relief. 



ARTICLE 13 

GENERAL 
  

	13.1	 Amendments.    This Licence Agreement may not be modified or supplemented by any purchase order, change order,
acknowledgement, order acceptance, standard terms of sale, invoice or the like. Any amendment or modification to this Licence Agreement shall be made in a writing expressly stated for such purpose and signed by an authorised officer of each Party.



  

	13.2	 Notices.    Any consent or notice required or permitted to be given or made under this Licence Agreement by one of the
Parties to the other shall be in writing, delivered personally or by facsimile (and promptly confirmed by personal delivery or courier), by a next business day delivery service of a nationally recognised overnight courier service or by courier,
postage prepaid (where applicable), addressed to such other Party at its address indicated below, or to such other address as the addressee shall have last furnished in writing to the addressor in accordance with this Article 13.2 and shall be
effective upon receipt by the addressee. 


  

			
	If to Celltech:	    	Celltech R&D Limited
		    	208 Bath Road
		    	Slough SL1 3WE
		    	Berkshire, England
		    	Attention: Company Secretary
		    	Facsimile: (XXX) (XX) XXXX XXXXXX


  
 47 










			
	If to Amgen:	    	Amgen Inc.
		    	One Amgen Center Drive
		    	Thousand Oaks, CA 91320-1799 U.S.A.
		    	Attention: Vice President, Licensing
		    	Marked to be copied to: Corporate Secretary
		    	Facsimile: (XXX) (XXX) XXX-XXXX

  

	13.3	 Force Majeure.  Neither Party shall be held liable or responsible to the other Party nor be deemed to have defaulted under or
breached this Licence Agreement for failure or delay in fulfilling or performing any term of this Licence Agreement to the extent such failure or delay is caused by or results from Force Majeure; provided however, that the Party so affected
shall use Commercially Reasonable Efforts to avoid, remove or mitigate such causes of non-performance and shall continue performance with reasonable dispatch wherever such causes are removed. Each Party shall provide the other Party with prompt
written notice of any delay or failure to perform that occurs by reason of Force Majeure. Such excuse shall be continued so long as the condition constituting Force Majeure continues. The Parties shall mutually seek in good faith a resolution
of the delay or failure to perform. 


  

	13.4	 Use of Names, Logos or Symbols.    Subject to Article 2.2, Article 8.6 and Article 11.7(b)(iii), no Party hereto shall
use and no rights are granted to the Trademarks (including the names “[*]” and “[*]”), physical likeness, employee names or owner symbol of the other Party for any purpose (including private or public securities placements)
without the prior written consent of the other Party, such consent not to be unreasonably withheld or delayed so long as use of such name is limited to objective statement of fact rather than for endorsement purposes. Neither Party shall use any
Trademark or domain name in connection with the subject matter of this Licence Agreement which either substantially resembles or is confusingly similar to, misleading or deceptive with respect to, or which dilutes any of the other Party’s
Trademarks or domain names, other than its own Product Trademark or domain names actually used in connection with a Licensed Antibody Product. 



  
 48 










	13.5	 No Strict Construction.    This Licence Agreement has been prepared Jointly and shall not be strictly construed against
either Party. 


  

	13.6	 Assignment. 


  

	 	(a)	 This Licence Agreement may not be assigned or otherwise transferred by any Party without the consent of the other Party, not to be unnecessarily
withheld or delayed; provided however, that either Celltech or Amgen may, without such consent, assign its rights and obligations under this Licence Agreement (i) to any Affiliate, provided such interest shall be retransferred to
the relevant Party if such entity ceases to be an Affiliate of such Party, and provided further that the assigning Party shall remain responsible for the acts and omissions in the performance of this Licence Agreement, by its Affiliate or
(ii) in connection with a merger, consolidation or sale of substantially all of the business to which this Licence Agreement relates to an unrelated Third Party of [*]. 



 

	 	(b)	 Except as aforesaid, any permitted assignee shall assume all rights and obligations of its assignor under this Licence Agreement; accordingly, all
references to the assigning Party shall be deemed references to the assignee to whom the Licence Agreement is so assigned. The assigning Party shall forward to the other Party a copy of those portions of each such fully executed assignment agreement
which relate to the assumption of the rights and responsibilities of the assigning Party, within [*] of the execution of such assignment agreements. 


  

	 	(c)	 Any assignment or attempted assignment by either Party in violation of the terms of this Article 13.6 shall be null and void and of no legal
effect. 


  

	13.7	 Severability.    If any provision hereof should be held invalid, illegal or unenforceable from which no appeal can be or
is taken, in any respect in any jurisdiction, the invalidity, illegality or unenforceability of one or several provisions of this Licence Agreement shall not affect the validity of this Licence Agreement as a whole. The Parties shall make a good
faith effort to replace the invalid or unenforceable provision with a valid one which in its economic effect is most consistent with the objectives contemplated by the Parties as evidenced by the terms and conditions of this Licence Agreement when
entering into such invalid or unenforceable one. 



  
 49 










	13.8	 Interpretation and Schedules.  


  

	 	(a)	 The captions or headings of the Articles or other subdivisions hereof are inserted only as a matter of convenience or for reference and shall have
no effect on the meaning of the provisions hereof. 


  

	 	(b)	 Unless otherwise specified, (i) references in this Licence Agreement to any Article, or Schedule shall mean references to such Article or
Schedule of this Licence Agreement; and (ii) references to any agreement, instrument or other document in this Licence Agreement refer to such agreement, instrument or other document as originally executed or, if subsequently varied, replaced
or supplemented from time to time, as so varied, replaced or supplemented and in effect at the relevant time of reference thereto. 


  

	 	(c)	 Any statute defined or referred to herein or in any agreement or instrument that is referred to herein means such statute as from time to time
amended, modified or supplemented, including by succession of comparable successor statutes and references to all attachments thereto and instruments incorporated therein. References to a person are also to its permitted successors and assigns.



  

	 	(d)	 All Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this Licence Agreement as if set forth in full
herein. Any capitalised terms used in any Schedule but not otherwise defined therein, shall have the meaning as defined in this Licence Agreement. 


  

	 	(e)	 Whenever the words “include”, “includes” or “including” are used in this Licence Agreement, they
shall be deemed to be followed by the words “without limitation”. 


  

	13.9	 No Consequential Damages.    NEITHER PARTY HERETO WILL BE LIABLE (WHETHER UNDER AN INDEMNITY OR OTHERWISE) FOR SPECIAL,




  
 50 










	 	 
INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR RELATING TO THIS LICENCE AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING WITHOUT LIMITATION LOST PROFITS, ANTICIPATED PROFITS,
LOST GOODWILL, LOST REVENUE, LOST PRODUCTION, LOST CONTRACTS AND LOST OPPORTUNITY, ARISING FROM OR RELATING TO ANY BREACH OF THIS LICENCE AGREEMENT, WHETHER DENOMINATED IN OR ARISING IN CONTRACT, TORT OR OTHERWISE REGARDLESS OF ANY NOTICE OF SUCH
DAMAGES. NOTHING IN THIS ARTICLE 13.9 IS INTENDED TO LIMIT OR RESTRICT ANY PAYMENT OBLIGATION EXPLICITLY SET FORTH UNDER THIS LICENCE AGREEMENT. 


  

	13.10	 Governing Law; Jurisdiction. 


  

	 	(a)	 This Licence Agreement shall be governed and interpreted in all respects under the substantive laws of the State of New York, United States, as
applied to agreements executed and performed entirely in the State of New York by residents of the State of New York, without regard to conflicts of law rules and without regard to the United Nations Convention on International Contracts for the
Sales of Goods. 


  

	 	(b)	 Each Party consents to the exclusive jurisdiction of the federal or state courts in the State of New York for any suit, action or other proceeding
arising out of or relating to this Licence Agreement whether denominated or arising in contract, tort or otherwise, and further agrees that any process, notice of motion or other application to either such court or judge thereof may be served
outside of New York City, New York by personal service, provided that a reasonable time for appearance is allowed. Each Party hereby irrevocably and unconditionally waives any objection to the laying of venue of any action, suit or proceeding
arising out of or relating to this Licence Agreement whether denominated or arising in contract, tort or otherwise, in the federal or state courts in the State of New York. Each Party hereby irrevocably and unconditionally waives and agrees not to
plead or claim in any such court that any action, suit or proceeding brought in any such 



  
 51 










	 	 
court has been brought in inconvenient forum. As between the Parties, any dispute, controversy or claim relating to the scope, validity, enforceability or infringement of any Patent Rights
claiming the use or sale of any Antibody Product or of any Trademark rights relating to an Antibody Product shall be submitted to a court of competent jurisdiction in the Territory in which such Patent Rights or Trademark rights were granted or
arose, which in the case of any United States Patent Rights or Trademark rights shall be a court of competent jurisdiction in the State of New York. 


  

	 	(c)	 Each Party hereby waives, to the fullest extent permitted by applicable law, any right it may have to a trial by jury in respect to any litigation
directly or indirectly arising out of or relating to this Licence Agreement. 
	 

  

	13.11	 General Provisions.  


  

	 	(a)	 The covenants and agreements set forth in this Licence Agreement are for the sole benefit of the Parties hereto and their successors and permitted
assigns, and a person who is not a Party to this Licence Agreement may not enforce any of its terms. 
	 

  

	 	(b)	 A waiver (whether express or implied) by one of the Parties of any of the provisions of this Licence Agreement or of any breach of or default by the
other Party in performing any of those provisions must be in writing executed by a responsible officer of the Party providing the waiver and expressly waiving such provisions or breach or default by reference to this Licence Agreement, and any
waiver shall not constitute a continuing waiver, and that waiver shall not prevent the waiving Party from subsequently enforcing any of the provisions of this Licence Agreement not waived or from acting on any subsequent breach of or default by the
other Party under any of the provisions of this Licence Agreement. 
	 

  

	 	(c)	 Each Party undertakes to execute all documents which may be reasonably necessary to give full effect to this Licence Agreement. 
	 


  
 52 










	 	(d)	 Each Party shall pay its costs and expenses incurred by it in connection with negotiation and execution of this Licence Agreement. 
	 

  

	 	(e)	 It is expressly agreed that for tax, legal or all other purposes (i) this Licence Agreement or any portion of this Licence Agreement shall not
be considered to be a partnership agreement, and (ii) the relationship between the two Parties shall not constitute an employee-employer, partnership, Joint venture, agency or similar business relationship between the Parties. Neither Celltech
nor Amgen shall have the authority to make any statements, representations, warranty, guarantee or commitments (express or implied) of any kind or to take any action which shall bind the other Party to a Third Party, without the prior consent of the
other Party to do so. Each Party shall use its own discretion, shall have complete and authoritative control over its employees and the methods and means by which it performs its activities under this Licence Agreement (including the management of
permitted subcontractors). 
	 

  

	 	(f)	 This Licence Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. 
	 

  

	13.12	 Whole Agreement. This Licence Agreement and the Schedules referred to in this Licence Agreement constitute the entire agreement between the
Parties with respect to the subject matter hereof, and supersede all previous understandings, arrangements and agreements with respect to the subject matter hereof, whether written or oral. Each Party acknowledges that in entering into this Licence
Agreement it has not relied on any representation, warranty, collateral contract or other assurance (except those expressly set out in this Licence Agreement, together with its Schedules) made by or on behalf of any other Party. Each Party waives
all rights and remedies which, but for this Article 13.12, might otherwise be available to it in respect of any such representation, warranty, collateral contract or other assurance. As of the Licence Agreement Effective Date, with respect to the
subject matter licensed hereunder the terms and conditions of this Licence 



  
 53 










	 	 
Agreement shall apply and the terms and conditions of the Collaboration Agreement (other than with respect to accrued or surviving obligations under the Collaboration Agreement) are hereby
superseded. 



  
 54 









 SCHEDULE ONE 
 Defined Terms 
 “Affiliate” means any
corporation, company, partnership, Joint venture and/or firm which controls, is controlled by, or is under common control with a Party. For purposes of this definition, “control” shall be presumed to exist if one of the following
conditions is met: (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares having the right to vote for the election of directors, and (b) in the case of non-corporate
entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with the power to direct the management and policies of such non-corporate entities. The Parties acknowledge that in the case of certain entities
organised under the laws of certain countries outside of the United States, the maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%), and that in such case such lower percentage shall be
substituted in the preceding sentence, provided that such foreign investor has the power to direct the management and policies of such entity. 
 “Amgen Know-How” means, other than [*] Know-How and [*]Know-How, all Information and Materials which are [*] for the [*] of Licensed Antibody Products to the extent the same are [*] as
existing on the Licence Agreement Effective Date or during its Term. 
 “Amgen Patent Rights”
means, other than [*] Patent Rights and [*] Patent Rights, (i) all Patent Rights to the extent the same are [*] and which claim [*] Know-How and (ii) all Patent Rights [*] to the extent the same are [*]; and in each case which would be
infringed by [*] Licensed Antibody Products. 
 “Amgen [*] Know-How” means all
Information and Materials characterised, conceived, developed, derived, discovered, generated or identified solely by employees of or consultants to Amgen in the course of the [*] of Antibody Products [*] and, in each case, [*] of [*]. 

“Amgen [*] Patent Rights” means those Patent Rights of [*] which specifically disclose and claim
[*] Know-How. 

  
 S1-1









 “Amgen Technology” means, collectively, [*] Know-How, [*]
Know-How, [*] Patent Rights, [*] Patent Rights, and Amgen’s interest in [*] Know-How and Amgen’s interest in [*] Patent Rights. 
 “Antibody” means a polyclonal or monoclonal antibody, whether multiple or single chain, recombinant or naturally-occurring or a combination of the foregoing, whole or fragment,
monospecific or multi-specific, and any analogs, constructs, conjugates, fusions or chemical or other modifications and/or attachments thereof. 
 “Antibody Raw Material” means the bulk Licensed Antibody Product (including, if appropriate, [*] suitable for use in the manufacture of Licensed Antibody Product in Finished Form.

 “BEER” means any protein or a portion thereof comprising the polypeptide sequence of [*] and
any polypeptide sequence having [*] ([*]%) [*] and any [*]. 
 “Business Day” means a day on
which banking institutions in both New York, New York, USA, and London, England are open for business. 

“Calendar Quarter” means the respective periods of three (3) consecutive calendar months ending on
either March 31, June 30, September 30, or December 31 for so long as this Licence Agreement is in effect. 
 “Calendar Year” means each successive period of twelve (12) months commencing on January 1 and ending on December 31. 

“Celltech [*] Patent Rights” means the patent applications and patents set forth in Part A of
Schedule Two and all Patent Rights that issue from or claim priority from those Patent Rights and foreign counterparts thereof. 
 “Celltech [*] Patent Rights” means the Patent Rights set forth in Part B of Schedule Two (and all Patent Rights that issue from or claim priority from those Patent Rights
and foreign counterparts thereof); provided that if Amgen has exercised rights under Section 3.2.1(e) of the Collaboration Agreement, unless otherwise agreed in writing the [*] Patent Rights shall be excluded from this Licence Agreement.
For the avoidance of doubt, [*] Patent Rights shall not include [*] Patent Rights. 

  
 S1-2









 “Celltech Know-How” means, other than [*] Know-How and [*]
Know-How, all Information and Materials relating to Antibodies, which are [*] for the [*] of Licensed Antibody Products to the extent the same are [*] as in each case [*]; provided that if Amgen has exercised rights under
Section 3.2.1(e) of the Collaboration Agreement, unless otherwise agreed in writing the [*] Know-How shall not include any Information or Materials [*] any invention claimed by any of the [*] Patent Rights. 

“Celltech Patent Rights” means, other than [*] Patent Rights, [*] Patent Rights and [*] Patent Rights,
(i) all Patent Rights to the extent the same are [*] and which claim [*] Know-How and (ii) all Patent Rights of a [*] to the extent the same are [*]; and in each case which if not licensed herein would be infringed by [*] Antibody
Products. [*] Patent Rights include [*] Patent Rights; provided that if Amgen has exercised rights under Section 3.2.1(e) of the Collaboration Agreement, unless otherwise agreed in writing, the [*] Patent Rights shall be excluded from
this Licence Agreement. 
 “Celltech [*] Know-How” means all Information and Materials
characterised, conceived, developed, derived, discovered, generated or identified solely by employees of or consultants to Celltech in the course of the [*] of Antibody Products [*] and, in each case, [*] of [*]. 

“Celltech [*] Patent Rights” means those Patent Rights of [*] which specifically disclose and
claim [*] Know-How. 
 “Celltech Technology” means, collectively, [*]Know-How, [*] Know-How,
[*] Patent Rights, [*] Patent Rights, [*] Patent Rights, and Celltech’s interest in [*] Know-How and Celltech’s interest in [*] Patent Rights. 
 “Celltech Trademarks” means the Trademarks including house marks and house dress [*] from time to time [*] and used on or in connection with Licensed Antibody Products, but excluding the
[*] Trademarks. 

  
 S1-3









 “Collaboration Agreement” means that certain Collaboration
and Licence Agreement by and between the Parties, dated May       , 2002. 

“Commercialisation” or “Commercialise” means any and all activities (whether before or
after Regulatory Approval) directed to the marketing, detailing and promotion of a Licensed Antibody Product after Regulatory Approval for commercial sale has been obtained and shall include pre-launch and post-launch marketing, manufacturing for
commercial sale, promoting, detailing, distributing, offering to sell and selling a Licensed Antibody Product, importing a Licensed Antibody Product for sale, conducting marketing clinical studies (but not Development clinical studies) and
interacting with Regulatory Authorities regarding the foregoing. When used as a verb, “Commercialising” means to engage in Commercialisation and “Commercialised” shall have a corresponding meaning. 

“Commercially Reasonable Efforts” means efforts and resources commonly associated with good business
practice and standards in the research-based pharmaceutical industry to research, develop or commercialise (as appropriate) a product of similar market potential at a similar stage in its product life, taking into account efficacy, the
competitiveness of alternative products and product candidates in the marketplace (excluding other products owned or controlled or marketed by a Party or any of its Affiliates), the patent and other proprietary position of the product, the
likelihood of regulatory approval given the regulatory structure involved, the profitability of the product including the royalties payable to licensors of patent rights, alternative Third Party products and product candidates and other relevant
factors. Commercially Reasonable Efforts where appropriate shall be determined on a market-by-market basis for a particular product, and the level of effort may change over time, reflecting changes in the status of the product and the market
involved. 
 “Competitive Product” means any [*] product, other than a Licensed Antibody
Product, that contains [*] in either bulk or final finished form. 
 “Confidential Information”
means all Information disclosed in good faith for the purposes of this Licence Agreement which is designated as confidential in writing by the disclosing Party, whether by letter or by the use of an appropriate stamp or legend, prior to or at the
time any such Information is disclosed by the disclosing Party to the other Party. 

  
 S1-4









 
Notwithstanding anything in the foregoing to the contrary, Information which is disclosed in good faith for the purposes of this Licence Agreement, whether orally, electronically, visually or in
writing without an appropriate letter, stamp or legend, shall constitute Confidential Information of a Party (a) if the disclosing Party within thirty (30) days after such disclosure, delivers to the other Party a written document or
documents describing the Information and referencing the place and date of such oral, visual, electronic or written disclosure and the names of the persons to whom such disclosure was made or (b) if such Information is of the type that is
customarily considered to be confidential information by persons engaged in activities that are substantially similar to the activities being engaged in by the Parties. The terms of this Licence Agreement shall be considered Confidential Information
of each Party. 
 “Control” or “Controlled” or “Controlling” means with
respect to any (a) Material or Information or (b) intellectual property right, in each case the possession (whether by ownership, licence or other right, other than pursuant to this Licence Agreement) by a Party or its Affiliates of the
ability to grant to the other Party access and/or a licence (or sublicence) as provided herein under such item or right without violating the terms of any agreement or other arrangement with any Third Party existing on the Licence Agreement
Effective Date or during the Term of this Licence Agreement and existing as of the date such Party obtains such ownership, licence or other right in such Material, Information or intellectual property. 

“Development” or “Develop” means all clinical and other activities undertaken to obtain
Regulatory Approval of a Licensed Antibody Product after the filing of an IND for a Licensed Antibody Product and up to and including the obtaining of Regulatory Approval for commercial sale of such Licensed Antibody Product in the Field in the
Territory. For the avoidance of doubt, these activities shall include clinical drug development activities, including, among other things: test method development and stability testing, toxicology, formulation, process development, manufacturing,
manufacturing scale-up, development-stage manufacturing, quality assurance/quality control development, statistical analysis and report writing, product approval and registration, and regulatory affairs related to the foregoing. When used as a verb,
“Developing” means to engage in Development and “Developed” shall have a corresponding meaning. 

  
 S1-5









 “Dollar” means a United States dollar, and
“$” shall be interpreted accordingly. 
 “Drug Approval Application” means an
application for any Regulatory Approval required before commercial sale or use of a Licensed Antibody Product as a drug or to treat a particular indication in a regulatory jurisdiction, including: (a) (i) a Biologics Licence Application
(BLA) pursuant to 21 C.F.R. 601.2 (or any successor application or procedure) submitted to the FDA and (ii) any counterpart of a U.S. BLA in any other country in the Territory; and (b) all supplements and amendments that may be filed with
respect to the foregoing. 
 “Effective Date of Termination of the Collaboration Agreement”
means the Termination Date of the Collaboration Agreement as set forth in Article 14.8 of the Collaboration Agreement. 
 “FAMC” means the Fully Absorbed Manufacturing Cost as defined in Schedule E of the Collaboration Agreement. 

“FDA” means the United States Food and Drug Administration or a successor agency thereto. 

“Field” means [*]. 

“First Commercial Sale” means in relation to any Licensed Antibody Product the first shipment of such
Licensed Antibody Product sold on arm’s-length terms to a non-sublicensee Third Party by Amgen, its Affiliates or its Sublicensees, in a country in the Territory after the first Regulatory Approval for Commercialisation has been achieved for
such Licensed Antibody Product in such country in any indication. Sales for test marketing, sampling and promotional uses, clinical trial purposes or compassionate or similar use shall not constitute a First Commercial Sale. 

“Force Majeure” means any occurrence beyond the reasonable control of a Party that prevents or
substantially interferes with the performance by a Party of any of its obligations hereunder. 

“GAAP” means United States generally accepted accounting principles. 

  
 S1-6









 “IND” means (a) (i) an Investigational New Drug
Application (as defined in the U.S. Federal Food, Drug and Cosmetic Act, as amended from time to time, and the regulations promulgated thereunder) that is required to be filed with the FDA before beginning clinical testing of a Licensed Antibody
Product in human subjects, or any successor application or procedure and (ii) any counterpart of a U.S. Investigational New Drug Application in any other country in the Territory; and (b) all supplements and amendments that may be filed
with respect to the foregoing. 
 “Information” means tangible or intangible know-how, trade
secrets, inventions (i.e., conceived or reduced to practice, constructively or actually), methods, knowledge, conclusions, skill, experience, test data and results (including but not limited to, chemical, biological, biochemical, pharmaceutical,
pharmacological, toxicological and research, pre-clinical and clinical data, assay, control and manufacturing processes, test data and results), analytical and quality control methods and data, results or descriptions, software and algorithms or
other information (whether or not patentable) regarding technology, techniques, practices, products, business information or objectives. 
 “Joint Know-How” means all Information or Materials that are conceived or developed [*] and, in each case, [*] of [*]. 

“Joint Patent Rights” means Patent Rights in any country within the Territory which claim [*] Know-How
and which identify employees or contractors of [*] as inventors. 
 “Licensed Antibody
Product(s)” means (i) any Antibody Product and Subsequent Products (as each is defined in the Collaboration Agreement) for which Celltech elected to opt out in accordance with Article 3.4 of the Collaboration Agreement, or
(ii) where (i) does not apply, all Antibody or Antibodies in whatever form that [*], and any product incorporating any such Antibody or Antibodies. 
 “Materials” means biological and chemical materials including, Antibodies, Licensed Antibody Products, screens, animal models, cell lines, cells, vectors, nucleic acids, receptors and
reagents. 

  
 S1-7









 “Net Sales” means with respect to any Licensed Antibody
Product, all revenues recognised in accordance with GAAP, consistently applied as between the Parties, from sales of a Licensed Antibody Product by Amgen, its Affiliates and Sublicensees, to Third Parties (but not including sales relating to
transactions between a Party, its Affiliates, and their respective Sublicensees), less the total of the following: 
  

	 	a)	 Normal or customary trade, cash, prompt payment and/or quantity discounts actually allowed and taken; 



 

	 	b)	 Returns, allowances, free goods, rebates, chargebacks, other allowances or payments to government agencies actually allowed and taken;



  

	 	c)	 Retroactive price reductions applicable to sales of such product actually allowed and taken; 



 

	 	d)	 Credits or allowances (actively paid or allowed) for wastage replacement, whether cash or trade; 



 

	 	e)	 Non-recoverable sales taxes, excise taxes, tariffs and duties (excluding taxes when assessed on income derived from sales); and



  

	 	f)	 [*] ([*]%) of the amount invoiced to cover bad debt, freight or other transportation charges, insurance charges, additional special packaging, and
other governmental charges. 


 In the case of any sale of a Licensed Antibody Product between or among Amgen
and its Affiliates or Sublicensees for resale, Net Sales shall be calculated as above only on the first arm’s-length sale by any such Party, Affiliate or Sublicensee to a Third Party. 

Upon any sale or other disposal of any Licensed Antibody Product for any consideration other than an exclusively monetary consideration
on bona fide arm’s-length terms then for the purposes of calculating the Net Sales under this Licence Agreement, such Licensed Antibody Product shall be deemed to be sold exclusively for money at the average sales price during the applicable
reporting period generally achieved for such Licensed Antibody Product in the country in which such sale or other disposal occurred when such Licensed Antibody Product is sold alone and not with other products. 

  
 S1-8









 Where a Licensed Antibody Product is sold together with other pharmaceutical products for a
single price (whether sold together in the same package, or merely price bundled), then for the purposes of calculating the Net Sales payable under this Licence Agreement such Licensed Antibody Product shall be deemed sold for an amount equal to the
following: 
 (X divided by Y) multiplied by Z 

where X is the average sales price during the applicable reporting period generally achieved for such Licensed Antibody Product in the
country in which such sale or other disposal occurred when such Licensed Antibody Product is sold alone and not with other pharmaceutical products; Y is the sum of the average sales price during the applicable reporting period generally achieved in
that country when sold alone by each product (including the Licensed Antibody Product) included in the bundle of pharmaceutical products that is sold for the single price; and Z equals the single price at which the bundle of pharmaceutical products
represented in Y was actually sold. In the event one or more of the products in the bundled product are not sold separately, the Parties shall confer in good faith to determine a fair market price for the value of the Licensed Antibody Product(s)
within the bundled product. 
 “Party” means Amgen or Celltech; “Parties”
means Amgen and Celltech. 
 “Patent Rights” means all (a) existing issued, unexpired
patents (with the term “patent” being deemed to encompass an inventor’s certificate), including any reissue, re-examination, renewal or extension (including any supplementary protection certificate) of any such patent, and any
confirmation patent or registration patent or patent of addition based on any such patent and (b) existing patent applications and patent applications hereafter filed, including any continuations, continuations-in-part, divisionals,
provisionals, converted provisional, continued prosecution application, or any substitute applications, any patent issued with respect to any such patent applications, any reissue, re-examination, renewal or extension (including any supplementary
protection certificate) of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent; and all foreign counterparts of any of the foregoing. 

  
 S1-9









 “[*] Antibody” means an Antibody which is [*] of any
[*] and claimed by any of the [*] Patent Rights. 
 “Phase II Study” means a clinical trial
that is designed to establish the safety and preliminary efficacy of a drug for its intended use, and to define warnings, precautions and adverse reactions that are associated with the drug in the dosage range to be prescribed and that satisfy the
requirements of 21 CFR 312.21(b) (or its successor regulation), or its equivalent in any other jurisdiction. 

“Pivotal Study” means a clinical trial that, if the defined end-points are met, is designed (and agreed
to in advance by a Regulatory Authority(ies) having jurisdiction in the country(ies) in which the trial is to be conducted, based upon existing data in the same patient population as of the start of such clinical trial) to definitively establish
that a Licensed Antibody Product drug is safe and efficacious for its intended use, and to define warnings, precautions and adverse reactions that are associated with the Licensed Antibody Product in the dosage range to be prescribed, and provide
pivotal data supporting Regulatory Approval of such Licensed Antibody Product and that satisfies the requirements of 21 CFR 321.21(c) (or its successor regulation), or its equivalent in any other jurisdiction. 

“Product Trademark” means any trademarks and trade names (and trademark applications (whether or not
registered), and any renewals, extensions or modifications thereto in the Territory) together with all goodwill associated therewith, trade dress and packaging which (a) are Controlled by either Party and (b) are applied to a Licensed
Antibody Product or any Promotional Materials and (c) distinguishes that Licensed Antibody Product; but excluding any house marks or house dress or any reserve trademarks and trade names (and trademark applications (and any resulting
trademarks) which are Controlled by a Party and are filed with a trademark office for use with a Licensed Antibody Product but which shall not have been applied to a Licensed Antibody Product. 

  
 S1-10









 “Promotional Materials” means all sales representative
training materials and all written, printed, graphic, electronic, audio or video matter including, but not limited to, journal advertisements, sales visual aids, direct mail, direct-to-consumer advertising, Internet postings, product inserts,
broadcast advertisements, and sales reminder aids (e.g., scratch pads, pens and other such items) intended for use or used by a Party in connection with any promotion or detailing of a Licensed Antibody Product. 

“Regulatory Approval” means any and all approvals (including any applicable supplements, amendments,
pre- and post-approvals, governmental price and reimbursement approvals and approvals of applications for regulatory exclusivity), licences, registrations, or authorisations of any federal, national, multinational, state, provincial or local
regulatory agency, department, bureau, commission, council or other governmental entity necessary for the manufacture, distribution, use, storage, import, export, transport, promotion, marketing and sale of a Licensed Antibody Product in a country
or jurisdiction. 
 “Regulatory Authority” means any governmental or regulatory authority
involved in granting Regulatory Approvals of any Licensed Antibody Product including in the United States the FDA. 
 “Regulatory Filings” means, collectively, INDs, Drug Approval Applications, establishment licence applications (ELAs) and drug master files (DMFs) or any other similar filings (including
any equivalents in other jurisdictions and further including any related correspondence and discussions) and applications for regulatory exclusivity, and all data contained therein, as may be required by the FDA or equivalent Regulatory Authorities
in other jurisdictions, for the Development or Commercialisation of a Licensed Antibody Product. 

“Research” means all research and pre-clinical activities including the filing of any IND for a Licensed
Antibody Product. When used as a verb “Research” means to engage in Research, and “Researched” and “Researching” shall have a corresponding meaning. 

“Royalty” or “Royalties” means those amounts payable as royalties by Amgen to Celltech
pursuant to Article 4.2 of this Licence Agreement. 

  
 S1-11









 “Sublicensee” means a Third Party to whom Amgen shall have
granted a licence or sublicense under Amgen’s rights pursuant to Article 2.3 to Research, Develop, Commercialise, make, have made, use, sell, have sold, offer to sell or resell, import, export, distribute or otherwise transfer physical
possession of or otherwise transfer title in or to a Licensed Antibody Product in one or more countries in the Territory. Solely for the purpose of any compensation payable to Celltech hereunder, “Sublicensee” shall include a Third Party
to whom Amgen or another Sublicensee shall have granted the right to distribute one or more Licensed Antibody Product(s) but, notwithstanding the foregoing, shall not include (i) [*]; or (ii) [*]. 

“Term” shall have the meaning set forth in Article 11.1. 

“Territory” means all the countries of the world. 

“Third Party” means any person, partnership, Joint venture, corporation, trust, estate, unincorporated
organisation, government or any department or agency thereof, or any entity other than a Party or any of its Affiliates. 
 “Third Party Payment” means all fees, milestones, royalties and any other payments paid to Third Parties under patent or technology licences that are necessary in order to Research,
Develop, Commercialise, make, have made, use, sell, have sold, offer to sell or resell, import, export, distribute or otherwise transfer physical possession of or otherwise transfer title in or to the Licensed Antibody Products. 

“Trademark” means any and all corporate names, service marks, logos or trademarks and trademark
applications (whether or not registered) together with all good will associated therewith, and any renewals, extensions or modifications thereto either filed or used. 

“Transition Date” shall have the meaning set forth in Article 5.2.8. 

“Valid Claim” means a claim of any issued, unexpired Patent Right which has not been revoked or held
unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction from which no appeal can be taken, or with respect to which an appeal is not taken within the time allowed for appeal, and which has not been
disclaimed, denied or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise. 

  
 S1-12









 Each of the following definitions are found in the body of this Licence Agreement as
indicated: 
  

					
	 Defined Terms
	  	 Page/Article
	  	  
	“Amgen”	  	Page 1, 1st paragraph	  	
	“Amgen Indemnitees”	  	Article 10.1	  	
	“Amgen Loss(es)”	  	Article 10.1	  	
	“Celltech”	  	Page 1, 1st paragraph	  	
	“Celltech Indemnitees”	  	Article 10.2	  	
	“Celltech Loss(es)”	  	Article 10.2	  	
	“Consultation Rights”	  	Article 5.2.2(b)	  	
	“Defaulting Party”	  	Article 11.3(a)	  	
	“include”, “includes”, and “including”	  	Article 13.8(e)	  	
	“Indemnify”	  	Article 10.1	  	
	“intellectual property”	  	Article 11.4(a)	  	
	“Licence Agreement”	  	Page 1, 1st paragraph	  	
	“Licence Agreement Effective Date”	  	Page 1, 1st paragraph	  	
	“[*] Patent Rights”	  	Article 5.2.2(a)	  	
	“Milestone Events”	  	Article 4.1(a)	  	
	“Milestone Payments”	  	Article 4.1(a)	  	
	“Non-Defaulting Party”	  	Article 11.3(a)	  	
	“Notice of Default”	  	Article 11.3(a)	  	
	“[*]”	  	Article 12.1	  	
	“patent”	  	Page S1-10 (part of “Patent Rights” def)
	“Performance Default”	  	Article 11.3(a)	  	
	“Pre-Effective Date Losses”	  	Article 10.4	  	
	“Representation Default”	  	Article 11.3(a)	  	
	“Termination Date”	  	Article 11.6	  	
	“Transition Date”	  	Article 5.2.7	  	
	“Transition Plan”	  	Article 11.7(b)	  	


  
 S1-13









 SCHEDULE TWO 
 PART A 
 [*] PATENT RIGHTS 

a)  [*] 
  

			
	[*] Ref. No.	  	[*]
		
	Subject Matter:	  	[*]
		
	Title:	  	[*]
		
	Inventors:	  	[*]
		  	[*]
		  	[*]
		  	[*]
		  	[*]
		  	[*]
		  	[*]

  

			
	Priority Application Date:	  	[*]
	Earliest Publication Date/No.	  	[*]

  

									
	Territory	  	Application Date	  	Application No.	  	Patent No.	  	Expiry Date
					
	     [*]
	  	     [*]
	  	     [*]
	  		  	
	     [*]
	  	     [*]
	  	     [*]
	  		  	
	     [*]
	  	     [*]
	  		  		  	
	     [*]
	  	     [*]
	  	     [*]
	  		  	
	     [*]
	  	     [*]
	  	     [*]
	  		  	
	     [*]
	  	     [*]
	  	     [*]
	  		  	
	     [*]
	  	     [*]
	  	     [*]
	  		  	
	     [*]
	  	     [*]
	  	     [*]
	  		  	
	     [*]
	  	     [*]
	  	     [*]
	  		  	
	     [*]
	  	     [*]
	  	     [*]
	  		  	
	     [*]
	  	     [*]
	  	     [*]
	  		  	
	     [*]
	  	     [*]
	  	     [*]
	  		  	
	     [*]
	  	     [*]
	  	     [*]
	  		  	
	     [*]
	  	     [*]
	  	     [*]
	  		  	
	     [*]
	  	     [*]
	  	     [*]
	  		  	
	     [*]
	  	     [*]
	  	     [*]
	  		  	
					
	     *[*]
	  		  		  		  	


  
 S2-1









 SCHEDULE TWO 
 PART B 
 [*] PATENT RIGHTS 

b)  [*] 
  

			
	[*] Ref. No:	  	[*]
		
	Subject Matter:	  	[*]
		
	Title:	  	[*]
		
	Inventors:	  	[*]
		  	[*]
		
	Priority Application Date:	  	[*]
	Earliest Publication Date/No:	  	[*]

  

									
	Territory	  	Application Date	  	Application No.	  	Patent No.	  	Expiry Date
					
	  [*]
	  	   [*]
	  	  [*]
	  	  [*]
	  	     [*]

	  [*]
	  	   [*]
	  	  [*]
	  	  [*]
	  	     [*]

	  [*]
	  	   [*]
	  	  [*]
	  	  [*]
	  	     [*]

					
	  *[*]
	  		  		  		  	


  
 S2-2









 SCHEDULE TWO 
 PART B 
 [*] PATENT RIGHTS 

b)  [*] 
  

			
	[*] Ref. No:	  	[*]
	 	 
	 	  	 
	Subject Matter:	  	[*]
	 	 
	 	  	 
	 	 
	 	  	 
	Title:	  	[*]
	 	 
	 	  	 
	Inventors:	  	[*]
	 	  	[*]
	 	 
	 	  	 
	Priority Application Date:	  	[*]
	Earliest Publication Date/No:	  	[*]

  

									
	Territory	  	Application Date	  	Application No.	  	Patent No.	  	Expiry Date
					
	  [*]
	  	     [*]
	  	   [*]
	  	  [*]
	  	  [*]

	  [*]
	  	     [*]
	  	   [*]
	  	  [*]
	  	  [*]

					
	  *[*]
	  		  		  		  	


  
 S2-3









 SCHEDULE TWO 
 PART B 
 [*] PATENT RIGHTS 

c)  [*] 
  

			
	[*] Ref. No.	  	[*]
	 	 
	 	  	 
	Subject Matter:	  	[*]
	 	 
	 	  	 
	Title:	  	[*]
	 	 
	 	  	 
	Inventors:	  	[*]
	 	  	[*]
	 	 
	 	  	 
	Priority Application Date:	  	[*]
	Earliest Publication Date/No.	  	[*]

  

									
	Territory	  	Application Date	  	Application No.	  	Patent No.	  	Expiry Date
					
	  [*]
	  	      [*]
	  	     [*]
	  	  [*]
	  	     [*]

	  [*]
	  	      [*]
	  	     [*]
	  		  	
	  [*]
	  	      [*]
	  	     [*]
	  		  	
	  [*]
	  	      [*]
	  	     [*]
	  		  	
	  [*]
	  	      [*]
	  	     [*]
	  		  	
	  [*]
	  	      [*]
	  	     [*]
	  	  [*]
	  	     [*]

	  [*]
	  	      [*]
	  	     [*]
	  	  [*]
	  	     [*]

	  [*]
	  	      [*]
	  	     [*]
	  		  	
					
	 *[*]
	  		  		  		  	


  
 S2-4









 SCHEDULE TWO 
 PART B 
 [*] PATENT RIGHTS 

c)  [*] 
  

			
	[*] Ref. No:	  	[*]
		
	Subject Matter:	  	[*]
		
	Title:	  	[*]
		
	Inventors:	  	[*]
		  	[*]
		
	Priority Application Date:	  	[*]
	Earliest Publication Date/No:	  	[*]

  

									
	Territory	  	Application Date	  	Application No.	  	Patent No.	  	Expiry Date
					
	  [*]
	  	     [*]
	  	     [*]
	  		  	
	  [*]
	  	     [*]
	  	     [*]
	  		  	
	  [*]
	  	     [*]
	  		  		  	
	  [*]
	  	     [*]
	  	     [*]
	  		  	
	  [*]
	  	     [*]
	  	     [*]
	  		  	
	  [*]
	  	     [*]
	  	     [*]
	  		  	
					
	  *[*]
	  		  		  		  	


  
 S2-5









 Note: Redacted portions have been marked with [*]. The redacted portions are subject to a
request for confidential treatment that has been filed with the Securities and Exchange Commission. 
  

			
	



      	  	
		
		  	Amgen
		  	One Amgen Center Drive
		  	Thousand Oaks, CA 91320-1799
		  	805.447.1000

 Via facsimile (XXX) (XX) XXXX XXXXXX and DHL Courier 
 Celltech R&D Limited 
 208 Bath Road 
 Slough SL1 3WE 
 Berkshire, England 
 Attention: Company Secretary 
  

	 	Re:	Amendment No. 1 to Collaboration and Licence Agreement 


	 	    	Between Amgen Inc. and Celltech R&D Limited 


	 	    	Amgen Ref. No. XXXXXXXXX (the “Agreement”) 

 To Whom It May Concern: 
 Celltech R&D Limited (“Celltech”) and Amgen Inc.
(“Amgen”) entered into the captioned Agreement effective May 10th, 2002. The Parties agree that the Agreement is hereby amended as set forth below (“Amendment”), and that the Amendment shall have an effective date of June 9th, 2003 (the “Amendment Effective Date”). Unless specified
herein, each capitalized term shall have the meaning assigned to it in the Agreement. 
 Section 3.2.1(d) and Section 3.2.1(e) of the
Agreement are hereby amended in their entirety as follows: 
 3.2.1    Research  

 

	 	(d)	If (i) Celltech has not achieved Milestone 1 as set out in Schedule A by [*]; or (ii) if Celltech achieves Milestone 1 but subsequently fails to achieve
Milestone 3 as set out in Schedule A within [*] of Amgen notifying Celltech in writing (pursuant to Article 3.2.1(g) below) of [*] as determined by the [*] study results; the Parties (upon the written request of [*]) shall for a period of [*] of [*]
with respect to unachieved Milestone 1 or unachieved Milestone 3 (as applicable) discuss the possibility of extending such time period for an additional, mutually agreed period. Each Party acknowledges that it shall be at its sole discretion as to
whether or not to agree to such an extension of any such time period. 


  
 1 









 July 10, 2003 
  


	 	(e)	Within [*] of expiry of the [*] period referred to in Article 3.2.1(d) or any extension to such date agreed to by the Parties, Amgen shall notify Celltech in writing
that Amgen will either: 

  

	 	(i)	assume the right and obligation to Research, Develop, and supply either itself or through agreement with a Third Party the [*] referred to in Milestone 1 and/or (as
appropriate) the [*] referred to above in Article 3.2.1(d); or 

  

	 	(ii)	terminate this Agreement. 

 If
Amgen does not serve such a notice it will be deemed to have exercised the option set out in Article 3.2.1(e)(i). 
  
 Section 3.6.3 of the Agreement is amended in its entirety as follows: 

3.6.3    Late Stage Development Costs 
 All Research and Development Costs cumulatively incurred (whether FTE Cost incurred directly by Amgen or Celltech or amounts payable to Third Parties engaged by Celltech or Amgen) for Late Stage
Development of Antibody Products shall be shared as follows: 
 (a) up to [*] Dollars ($[*]) of such cumulative Research and
Development Costs, on the basis of [*]:[*] Amgen:Celltech; 
 (b) over [*] Dollars ($[*]) of such cumulative Research and
Development Costs, on the basis of [*]:[*] Amgen:Celltech. 
 The costs of manufacture, including scale-up and validation of
Antibody Raw Material and Antibody Product in Finished Form, shall be deemed Research and Development Costs of Late Stage Development to the extent only that Antibody Raw Material and Antibody Product in Finished Form so produced is not used for
Commercialisation and otherwise shall be a Cost of Goods. 
 Amgen and Celltech warrant and represent that they have the right to
enter into this Amendment and that the terms of this Amendment are not inconsistent with other contractual obligations (express or implied) which they may have. No amendment, modification or supplement of any provision of this Amendment shall
be valid or effective unless made in writing and signed by a duly authorized officer of each party. This Amendment shall be governed by the laws of the State of New York. 

  
 2 









 July 10, 2003 

 

 Except as amended and supplemented hereby, all of the terms and conditions of the Agreement shall remain
in full force and effect. The Agreement as amended pursuant to this Amendment, constitutes the entire understanding of the parties and each reference to “Agreement” contained in the Collaboration and Licence Agreement shall from and after
the date of the Amendment Effective Date refer to the Collaboration and Licence Agreement as modified hereby. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. If this Amendment is acceptable to you, please confirm by signing and returning the duplicate copy of this agreement to XXXXX X. XXXXXXXXX, M/S XX-X-X, at Amgen. 

Yours sincerely, 
 /s/ David L. Lacey

 David L. Lacey, M.D. 
 Vice
President, Basic Research & Metabolic Disorders 
  

			
	 Celltech R&D Limited

		
	By:	 	 /s/ Melanie G. Lee



			
	Title:	 	 R&D Director



			
	Date:	 	 24th July 2003


  

	copy:	Ian J. Nicholson 


	    	Senior V.P. Business Development, Celltech 

  

	    	XXX XXXXXXXX, Esq. 


	    	XXXXX XXXXXX 


  
 3